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Summary
Promyelocytic leukaemia (PML) proteins consist of a collection of related isoforms
that are the nucleating components of sub-nuclear structures termed PML nuclear
bodies (PML NBs). Numerous functions are attributed to PML and PML NBs,
including a role in antiviral responses. Adenovirus type 5 (Ad5) has previously been
shown both to disrupt PML NBs and to cause the appearance of a novel PML protein
species, termed PML-A, in a manner dependent on the viral E4 Orf3 protein. Here,
the interactions between Ad5 and PML proteins were further investigated.
The E4 Orf3-dependent species of PML (PML-A) was found to be related to the full-
length PML II isoform. In addition, two previously unknown infection-specific
species of PML were detected (PML-B and PML-C). Both PML-B and PML-C
were produced independently of Ad5 E4 Orf3, though their appearance required viral
DNA replication. PML-C was found to be localised within the cytoplasm of infected
cells and to be related to PML I.
To test the hypothesis that these changes in PML were related to virus effects on
antiviral responses, the roles of individual PML proteins in type I interferon (IFN)
signalling were investigated. Depletion of PML II by siRNA resulted in a 50%
decrease in activity of an IFNβ promoter reporter plasmid during stimulation by poly 
(I:C).  Exogenous expression of a ΔRBCC truncated mutant, but not full-length, 
PML II resulted in enhanced IFNβ promoter activity, suggesting a role of a PML II-
related species in type I IFN signalling. Moreover, expression of the Ad5 E4 Orf3
protein was sufficient to inhibit the activity of the IFNβ promoter, an activity that 
correlated with Orf3’s ability to bind PML II. Collectively, these data indicate that a
PML II-related molecule is involved in the interferon response and that the E4 Orf3-
PML II interaction may therefore facilitate Ad5 in mitigating this activity.
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Chapter 1
Introduction
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Overview
Upon infection of a cell, a virus faces substantial challenges that must be overcome
in order to replicate successfully. For instance, the virus must elude or deactivate
antiviral responses initiated by the host cell upon infection. This study primarily
concerns an investigation of the nature and function of cellular promyelocytic
leukaemia (PML) proteins. As previously stated, PML proteins are the nucleating
factor of sub-nuclear structures termed PML nuclear bodies (PML NBs). PML NBs
have been implicated in a vast array of cellular functions though, for this study,
particular interest lies in their proposed involvement in antiviral mechanisms. Many
viruses target and disrupt PML protein and PML NBs, including the adenovirus Ad5,
the virus utilised during the course of this study. Alongside this, the roles of PML
protein in a specific antiviral response, the type I interferon (IFN) response, are
considered.
The following sections provide a more detailed examination of the topics mentioned
above. Initially, the basic facets of adenovirus biology are discussed. Attention then
moves to the various aspects of IFN responses, including a description of the main
signalling cascade as well as the various stimuli that may trigger this response.
Finally, the nature of both PML protein and PML NBs are discussed. Whereas the
many proposed functions of PML protein are summarised, particular attention and
detail are paid to the roles of these proteins in a variety of viral infections, including
Ad5. The main aims of this investigation are then stated.
1.1 Adenovirus
1.1.1Classification and structure
Adenoviruses (Ad) are large double stranded DNA viruses that possess a linear
genome that may vary from 34-36kbp (Berk, 2007). There are at least 51 human Ad
serotypes that may be divided into six subgroups, termed A-F, also now known as
species. Subgroup B may be further split into B1 and B2 based on molecular
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phylogeny (Berk, 2007). Ad5, the virus used during the course of this study, belongs
to subgroup C. Adenoviruses are non-enveloped viruses that possess an icosahedral
capsid. The capsid is primarily composed of three major proteins. The hexon
protein is the most abundant of these, and forms each of the faces of the icosahedron
(Russell, 2009). The hexon protein forms homotrimers, and 240 of these hexon
capsomeres are incorporated into the capsid. At each of the 12 vertices of the capsid
there is a penton capsomere. This is composed of a homopentameric penton base
and the homotrimeric fibre protein, which forms an extension from each vertex
(Devaux et al., 1987). Fibre protein is itself divided into three regions; the tail, shaft
and knob (Russell, 2009). Proteins IIIa, VI, VIII and IX are minor components of
the capsid but are important for its stability. Six proteins, termed V, VII, Mu, IVa2,
TP and 23K, form the core of the particle. All but one of these proteins are
associated with the viral genomic DNA. 23K is a viral protease that is not
associated with viral DNA, and is important both for the maturation of the particle to
its infectious form and for the disassembly of the capsid upon infection of a cell
(Russell, 2000).
1.1.2 Replication cycle
Ad5 binds to its host receptor, the Coxsackie/adenovirus receptor CAR, through its
fibre protein (Russell, 2009). Upon binding, Ad5 may enter the cell through
endocytosis in a clathrin-dependent manner (Meier & Greber, 2004). Within the
endosome the 23K protease degrades protein VI in order to destabilise the capsid
(Greber et al., 1996). Upon contact with the nuclear membrane, the viral genomic
DNA enters the nucleus through the nuclear pore (Russell, 2000). Once there, early
gene transcription begins with the E1A region. E1A gene products alter the cell to
make it more permissive for viral replication and activate transcription of other early
gene products, including E1B proteins which also affect the host environment and
response to infection (Berk, 2005). The E2 region encodes the machinery required
for the replication of viral DNA (Berk, 2007). The protein products of the E3 region
are responsible for evasion of the host immune response, and are dispensable for
viral propagation in tissue culture (Berk, 2007). The E4 region encodes several
proteins involved in viral mRNA metabolism and the promotion of viral DNA
replication (Berk, 2007).
Viral DNA synthesis occurs by initiation from both ends of the linear genome
primed by the terminal protein precursor (pTP) that becomes attached to the 5’ ends
of the newly synthesised DNA strands (Berk, 2007, Russell, 2000). The pattern of
viral gene expression changes after the initiation of DNA replication. The IVa2, IX
and L4 proteins are expressed and subsequently activate the major late promoter
(MLP). The MLP drives expression from the L1-5 regions, which encode proteins
involved in the late phase of replication, including structural proteins and proteins
involved in assembly (Berk, 2007, Morris & Leppard, 2009, Russell, 2000). Viral
assembly occurs within the nucleus, where the viral DNA enters pre-formed viral
particles, after which the virus exits the nucleus and the cell altogether (Berk, 2007).
1.1.3 The E4 Region
T
a
r
iFigure 1.1 The Ad5 E4 region. Diagram showing the relationship of the Ad5
E4 proteins. All E4 proteins are derived from mRNAs generated by splicing
from a single transcript. Overlapping boxes of the same number share reading
frames, otherwise amino acid sequences are different between proteins. A
dashed line indicates a split in the coding regions by intron sequences. The
numbers at the bottom represent the postion within the Ad5 genome in base
pairs. Adapted with permission from K. Leppard (Leppard, 1997).16
he E4 region encodes at least seven protein products that are derived from
lternative splicing of a single primary transcript (Leppard, 1997, Fig. 1.1). The E4
egion contains one promoter that is activated by E1A during the early phase of
nfection. At later time points, however, the activity of the promoter decreases due
to an inhibition of E1A by E4 Orf4, and the increasing presence of the E2A repressor
(Bondesson et al., 1996, Shenk, 1996).
E4 Region Gene Product Function(s)
Orf1 Unknown; Oncogenic in rats
Orf2 Unknown function
Orf3 Reorganisation of PML NBs
Reorganisation of MRN
complex
Regulation of viral mRNA
processing
Orf3/4 Unknown
Orf4 Binds and modulates activity of
phosphatase 2A
Regulation of viral mRNA
processing
Inhibits E1A activity
Orf6 Regulation of viral mRNA
processing
Degradation of p53 and Mre
Orf6/7 Regulates E2F activity
Regulation of viral E2 region
Regulation of cellular genes
T
v
T
p
m
p
g
o
a
c
f
c
O
(Table 1.1 Function of the E4 region of adenovirus. The known functions of17
he function of E4 gene products primarily concerns the processing and transport of
iral mRNA and overcoming host antiviral responses (Weitzman & Ornelles, 2005).
he functions are summarised in Table 1.1. The most intensively studied E4
roducts are Orf3 and Orf6, as these proteins are largely responsible for the functions
entioned above. The MRN (Mre11-RAD50-NBS1) host cell protein complex
oses a significant problem to adenovirus, as it detects the ends of the linear viral
enome as it would double-strand breaks (DSBs) in host cell DNA. The end result
f activation of the DSB repair pathway is concatemerisation of the viral genome
nd inhibition of viral replication (Weitzman & Ornelles, 2005). Orf3 expression
auses the redistribution of the MRN DNA damage response protein complex away
rom viral replication centres (Stracker et al., 2002). Orf3 also induces the
ytoplasmic localisation of Mre11 into aggregates (Weitzman & Ornelles, 2005). E4
rf3 also causes the rearrangement of PML NBs into ‘track-like’ structures
Carvalho et al., 1995), and this is discussed in detail later.
each of the E4 gene products are summarised.
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E4 Orf6 forms a complex with E1B 55K that can recruit cellular Cullin proteins to
form an E3 ubiquitin ligase (Berk, 2005, Weitzman & Ornelles, 2005). Orf6
contributes to overcoming the DNA damage response mentioned above by initiating
the degradation of Mre11 via this activity (Stracker et al., 2002). The actions of
Orf3 and Orf6 on Mre11 and the MRN complex together lead to a decrease in ATM
and ATR kinase activitiy. This therefore decreases the phosphorylation and
activation of a number of proteins involved in the DNA repair pathway (Carson et
al., 2009, Weitzman & Ornelles, 2005). The E4 Orf6/E1B 55K ubiquitin ligase
complex is also responsible for the ubiquitination and degradation of p53 during
adenovirus infection, and hence for blocking the cell cycle arrest/pro-apoptotic
activities of this protein (Berk, 2005, Querido et al., 2001).
Finally, both E4 Orf3 and Orf6 act as splicing factors on viral RNA transcribed from
the MLP. Orf3 promotes exon inclusion whereas Orf6 promotes exon exclusion
(Nordqvist et al., 1994). However, despite having opposing functions in this regard,
Orf3 and Orf6 are to a degree functionally redundant, as both proteins stabilise viral
mRNA, though this is achieved through independent mechanisms (Öhman et al.,
1993).
Other E4 gene products are less well understood. Orf1 is known to possess
oncogenic activity during Ad9 infection of rats, and this ability correlates with high
levels of expression (Weiss et al., 1996). E4 Orf2 is known to be expressed but has
no known function (Dix & Leppard, 1995). E4 Orf4 binds the cellular protein
phosphatase 2A and modulates its activity in regulating cellular SR proteins.
Through this mechanism Orf4 regulates viral mRNA splicing (Kanopka et al., 1998).
Orf4 also inhibits the activity of E1A and has been suggested to therefore inhibit
viral replication (Bondesson et al., 1996). Orf6/7 regulates the cellular transcription
factor E2F, and there is evidence that it promotes transcription of the E2 early region
of adenovirus (Leppard, 1997).
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1.2 The interferon (IFN) response
Interferons were the first cytokines that were discovered in 1957 when they were
shown to interfere with viral replication. They form the first line of defence against
infection, and are produced in large amounts upon viral infection. IFNs are secreted
from infected cells to act in an autocrine and paracrine manner. In infected cells,
IFNs act to induce apoptosis and therefore limit the spread of virus. In uninfected
cells, IFNs act to induce an antiviral state to limit subsequent viral infection. They
also play an important role in modulating the activity of natural cytotoxic T-
lymphocytes (CTLs) and macrophages (Stetson & Medzhitov, 2006). Alongside
their antiviral properties, interferons also confer anti-proliferative effects and have
been proposed to perform functions unrelated to antiviral defence (Taniguchi &
Takaoka, 2002).
Interferons may be sub-divided into either type I, II or III groups (Takaoka & Yanai,
2006).  Type I IFNs are produced in cells upon virus infection, and they consist of α, 
β, δ, ω and τ interferons, although only the production of IFN α/β has been well 
described and is initiated via a complex signalling pathway that is described below.
In humans there are at least 13 subtypes of IFNα (Randall & Goodbourn, 2008), 
though only a single gene exists for IFNβ.  IFNγ is the only member of the type II 
IFNs, and its production is limited to NK cells and activated T-cells (Takaoka &
Yanai, 2006).  IFNγ is required for macrophage-mediated immune responses against 
pathogens such as intracellular bacteria (Takaoka & Yanai, 2006). Type III IFNs are
the most recent group to be characterised and are also induced upon viral infection of
cells.  There are three homologous members, IFNλ1-3, and they act in a manner 
similar to that of type I IFN. However, they differ from type I IFNs as they possess
a different structure and utilise an independent membrane receptor for signalling
(Kotenko et al., 2003, Sheppard et al., 2003)
1.2.1 The classical type I IFN signalling pathway
The type I IFN signalling pathway is induced upon viral infection (Fig. 1.1).
Various indicators of viral infection may be detected by membrane-bound toll-like
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receptors (TLRs), or by cytoplasmic receptors such as the RNA helicases RIG-I or
MDA5. A summary of the variety stimulants of the IFN response is discussed in
Section 1.2.2.
The most well-defined pathway of type I IFN induction is that of the response to
viral RNA, which is detected by RIG I and MDA5. Both of these surveillance
molecules are ubiquitously expressed and are themselves IFN-inducible, therefore
forming part of the IFN positive feedback loop (Haller et al., 2006). RIG-I and
MDA5 both possess a caspase recruiting domain (CARD) in their N terminus, and it
is thought that upon binding to their respective activators the CARD undergoes a
conformational change. This change permits the interaction of RIG-I and MDA5
with interferon β promoter stimulator 1 (IPS-1) or mitochondrial antiviral signalling 
protein MAVS (Haller et al., 2006). MAVS localises to the outer membrane of
mitochondria, though the reason for this remains unclear. It has been proposed that
the mitochondrial localisation keeps the antiviral sensing machinery in close
proximity to intracellular membranes, which are often sites for viral replication
factories (Haller et al., 2006).
Activated IPS-1 and MAVS in turn activate the interferon regulatory factor 3 (IRF3)
kinases IKKε (IкB kinase) and TBK-1 (TANK-binding kinase 1).  TBK-1 may also 
be activated by an alternative mechanism. Toll-like receptor TLR3 can detect
dsRNA in endocytic compartments, and signals to TBK-1 via TRIF, leading to the
phosphorylation of IRF3 (Haller et al., 2006). IRF3 is a constitutively expressed
transcription factor. In its unphosphorylated form, IRF3 is monomeric, cytoplasmic
and inactive (Honda et al., 2006, Mercurio et al., 1997). However, phosphorylation
of the C-terminal domain of IRF3 by its respective kinases results in its dimerisation
and migration to the nucleus (Honda et al., 2006).  Once there, IRF3 binds the IFNβ 
promoter and recruits transcriptional co-activators p300 and CBP (CREB-binding
protein).  The DNA-binding transcription factors AP-1 and NF-кB are also recruited 
in a manner dependent on dsRNA, resulting in the production of an enhanceosome
that directs IFNβ mRNA expression (Merika et al., 1998, Thanos & Maniatis, 1995,
Yie et al., 1999).  NF-кB normally resides in the cytoplasm in an inactive form due 
to its binding to IкB.  Upon IKKε activation, IкB is phosphorylated and subsequently 
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degraded, allowing NF-кB to migrate to the nucleus in its active form (Mercurio et
al., 1997).
IFNα/β is secreted from cells where it acts in an autocrine and paracrine pathway to 
bind membrane-bound type I interferon receptors (IFNAR). IFNARs are composed
of two subunits termed α and β, and both subunits are required for IFN signalling 
(Bogdan, 2000). Upon IFN binding, IFNARs signal to the Janus kinases Jak-1 and
Tyk-2, which in turn phosphorylate and activate the transcription factors STAT-1
and STAT-2 (signal transducing activators of transcription) (Haller et al., 2006).
Phosphorylated STAT 1/2 recruits IRF9 to form a complex known as IFN stimulated
gene factor 3 (ISGF-3) (Haller et al., 2006). ISGF-3 translocates to the nucleus and
binds interferon response elements (ISREs) that are located in the promoters of
interferon stimulated genes (ISGs) (Takaoka & Yanai, 2006).
Amongst these ISGs is IRF7, which upon expression is activated by phosphorylation
in a manner dependent on viral infection. IRF7 is considered the ‘master regulator’
 of the IFN response, as it induces the expression of IFNα (Honda et al., 2005) as
well as numerous ISGs. Both IRF3 and IRF7 may homo- or hetero-dimerise, and
each complex possesses its own promoter specificity (Honda et al., 2005). Induction
of IRF7 is important for the positive feedback loop of the IFN response, and it is
responsible for the massive amplification in the amount of IFNα/β during virus 
infection (Honda et al., 2005). IRF7 has a short half-life, and therefore is only
present in high concentrations when a viral infection is in progress (Taniguchi &
Takaoka, 2002).
1.2.2. Alternative pathways and other stimuli of the IFN response
Mammalian cells are subject to infection by a wide range of viruses that may use
either RNA or DNA as their genetic material. The pathway described above
demonstrates the classical mechanism of IFN induction by dsRNA. However, until
recently it has been unclear as to how cells detect the presence of DNA virus
infection. TLRs capable of sensing dsDNA in endosomes were known (Randall &
Goodbourn, 2008). However, recent studies have demonstrated that cytosolic
  
 Figure 1.2 The classic type I IFN
signalling pathway. Upon
infection viral RNA in the
cytoplasm is detected by
MDA5/RIG-I which leads to a
signalling cascade within the cell,
ultimately leading to the induction
of the IFNβ gene.  IFNβ acts
through autocrine and paracrine
pathways to induce the Jak-STAT
signalling pathway. This results in
production of IRF7 and ultimately,
the amplification of the IFN
response through the positive
feedback actions of both IFNα and
IFNβ.  The dashed line in the right
hand cell summarises the pathway
indicated in the left hand cell.22
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dsDNA can also activate the IFN response using pathways involved in the response
to dsRNA.  Transfection of cells with synthetic dsDNA was found to enhance IFNβ  
promoter activity in a manner dependent on RIG-I (Cheng et al., 2007). The
mechanism of this was demonstrated in further studies by independent groups. RNA
polymerase III was found to transcribe RNA from cytosolic DNA templates.
Furthermore, the generated RNA possessed 5’ tri-phosphate (5’ppp), which is
recognised by RIG-I and leads to its activation (Ablasser et al., 2009, Chiu et al.,
2009). Adenovirus and herpes simplex virus type 1 (HSV-1) genomic DNA were
both found to induce IFNβ promoter activity (Cheng et al., 2007, Chiu et al., 2009),
and this was indeed dependent on RNA Pol III (Chiu et al., 2009).
The IFN response may also respond to stimuli other than dsRNA, and this is
mediated through the use of various TLRs. TLRs may be found on the plasma
membrane as well as endosomal membranes. TLRs 7 and 8 can detect ssRNA, TLR
9 can detect unmethylated DNA and TLR 4 can detect lipopolysaccharide (LPS)
(Stetson & Medzhitov, 2006).  TLR 3 can signal through to IKKε/TBK-1 via adaptor 
protein TRIF, whereas TLRs 7 and 9 can activate IRF7 (Kumar et al., 2009).
Therefore there are numerous molecular stimuli that can alert the IFN response to the
presence of a viral infection, and collectively these are termed pathogen-associated
molecular patterns (PAMPs) (Akira et al., 2006).
1.2.3. Antiviral effects of type I interferons
Interferons have been shown to perform both anti-viral and anti-proliferative
functions that are important for survival. Both mice and humans deficient in IFN
signalling succumb to viral infections at an early age (Haller et al., 2006). There are
several hundred ISGs, indicating that an IFN response induces a diverse and
complex cellular response. The products of a number of ISGs are antiviral proteins.
Three main families of antiviral proteins have been described; the protein kinase R
family (PKR), the oligoadenylate synthetase (OAS)/RNase L family and the Mx
family. Each family performs a number of antiviral functions and are usually more
potent against some viruses more than others (Stetson & Medzhitov, 2006). It
should be noted, however, that mouse knockouts of all three of these mechanisms
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still possess limited resistance to viral infection that is induced by IFN, reflecting the
presence of other cellular antiviral pathways (Haller et al., 2006).
The Mx proteins are important in mediating antiviral activity against
orthomyxoviruses in mice, and have protective activity against both influenza virus
and vesicular stomatitis virus (VSV) (Stetson & Medzhitov, 2006). Although their
precise mechanism of action is unknown, Mx proteins are large GTPases that are
thought to interfere with intracellular viral assembly and trafficking (Stetson &
Medzhitov, 2006). Activation of 2’-5’ OAS results in the production of
oligoadenylates and subsequent activation of RNase L. RNase L degrades viral
RNA as well as host mRNA (Stetson & Medzhitov, 2006). Activation of protein
kinase R (PKR) leads to the phosphorylation of the eukaryotic translation initiator
factor eIF2α, resulting in the inhibition of translation of both host and viral RNAs
known as ‘host cell shutoff’ (Stetson & Medzhitov, 2006).
The IFN response also leads to general antiviral responses other than those described
above. Treatment of cells with type I IFNs sensitizes them to apoptosis upon viral
infection (Stetson & Medzhitov, 2006). p53, a tumour suppressor which promotes
apoptosis, is directly induced by interferon and is thought to confer antiviral activity
through this function (Stetson & Medzhitov, 2006). This hypothesis is supported by
the observation that a number of viruses, including poliovirus and adenovirus,
actively degrade p53 during the course of infection (Pampin et al., 2006, Weitzman
& Ornelles, 2005).
1.3 PML protein and PML NBs
The promyelocytic leukaemia (PML) gene was identified by its involvement in the
chromosome translocation event responsible for acute promyelocytic leukaemia
(APL) (de The et al., 1990, Goddard et al., 1991). In APL, the PML locus
undergoes a t(15;17) translocation with the retinoic receptor α (RARα) gene, 
resulting in the production of a functional fusion protein which was later identified
as PML-RARα (de The et al., 1990, Goddard et al., 1991). PML protein was shown
to possess a distinctive nuclear localisation in the form of nuclear dots, variously
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known as ND10, PML oncogenic domains (PODs), Kremer bodies or PML nuclear
bodies (PML NBs). PML NBs derive their name from the observation that they do
not form in the absence of PML protein, and thus this protein is considered the
nucleating factor of these bodies (Ishov et al., 1999). As such, many of the functions
ascribed to NBs are often also attributed to PML protein. In APL, PML NBs are
dispersed, and their reconstitution via specific therapy is associated with regression
of the disease (Salomoni et al., 2008). Consequently, PML protein and PML NBs
have since been the subject of intensive investigation.
1.3.1 Structure of the PML protein
The pml gene locus is located on chromosome 15 and is approximately 35kb in
length (Goddard et al., 1991). The gene consists of nine exons, which are
alternatively spliced during gene expression to generate numerous protein isoforms,
and is expressed in almost all tissues (Jensen, 2001). All described PML isoforms
share exons 1-3, and are thus N-terminally related, though they may differ in
composition regarding exons 4-9 (Jensen, 2001). PML proteins can be extensively
post-translationally modified, the best studied example of which is sumoylation. The
various post-translational modifications of PML protein will be discussed later
within this chapter.
Within PML exons 1-3 lies a distinctive domain consisting of three separate
elements; a RING finger, two B-boxes and a coiled-coil. This motif is known as an
RBCC or a tripartite motif (TRIM). A whole family of TRIM proteins is known to
be produced by human cells, and indeed PML protein is also known as TRIM19
(Ozato et al., 2008). The RBCC is thought to play a key role in the biological
function of PML protein, and is required for the oncogenic activity of the PML-
RARα fusion protein. The RING finger, for instance, is crucial for the formation of
PML NBs (Shen et al., 2006), as a PML RING mutant does not form these
substructures. The RING has been hypothesised to possess activity similar to that of
an E3 ubiquitin-ligase, since other RING-domain proteins have such activity
(Freemont, 2000), though its substrate is thought to be the ubiquitin-like protein
SUMO (Ozato et al., 2008). Although evidence in mammalian cells is lacking, over-
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expression of PML in yeast leads to a general increase in sumoylation (Quimby et
al., 2006). The coiled-coil of PML is generally thought to allow both homo- and
hetero-oligomerisation of PML isoforms, and therefore may also play a role in the
assembly of PML NBs (Cao et al., 1997, Jensen, 2001). As well as being subject to
sumoylation, PMLs I-V possess a SUMO-interacting motif (SIM) that is encoded in
exon 7a (Shen et al., 2006), which mediates non-covalent associations with other
SUMO-modified proteins. The SIM, as well as the RBCC domain, is crucial for the
formation of PML NBs.
There are currently seven described isoforms of PML that are defined by their
unique carboxyl-terminal sequences. Termed PMLs I-VII, only PMLs I-VI are
known to be incorporated into PML NBs (Jensen, 2001). PML VII is a cytoplasmic
variant of PML and is thus excluded from the nucleus. With the exception of PML
VII, full-length isoforms possess all of exons 1-6, though they differ in their
subsequent exon content. However, it should be noted that the structure of the PML
gene allows cytoplasmic variants of PML I-V to be produced by splicing from exon
3 to exon 7a (Fig. 1.2). Each of PML I-V may occur as several variants depending
on the splicing pattern of exons 4-6 (Jensen, 2001). These exons may be
differentially excluded from the primary transcript to generate three possible variants
of each of PML I-V. Exon 5 may solely be excluded to create a presumptively
nuclear form of each of PML I-VI, exons 5 and 6 may be excluded together, altering
the reading frame or all of exons 4, 5 and 6 may be excluded together, retaining the
reading frame (Jensen, 2001). Since the nuclear localisation signal (NLS), as well as
a sumoylation site, of PML is located in exon 6, PML species lacking this exon are
expected to exhibit a cytoplasmic localisation. Indeed cytoplasmic PML VII, an
exon 4-7b splice variant that uses an alternative reading frame in exon 7b, lacks exon
6 (Jensen, 2001). PML I is unique among the nuclear isoforms in that it also
contains, in its C-terminal domain, a nuclear export signal (NES) (Condemine et al.,
2006), meaning that it may move between cell compartments.
All PML isoforms are expressed in both primary cells and cell lines, but each cell
type displays a distinct and consistent pattern of PML isoform expression
(Condemine et al., 2006). PML I and PML II were found to be the most heavily
expressed isoforms in normal cells, whereas PMLs III-V were expressed to lower
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levels. PML VI appeared to be the least abundant PML isoform (Condemine et al.,
2006).
1.3.2 Post-translational modification of PML protein
The PML protein can be post-translationally modified in a variety of ways. All
known post-translational modifications of PML affect regions of the protein that are
shared by multiple isoforms. Very little is known about isoform-specific
modifications.
Sumoylation
PML may be covalently conjugated with the small ubiquitin-like modifier SUMO at
lysines 65, 160 and 490 (Duprez et al., 1999). Lysine 490 lies within exon 6 and is
therefore absent in cytoplasmic variants of PML (Jensen, 2001). Sumoylation of
PML is critical for the assembly of PML NBs, and dispersal of these bodies has been
shown to correspond with desumoylation (Bernardi & Pandolfi, 2007). Over-
expression of SUMO proteases, for instance, leads to the loss of PML NBs (Nichol
et al., 2009). Many PML-unrelated components of PML NBs, such as Daxx, are
also sumoylated and PML mutants unable to be sumoylated are unable to recruit
other NB components (Bernardi & Pandolfi, 2007). The formation of PML NBs is
also facilitated through non-covalent interactions between SUMO, and unrelated
proteins possessing a SIM. The SIM of PML, for example, is crucial in interacting
with unrelated sumoylated proteins in PML NBs (Shen et al., 2006).
Figure 1.3 The structure of PML isoforms I-VI. All of PML I-VI share a common N-terminal domain (exons
1-6), but differ in composition of exons 7a-9. PML VI is formed by an alternative splice from exons 6 to 7a that
alters the reading frame as compared to other isoforms. R – RING finger. B – B-Box. CC – Coiled coil. N –
nuclear localisation signal. The position of the three sumoylatable lysine residues (K65, K160, K490) are
indicated in red with an S. The SUMO interaction motif (SIM) in exon 7a is also indicated in red. The amino-
acid length of each isoform is indicated on the right hand side of the figure.28
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A further layer of complexity is generated regarding sumoylation modification as
there are at least four SUMO homologs described in mammalian cells (Nichol et al.,
2009). PML protein, for instance, may be sumoylated by each of SUMO 1-3, though
the functional significance of each form of modification is incompletely understood
(Bernardi & Pandolfi, 2007). For instance, PML may be mono-sumoylated by
SUMO 1, which is unable to form polymeric chains, and was the original SUMO
protein found to couple with PML. However, it has since been found that poly-
sumoylation may occur by SUMO 2 and 3, although SUMO 1 always forms the last
subunit of the chain. Poly-sumoylation by SUMO 2 and 3 is required for the
formation of PML NBs (Bernardi & Pandolfi, 2007).
Sumoylation of PML has been shown to be mediated by Ubc9, an E2 SUMO-
conjugating enzyme (Duprez et al., 1999). However, the E3 ligase required for
sumoylation of PML is currently unknown, prompting speculation that PML may act
as its own E3 ligase through its RING domain (Jensen, 2001). The RING has been
shown to possess auto-sumoylation activity in yeast, but as yet no data exist
concerning mammalian cells (Quimby et al., 2006). Further weight has been lent to
this hypothesis by Duprez et al, who demonstrated that SUMO modification of PML
requires an interaction between Ubc9 and the RING domain (Duprez et al., 1999).
Ubc 9 is also a potential PML NB component, suggesting that other PML NB
components may be recruited to PML NBs in order to be sumoylated (Nichol et al.,
2009). Sumoylation has also been shown to regulate the dynamics of exchange of
components between PML NBs and the nucleoplasm, including PML isoforms I-VI
as well as other NB components such as Sp100 (Weidtkamp-Peters et al., 2008).
The reciprocal release of SUMO from PML is mediated by at least two members of
the SUMO-specific protease family, also known as SENPs. SENP2 is likely to be
responsible for de-conjugation of SUMO 1 and SUMO 3 modifications, whereas
SENP5 removes all of SUMO 1-3 (Nichol et al., 2009). Therefore sumoylation is a
reversible and dynamic process that plays an important role in regulating the
formation and function of both PML proteins and PML NBs.
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Alongside PML, there are numerous reported substrates for SUMO modification,
including many factors involved in transcription and genomic stability. The function
of sumoylation is very diverse, and varies depending on the substrate being modified
(Gill, 2004, Muller et al., 2004). For instance, sumoylation regulates the localisation
of PML protein to PML NBs, whereas sumoylation of p53 can regulate its ability to
function as a transcription factor (Muller et al., 2004).
It has recently been shown that sumoylation of PML may either promote or inhibit
its degradation depending on the pattern of sumoylation. RNF4/SNURF, an E3
ubiquitin ligase, recognises both mono- and poly-sumoylated PML via its own SIM
and promotes the ubiquitination and subsequent degradation of PML (Percherancier
et al., 2009, Tatham et al., 2008). This was somewhat surprising, as sumoylation
had previously been thought to protect PML from such degradation. For example,
sumoylation has been reported to protect PML from degradation dependent on the
activity of the prolyl-isomerase Pin1 (Reineke et al., 2008). These conflicting data
suggest that the precise pattern of sumoylation on PML may play an important role
in regulating the stability of PML protein
Phosphorylation
Transient phosphorylation of PML is known to regulate some of its functions, such
as its ability to promote apoptosis in response to arsenic trioxide (Hayakawa &
Privalsky, 2004). PML phosphorylation also occurs during the cell cycle. Work by
Everett and colleagues demonstrated that, during mitosis, a novel phosphorylated
form of PML protein was produced (Everett et al., 1999). Furthermore, the
appearance of this phosphorylated form coincided with the desumoylation of PML
and hence the dispersal of PML NBs (Everett et al., 1999). However, the functional
significance of this phosphorylated form of PML remains unknown.
A better characterised example of PML phosphorylation is that described by
Scaglioni et al. They showed that PML is selectively phosphorylated at serine 517
in exon5-deleted PML (Ser565 in full-length PML) by casein kinase 2 (CK2), which
is known to be up-regulated in many tumours. Phosphorylation of PML at this
residue results in the ubiquitination of PML and its subsequent degradation by the
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proteasome (Scaglioni et al., 2006). Therefore CK2 is thought to be an important
regulator of PML stability. Interestingly, Ser565 is located within exon 7a and is
only common to PMLs I-V, and thus PML VI is unlikely to be subject to degradation
via this mechanism. Phosphorylation has also been associated with the degradation
of PML in a manner dependent on the prolyl isomerise Pin1. Pin1 utilises its WW
domain to bind PML IV phosphorylated on Ser527, and initiates its degradation
(Reineke et al., 2008). SUMO-1 was found to negatively affect this process, as Pin1
was unable to bind sumoylated PML. Since Ser527 is encoded within exon 6, this
mechanism may apply to multiple PML isoforms.
There is increasing evidence that suggests that both SUMO and phosphorylation
modifications of PML may ‘cross-talk’, adding a further layer of complexity to the
regulation of these proteins. Cells treated with phosphatase inhibitors undergo
desumoylation of their PML proteins, suggesting that phosphorylation may
negatively regulate sumoylation (Muller et al., 1998). However, it is unclear
whether this applies to all of SUMO 1-3 or just to individual homologs, and other
studies have reported that phosphorylation promotes sumoylation (Hayakawa &
Privalsky, 2004). The explanation of this conflict is likely to be that phosphorylation
of specific residues may have very different effects on sumoylation. Overall, it is
likely that phosphorylation, acting in conjunction with sumoylation, performs an
important role in regulating PML function and stability.
Acetylation
It has recently come to light that PML is subject to acetylation on lysines 487 and
515 by the histone acetyltransferase (HAT) p300; both of these residues are encoded
in exon 6 (Hayakawa et al., 2008). These lysines were acetylated in vivo after the
addition of trichostatin A (TSA), an inducer of apoptosis. Expression of the acetyl
transferase p300 led to an increase in the sumoylation of wild-type PML, but not of
mutants substituted with arginine at lysines 487 and 515, suggesting that acetylation
may enhance sumoylation. Lysine 487 is located within the NLS of PML, though its
acetylation did not affect PML sub-cellular localisation (Hayakawa et al., 2008).
Since exon 6 is excluded from cytoplasmic PMLs, this acetylation can only occur on
nuclear PML proteins.
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1.3.3 PML NBs
By immunofluorescent staining, PML NBs appear as small spherical structures
within the nucleus that may be up to 1µm in diameter, and may number up to 30
bodies within a single nucleus (Bernardi & Pandolfi, 2007). Examination by
electron microscopy had shed light on the structure of PML NBs, as they were
initially thought to be composed of a ring-like structure (Bernardi & Pandolfi, 2007).
However, recent study has indicated that, during interphase, a PML NB is a hollow
shell composed of both PML and Sp100 (Lang et al., 2010). PML NBs are
therefore proteinaceous structures and, except for those associated with telomeres in
cell lines that maintain telomere length in the absence of telomerase (ALT cells), do
not contain any detectable levels of nucleic acid, though they do associate with
transcriptionally active chromatin. For example, PML NBs associate with the MHC
(Major Histocompatibility Complex) locus, where they are thought to indirectly
contribute to transcription by altering the higher-order structure of chromatin (Pavan
Kumar et al., 2007).
Both the size and number of NBs is dependent on numerous factors, reflecting their
highly dynamic nature. The number of NBs per nucleus varies between cell types,
though this number may further vary within a cell according to various stresses. For
example, DNA damage by UV irradiation or chemical agents leads to increase in
both the size and number of PML NBs (Dellaire, 2004, Dellaire et al., 2006a). This
reflects the involvement of these bodies in DNA damage responses, as a number of
DNA damage proteins co-localise with PML NBs (Krieghoff-Henning & Hofmann,
2008). Under certain circumstances PML NBs have also been shown to be formed
de novo. Incoming exogenous DNA, whether it be a viral genome or plasmid, is
often associated with the formation of new PML NBs, an observation thought to be a
general cellular defence mechanism that initiates gene repression (Bishop et al.,
2006, Everett & Murray, 2005, Tavalai & Stamminger, 2008).
As mentioned above, PML NBs are primarily composed of PML isoforms I-VI, and
indeed PML NBs do not form in the absence of PML protein. Sumoylated PML
protein is associated with PML NBs, and subsequent desumoylation leads to the
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disassembly of these structures, as seen during mitosis (Everett et al., 1999). A main
mechanism of PML NB assembly is thought to involve homo- and hetero-
oligomerisation of PML isoforms via the RBCC motif alongside interactions
between sumoylated proteins and the SIM located in PML exon 7a (Shen et al.,
2006). Experiments by Weidtkamp-Peters and colleagues have suggested that PML
V is likely to be an important scaffold component of PML NBs, since it shows little
exchange with the surrounding nucleoplasm in contrast to PMLs I-IV and VI.
(Weidtkamp-Peters et al., 2008). Interestingly, this study also suggested that the
sumoylation status of PML protein was an important regulator of its exchange
dynamics. Individual isoforms were also shown to exhibit unique rates of exchange
and thus, in terms of PML content, at any one time the composition of PML NBs
may vary considerably (Weidtkamp-Peters et al., 2008).
Over 50 proteins unrelated to PML have been shown to associate with PML NBs.
Such proteins are now thought to pass relatively freely through the PML/Sp100 shell
into the hollow interior, which is enriched with polymeric SUMO 2/3 chains (Lang
et al., 2010). These chains provide possible binding targets for any proteins
possessing a SIM, and therefore facilitate association with the PML NB. Therefore,
reflecting their diversity in structure and PML content, PML NBs are also highly
variable in protein composition (Bernardi & Pandolfi, 2007). It should be noted,
however, that the vast majority of proteins shown to co-localise with PML NBs do
so only in a transient manner and often only in response to certain stimuli. For
example, many factors associated with DNA repair move to PML NBs only in
response to DNA damage (Dellaire, 2004, Krieghoff-Henning & Hofmann, 2008).
Such observations have implications when trying to understand the functions of
PML NBs, as proposing a single function that reconciles the roles of all the protein
factors shown to interact with PML NBs is difficult and may not be appropriate.
Other NB components, such as Sp100 and Daxx, are more stably associated with
PML NBs. Daxx itself is sumoylated, and is recruited to PML NBs by SUMO-
modified PML (Ishov et al., 1999). However, such associations are not necessarily
exclusive, as Daxx has also been found in both the cytoplasm and nucleoplasm. It is
of note that both Daxx and Sp100, as well as numerous other proteins, are
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sumoylated at PML NBs, an observation thought to enhance their association with
these bodies (Van Damme et al., 2010).
1.3.4. Functions of PML and PML NBs
Since the main constituent of PML NBs is PML protein, many of the functions that
have been proposed for PML NBs have been attributed to PML protein. Care should
be taken with this assumption however, as a multitude of other proteins are known to
associate with PML NBs (Bernardi & Pandolfi, 2007). A further difficulty is the
diversity within the cellular PML protein population, which may be divided into at
least seven protein isoforms (Jensen, 2001). Since each of these has unique
sequence features, they may be assumed to possess unique functions. Further
functional diversity may also be generated by the extensive post-translational
modification that a PML protein may undergo. These considerations must be taken
into account when reviewing the functions of PML and PML NBs that are described
below.
Roles in the DNA damage response
The observed changes that occur to the PML NB organisation of a cell that receives
a DNA-damaging insult prompted investigations into their role in the DNA damage
response (Dellaire, 2004). PML NBs localise to sites of DNA damage and co-
localise with a number of proteins that are actively involved in DNA repair (Dellaire,
2004). Under normal conditions, a number of proteins involved in DNA repair, such
as ataxia telangiectasia-mutated gene product (ATM), localise to PML NBs upon
DNA damage (Salomoni et al., 2008). In contrast others, including Nijmegen
breakage syndrome gene product (NBS1) and Mre11, dissociate from PML NBs
upon DNA damage, though re-localise with PML at later time points (Mirzoeva &
Petrini, 2001). These somewhat conflicting observations have proved to be obstacles
to suggesting a unifying function of PML NBs in the DNA damage response
(Bernardi & Pandolfi, 2007). It has therefore been proposed that PML NBs may act
as sites of storage for various DNA repair proteins, and also may act as sensors of
DNA damage that can link DNA repair responses to signalling responses. This latter
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notion stems from observations that various kinases involved in regulating the cell
cycle, including ATR, ATM and the checkpoint kinase Chk2, also co-localise with
PML NBs (Krieghoff-Henning & Hofmann, 2008).
Role in apoptotic mechanisms and cell cycle control
The characteristic mutation of the pml gene in APL patients pointed to PML protein
as being a tumour suppressor, though little was known about its biological function.
Wang and colleagues later reported that PML protein played an integral role in
numerous apoptotic mechanisms and was required for caspase-1 and caspase-3-
dependent apoptosis (Wang et al., 1998). Indeed, Pml -/- mice were less sensitive to
multiple apoptotic stimuli such as ionising radiation, interferon treatment and
ceramide treatment than wild-type mice and are more susceptible than normal mice
to tumours (Wang et al., 1998). These activities can account for PML’s role as a
tumour suppressor. In other studies, caspase-2 and caspase-6 have both been
associated with PML NBs, and at least in the case of caspase-6, perform functions
within the vicinity of these bodies (Tan et al., 2008, Tang et al., 2005).
A well-documented example of a transient PML NB localisation is that of the
tumour suppressor p53. Upon DNA damage, p53 is recruited to PML NBs where it
is subsequently post-translationally modified and activated to perform its pro-
apoptotic functions (Fogal et al., 2000, Pearson et al., 2000). PML protein has been
shown to interact with p53 in a number of ways, and is an important regulator of p53
activity. For instance, p53 is recruited, along with the acetyltransferase p300, to
PML NBs by PML IV, allowing p53 to be acetylated (Fogal et al., 2000). Many
factors involved in the stability of p53 are also regulated by PML. For instance,
casein kinase 1 activity, a regulator of p53, is enhanced by PML protein (Alsheich-
Bartok et al., 2008). Also, the E3 ubiquitin ligase MDM2, a negative regulator of
p53, is itself inhibited by direct binding to PML, and thus PML prevents p53
degradation (Louria-Hayon et al., 2003). Upon DNA damage, PML protein was
found to bind MDM2 and sequester it in the nucleolus (Bernardi et al., 2004). This
interaction was mediated by the region around the coiled-coil domain which is
shared by all PML isoforms. Thus all members of the PML protein population may
be involved in p53 regulation.
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The structure of PML NBs is highly dynamic throughout the cell cycle, varying in
size and number depending on the phase. This is thought to be mainly due to
modifications in chromatin structure that inevitably cause fission of adjacent nuclear
bodies, as represented by the numerous PML NBs during the G2 phase (Dellaire et
al., 2006b). In contrast, PML becomes dispersed throughout the cytoplasm during
mitosis, leading to the formation of PML aggregates termed mitotic accumulations
of PML protein (MAPPs) (Dellaire et al., 2006c). These, however, are unlike PML
NBs as they lack other NB components such as Sp100 and Daxx. Whether or not
these changes in PML organisation during mitosis have an active role in the process
is not known.
A subset of PML NBs co-localises with telomeric DNA and contains factors
required for the alternative lengthening of telomeres (ALT). Termed ALT-
associated PML NBs (APBs), they contain factors required for DNA repair as well
as telomeric repeat binding factors (TRFs) 1 and 2 (Jiang et al., 2007). It has thus
been proposed that PML plays a role in maintaining telomere length. PML III
directly binds to TRF1 and is required for the formation of APBs, but not PML NBs
(Yu et al., 2009). In contrast, PML IV has been shown to interact directly with the
telomere reverse transcriptase (TERT) and inhibit it (Oh et al., 2009), suggesting a
complex regulatory role of specific PML isoforms in this subset of PML bodies.
PML isoform-specific functions
Despite the implication of PML in numerous cellular processes, very little is known
about specific functions of individual isoforms. However, there are examples where
a single PML isoform has been demonstrated to perform a distinct function. PML
IV, for example, directly interacts with p53 (Fogal et al., 2000). This interaction is
mediated by the C-terminus of this isoform, and results in the recruitment of p53 to
PML NBs where it is activated. PML relocalisation to the cytoplasm is thought to
inhibit p53 activity (Bellodi et al., 2006). PML IV has been implicated in causing
premature senescence (Bischof et al., 2002), an activity which is independent of both
the sumoylation state of PML and the presence of PML NBs. Roles for other PML
isoforms, however, cannot be discounted, as PML IV was unable to induce
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senescence in cells a pml -/- genotype (Bischof et al., 2002). PML IV also binds the
oncoprotein Myc and induces its degradation, a function that is dependent on its
RING domain (Buschbeck et al., 2007). These observations, in combination with
the negative activity of PML IV on TERT (Oh et al., 2009), suggest that this isoform
has important roles in regulating apoptosis, differentiation and senescence.
Studies on PML III have revealed a possible role in the maintenance of the
centrosome (Xu et al., 2005). PML III was shown to associate with the centrosome
and to inhibit its duplication by inhibiting the Aurora A kinase, over-expression of
which leads to centrosome duplication. PML III co-precipitated with Aurora A, and
furthermore led to a decrease in the amount of its phosphorylated, active form (Xu et
al., 2005). This suggests that PML III may bind to and regulate the post-
translational modification of Aurora A, though it should be noted that during
subsequent studies by another group PML III was not observed to localise to the
centrosome (Condemine et al., 2006).
Recently, other roles of PML III have been described. The tumour suppressor TIP60
was found to bind a region specific to PML III, and this binding was sufficient to
inhibit its MDM2-mediated degradation (Wu et al., 2009). This prompted the
authors to speculate that PML III may compete with MDM2 for TIP60 binding.
Also, as mentioned above, a study by Yu and colleagues demonstrated that PML III
was crucial in the recruitment of telomeric repeat binding factor 1 (TRF1) to APBs.
It was therefore suggested that PML III may be required for the formation of this
particular subset of PML NBs (Yu et al., 2009).
Cytoplasmic PML (cPML) may also perform important roles in a number of cell
processes. For instance, a cytoplasmic PML IV variant lacking exons 5 an 6 is
required for efficient TGF-β signalling in mouse embryonic fibroblasts (MEFs) 
(Salomoni & Bellodi, 2007) Furthermore, nuclear sequestration of cPML results in
a decrease in TGF-β signalling, indicating that its activity may be modulated by its 
sub-cellular localisation (Salomoni & Bellodi, 2007).  TGF-β has roles in 
proliferation and apoptosis, and through regulating its activity, cPML may exert
effects on these processes independently of nuclear PML proteins. cPML has also
been shown to bind directly to and suppress the activity M2-type pyruvate kinase
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(PKM2), indicating a role in the regulation of glycolysis (Nobukazu et al., 2008).
However, the biological significance of this is unclear, as the cPML utilised was a
NLS mutant of full-length PML VI and not a cytoplasmic splice variant of PML.
1.3.5. Antiviral activity of PML and PML NBs
As well as the functions listed above, PML protein and PML NBs have been
extensively implicated in anti-viral functions. There are several lines of evidence to
support this hypothesis, though as yet the precise mechanism of this activity remains
unknown. The following sections summarise the evidence supporting an anti-viral
role for PML proteins. Particular emphasis is placed on documented virus-PML
interactions.
1.3.6. PML is induced by interferon
Pml is a primary target gene for interferon activation (i.e. it is an ISG) and has
therefore been implicated in performing antiviral functions. The first intron of the
pml gene contains both ISRE and GAS elements, responsive to type I (α and β) and 
type II (γ) interferons respectively.  Upon interferon treatment, PML transcription is 
up-regulated, resulting in an increase in both the size and number of PML NBs
(Lavau et al., 1995). As well as PML, other components of PML NBs are
themselves encoded by ISGs, providing further evidence of an antiviral role for these
structures. Sp100, for instance, is also up-regulated by type I and II interferons.
However, there is also evidence which suggests that PML may act in a negative
feedback mechanism to inhibit the IFN response. Choi et al discovered that, in
mouse embryonic fibroblasts, PML acts as an inhibitor of IFN γ signalling (Choi et
al., 2006). A comparison of PML -/- cells with PML +/+ cells revealed that PML
explicitly inhibited the DNA binding capacity of STAT-1α, thereby reducing the
induction of IFNγ genes (Choi et al., 2006) The mechanism through which PML
achieves this remains unclear, but it was suggested to be mediated by protein-protein
interactions. Interestingly, the PML isoforms examined (I, III, IV) all exhibited this
same activity, though to varying degrees, suggesting a role for the common N-
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terminal domain of PML.  IFNγ is a type II IFN, and so these results do not apply to 
type I IFN signalling.
1.3.7. PML is a TRIM protein
As mentioned above, the RBCC motif possessed by PML protein is a defining
characteristic of the TRIM family of proteins. At present, genes for over 65
members of this protein family have been identified within the human genome,
though many of these remain to be characterised (Nisole et al., 2005). The role of
individual TRIM proteins within the cell varies considerably, though there is
increasing evidence to suggest that a number of TRIM proteins perform anti-viral
duties (Nisole et al., 2005, Ozato et al., 2008). For example, TRIM5α acts as a
restriction factor against retrovirus replication through an as-yet unknown
mechanism (Towers, 2007).
This view of TRIM protein function has been strengthened by a recent study that
analysed global expression levels of TRIM proteins in response to interferons.
Carthagena et al demonstrated that, out of 72 TRIM proteins tested in two cell types,
24 were directly up-regulated by either type I or type II interferons, including PML
protein and TRIM5 (Carthagena et al., 2009). The activity of individual TRIM
proteins may vary depending on the host cell, since TRIM protein expression
patterns can vary according to the cell type (Rajsbaum et al., 2008).
1.3.8. Viral interactions with PML protein and PML NBs
Perhaps the most compelling line of evidence supporting an anti-viral role of PML
and/or PML NBs is that they are subject to targeting and disruption by a number of
viruses (Leppard & Dimmock, 2006). A variety of DNA and RNA viruses are
known to interact with PML NBs and PML protein, though often the functional
consequences remain elusive. Below is a summary of known virus-PML
interactions (Table 1.2).
Virus Effect on PML/PML NBs
Lymphocytic
choriomeningitis
virus
(LCMV)
Lassa Fever virus
(LFV)
Relocalisation of PML to the cytoplasm
Respiratory
syncytial virus
(RSV)
Relocalisation of PML and Sp100 to
cytoplasm
Influenza A
(FLUAV)
Viral proteins M1, NS1 and NS2 localise to
PML NBs
Viral replication suppressed by PML III, IV
and VI
Human foamy virus
(HFV)
Viral gene expression suppressed by PML III
Vesicular stomatitis
virus
(VSV)
Viral gene expression suppressed by PML III
Rabies virus
(RABV)
Increase in size of PML NBs
Hepres simplex
virus type 1
(HSV-1)
Desumoylation and degradation of PML
Infection leads to production of truncated
PML Ib
Herpes simplex
virus type 2
(HSV-2)
Decreases PML II:PML V ratio
Human
cytomegalovirus
(HCMV)
Desumoylation of PML and dispersal of
PML NBs
Epstein-Barr virus
(EBV)
Accumulation of Unsumoylated PML
Degradation of PML, possibly via PML IV
Human Papilloma
virus (HPV)
Degradation of PML IV
Modulation of PML IV activity
Adenovirus
(AdV)
Loss of sumoylated PML
Production of novel PML species
Rearrangement of PML NBs via PML II
Formation of inclusion bodiesTable 1.2 Interactions between viruses and PML NBs. Table summarising
known interactions between RNA and DNA viruses and PML proteins and PML40
NBs. Where known, the PML isoform responsible is indicated.
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RNA viruses
Proteins from several RNA viruses have been shown to interact with PML NBs, and
in some cases cause active disruption of these bodies. PML re-localisation to the
cytoplasm was observed during infection by the arenavirus lymphocytic
choriomeningitis virus (LCMV) (Borden et al., 1998). It was subsequently shown
that the arenavirus Z protein was responsible for this phenomenon, as the Z proteins
of both LCMV and Lassa fever virus (LFV) target PML NBs through a direct
interaction with PML, and subsequently cause its re-localisation to the cytoplasm
(Kentsis et al., 2001). Once there, PML directly interacts with the translation
initiation factor eIF4E and reduces its affinity for the 5’ cap of cellular mRNA
(Kentsis et al., 2001), thus contributing to translational shutoff during these viral
infections.
Redistribution of PML to the cytoplasm is also observed during infection with the
paramyxovirus respiratory syncytial virus (RSV). RSV replicates exclusively in the
cytoplasm. However, upon infection PML protein and the PML NB component
Sp100 both dissociate from PML NBs and re-localise to the cytoplasm and by 24
hours post infection exhibit a diffuse staining pattern (Brasier et al., 2004).
A number of proteins encoded by the orthomyxovirus influenza A virus co-localise
with PML NBs. During infection the M1, NS1 and NS2 proteins migrate to the
nucleus and associate with PML NBs, though the reason for doing so remains
unclear (Sato et al., 2003). Influenza A virus replication is significantly repressed by
over-expression of PML IV and PML VI, and correspondingly, depletion of the total
PML content leads to an enhancement in viral propagation (Iki et al., 2005). This
suggests that PML protein exerts an antiviral activity against influenza A. However,
there is evidence to suggest that the effectiveness of this antiviral activity varies
depending on the subtype of influenza A virus (Li et al., 2009). The mechanism
underlying this variation remains unknown.
The expression of PML III has been shown to exert an inhibitory effect on some
virus infections. Over-expression of PML III during human foamy virus (HFV)
infection led to a decrease in viral mRNA and proteins levels (Regad et al., 2001).
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PML III mediated this effect by binding and sequestering the viral transactivator Tas,
preventing it from activating viral gene expression. Interferon-mediated inhibition
of HFV was also found to act in a PML-dependent manner, as IFN treatment of
wild-type, but not pml -/- cells, led to suppression of viral replication (Regad et al.,
2001). Both influenza A and the rhabdovirus vesicular stomatitis virus (VSV) also
showed markedly reduced viral titres in cells over-expressing PML III (Chelbi-Alix
et al., 1998). However, PML III over-expression had no effect on the replication of
the picornavirus encephalomyocarditis virus (EMCV) (Chelbi-Alix et al., 1998), or
rabies virus, a rhabdovirus (Chelbi-Alix et al., 2006). It should be noted though that
the rabies virus P protein does interact with PML NBs, causing them to increase in
size (Chelbi-Alix et al., 2006), and is also responsible for this virus overcoming the
IFN response (Chelbi-Alix et al., 2006).
PML protein is also implicated in the replication of poliovirus, albeit in a p53-
dependent manner. p53 exerts an antiviral effect on viral replication which requires
the presence of PML protein (Pampin et al., 2006). Upon poliovirus infection, PML
NBs become larger due to an influx of nucleoplasmic PML. PML proteins are then
phosphorylated by the mitogen activated protein kinase ERK, leading to their
subsequent sumoylation. This leads rapidly to p53 recruitment to PML NBs and its
activation in order to perform its pro-apoptotic functions. Poliovirus counters this by
initiating the degradation of p53 in a manner that is partly dependent on MDM2
(Pampin et al., 2006).
DNA viruses
The most intensive study of PML-virus interactions has been performed in the
context of infection by DNA viruses. Replication of a number of DNA viruses is
closely associated with PML NBs, and often leads to their disruption. Furthermore,
PML NBs have been strongly implicated in performing anti-viral functions against
these viruses (Everett, 2001, Everett, 2006).
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Herpes simplex virus type I and 2 (HSV-1, HSV-2)
The most intensively-studied example of virus-PML interactions is that observed
during the course of infection by the alphaherpesvirus HSV-1. Upon infection, new
PML NBs are formed around incoming viral DNA (Everett & Murray, 2005),
adjacent to which a number HSV-1 proteins accumulate, such as ICP4, VP13/14 and
VP22. The most dramatic association, however, occurs upon localisation of ICP0 to
PML NBs. After localisation to PML NBs, ICP0 initiates the desumoylation of
SUMO-1 modified PML proteins, resulting in their subsequent dispersal and
proteasome-mediated degradation (Everett et al., 1998), an action dependent on the
function of ICP0 as an E3 ubiquitin ligase (Boutell et al., 2002). Other PML NB-
associated proteins, such as Sp100, are also degraded in this manner. This precedes
the onset of viral DNA replication. ICP0 stimulates lytic infection and this ability
correlates with the dispersal of PML NBs. However, later in infection PML protein
is recruited into replication centres by the viral polymerase, suggesting that the role
PML in HSV-1 infection may include functions other than its antiviral activity
(Burkham et al., 1998).
There is compelling evidence that suggests that ICP0-mediated disruption of PML
NBs is closely linked to overcoming cellular antiviral responses. For instance,
unlike wild-type virus, ICP0-deficient HSV-1 viruses are sensitive to interferon and
grow to lower titres in mice (Everett et al., 2006, Leib et al., 1999, Mossman et al.,
2000). This growth defect was partially corrected in transgenic mice defective in
IFN I signalling (Leib et al., 1999). It was subsequently shown that ICP0 is required
by HSV-1 to overcome IFN responses (Härle et al., 2002, Mossman et al., 2000).
Both wild-type and ICP0 mutant viruses grew to similar titres in pml +/+ and pml -/-
mouse embryonic fibroblasts (MEFs) (Chee et al., 2003). However, interferon
treatment considerably reduces ICP0 mutant replication in pml +/+ MEFs, whilst
having no effect in pml -/- MEFs. This suggests that the ability of IFN to affect
HSV-1 replication is dependent on the PML protein. However, in human fibroblasts
(HFs) depleted of PML, both wild-type and ICP0-deficient HSV-1 remained
sensitive to IFN-β, though to a much lesser extent than that observed in HFs 
containing normal levels of PML (Everett et al., 2008). The mechanism whereby
ICP0 overcomes the IFN response is still unclear, as there are contrasting reports as
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to whether it can mitigate IFN signalling pathway and inhibit the expression of ISGs.
Initial reports found that ICP0 inhibited the activity of both IRF3 and IRF7, leading
to a decrease in the expression of ISGs (Lin et al., 2004). However, Everett and
colleagues subsequently found that the growth of ICP0-deficient mutants was not
improved in IRF3-deficient HFs (Everett et al., 2008), and that ICP0 did not
interfere with the IRF3-dependent induction of ISGs (Everett & Orr, 2009).
PML knock-down also has no effect on HSV-1 replication, though does result in an
increase in viral gene expression of ICP0 mutant HSV-1 (Everett et al., 2006),
offering a possible explanation for earlier observations where IFN treatment
repressed viral gene expression (Taylor et al., 2000). Over-expression of a subset of
PML isoforms (III, IV and VI), however, had no effect on virus replication, possibly
indicating a role for alternative isoforms in inhibiting HSV-1 replication (Tavalai &
Stamminger, 2008).
Recent work by McNally has indicated that upon infection with HSV-1, the ratio of
cytoplasmic PML proteins is increased amongst the PML population (McNally et al.,
2008). A novel cytoplasmic variant, termed PML Ib, which lack exons 5 and 6 and
possesses a stop codon in exon 7a, was demonstrated to exert a strong antiviral
activity against HSV-1. Cells over-expressing the variant displayed reduced
expression of ICP0 and Us11 proteins and viral titres were reduced by approximately
10-fold. In contrast, expression of full-length, nuclear PML I had no effect.
Interestingly, PML Ib appears to exert its effect through ICP0 by sequestering it
within the cytoplasm, thereby reducing expression of viral genes because PML NB
disruption is impaired (McNally et al., 2008).
Herpes simplex type 2 (HSV-2) also alters the relative ratio of PML isoforms. Upon
infection, the ratio of PML V to PML II transcripts is increased (Nojima et al.,
2009). The viral protein responsible for this was ICP27, which was shown to bind
PML pre-mRNA and inhibits splicing from the 3’ splice site of exon 7a, resulting in
intron retention and read-through to exon 7. The reason why the virus promotes this
isoform switching remains unclear, as over-expression of PML II was found
paradoxically to enhance viral replication (Nojima et al., 2009). The authors
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suggested that this may be a mechanism employed by the virus to favour a persistent
infection.
Human cytomegalovirus (HCMV)
In the case of HCMV, a betaherpesvirus, PML NBs exert a repressive effect on viral
gene activity. For instance, the PML NB component Daxx has been shown to alter
the chromatin structure of the viral major immediate early promoter (MIEP) into a
repressive state, an activity dependent on histone deacetylases (HDACs) (Saffert &
Kalejta, 2006). In order to overcome this, the viral protein pp71, a tegument protein
found in the incoming particle, migrates to the nucleus and localises to PML NBs via
a direct interaction with Daxx (Cantrell & Bresnahan, 2006, Saffert & Kalejta,
2006). pp71 then initiates the degradation of Daxx and thus relieves repression of
the MIEP. Indeed, siRNA-mediated knockdown of Daxx can complement the
growth defect of pp71-deficient virus and enhance wild-type virus titres, whereas
Daxx over-expression had the opposite effect (Saffert & Kalejta, 2006). PML NB
disruption also occurs during HCMV infection, and is maintained by the viral IE1
protein, which initiates the desumoylation and degradation of PML in a manner
independent of the proteasome, and hence causes the dispersal of PML NBs (Xu et
al., 2001). Knock-down of PML proteins can complement the growth of IE1-
deficient mutants, emphasising the importance of PML NBs in the limitation of virus
replication (Tavalai et al., 2006).
Other DNA viruses
Epstein-Barr virus (EBV), a gammaherpesvirus, BZLF-1 protein has been shown to
localise to PML NB and consequently to facilitate their dispersal through the
desumoylation of PML. Interestingly, the mechanism employed by EBV differs
from that of HSV-1 and HCMV as BZLF-1 is itself sumoylated, and is thought to
out-compete PML for SUMO binding (Adamson & Kenney, 2001). Unsumoylated
PML therefore accumulates, and PML NBs disintegrate into the nucleoplasm. The
ability of BZLF-1 to disperse PML NBs correlates with its ability to activate viral
gene transcription, thus further suggesting that PML NBs act to repress viral gene
expression (Adamson & Kenney, 2001). Whilst BZLF-1 is the key initiator of the
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cascade of EBV lytic gene expression, over-expression of the EBNA-1 protein,
which is expressed in latently infected cells, also led to the disruption of PML
nuclear bodies and a decrease in cellular PML protein levels, which was found to be
dependent on the cellular ubiquitin-specific protease USP-7 (Sivachandran et al.,
2008). EBNA-1 was found to preferentially bind PML IV, indicating that it is
through this interaction whereby PML disruption occurs (Sivachandran et al., 2008).
A number of proteins encoded by human papilloma virus (HPV) have been
associated with PML NBs. The E6 proteins of HPV-11 and HPV-18 were
demonstrated to co-localise with PMLs I-IV (Guccione et al., 2004). Subsequent
experiments showed that the E6 proteins of both virus subtypes interacted with
PMLs I, II and IV. The E6 protein of HPV-18, but not HPV-11, induced the
proteasome-mediated degradation of PML IV, thereby inhibiting its ability to induce
senescence (Guccione et al., 2004). The HPV-16 E7 protein was also found to
overcome PML-IV induced senescence by inhibiting its ability to activate p53
(Bischof et al., 2005).
Upon over-expression, the HPV L2 capsid protein has also been demonstrated to
associate with PML NBs through an interaction with Daxx (Day et al., 1998, Florin
et al., 2002, Heino et al., 2000). L2 expression causes disruption to PML NBs by
causing a decrease in levels of Sp100 (Florin et al., 2002). Depletion of Sp100
coincides with the recruitment of another capsid protein, L1, and viral protein E2 to
PML NBs. L2 association with PML has therefore been proposed to facilitate viral
assembly, though upon lower levels of expression, L2 only seldom associates with
PML NBs (Kieback & Müller, 2006). The significance of L2-mediated disruption of
PML NBs therefore remains unclear.
Adenovirus (Ad)
PML NBs become disrupted in a unique fashion during the early phase of infection
with Ad5. Carvalho et al first observed that upon infection PML NBs were
redistributed from their native spherical structures into elongated ‘tracks’ (Carvalho
et al., 1995). Through the use of transient over-expression of individual proteins and
viral mutants, this redistribution of PML NBs was found to be dependent on the viral
early gene product E4 Orf3 (Carvalho et al., 1995, Doucas et al., 1996); this function
was conserved across a variety of Ad subtypes (Stracker et al., 2005). Indeed, E4
Orf3 has subsequently been shown to directly interact with the C-terminal domain of
PML isoform II, and it is through this interaction whereby PML NBs become
redistributed (Hoppe et al., 2006, Leppard et al., 2009).
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EFigure 1.4. Ad5 infection results in reorganisation of PML NBs into tracks.
HEp-2 cells were mock-infected or infected with the Ad5 viruses indicated for
18 hours before being fixed and probed with an anti-PML antibody and
visualised by confocal microscopy. Images reflect a series of images through the
Z-axis. In mock-infected cells (left panel) PML NBs exhibit a spherical
appearance that becomes altered upon infection with wild-type Ad5 (centre
panel). In contrast, an Ad5 mutant unable to express E4 Orf3 does not
reorganise PML NBs, demonstrating the requirement for this protein in this
process. Scale bar - 8µm.47
nterestingly, E4 Orf3 also exerts two distinct effects on the PML protein population.
eppard and Everett reported that in the later phases of infection with wild-type Ad5,
igher molecular weight sumoylated PMLs were lost, and this coincided with the
ppearance of a novel, infection-specific species of PML (Leppard & Everett, 1999).
y 24 hours of infection, sumoylated PMLs were barely detectable by western blot
nd the novel species of PML was now amongst the most dominant species.
nfection with a virus mutant incapable of producing E4 Orf3 failed to cause either
oss of sumoylated PMLs or the appearance of this novel PML species (Leppard &
verett, 1999). Intriguingly, the novel species of PML was very similar to a mitosis-
48
specific species of PML previously observed by Everett and colleagues, which was
shown to be a phosphorylated species (Everett et al., 1999).
The role of PML NB disruption during the course of Ad5 infection remains elusive,
though there is evidence to suggest it may mitigate a cellular antiviral response.
(Ullman et al., 2007). In cells pre-treated with IFN α or γ, E4 Orf3-mutant Ad5 
replication was reduced 15-20 fold compared to untreated cells, in contrast to the
minimal effect of IFN on the replication of wild-type virus. The ability of E4 Orf3
to overcome the antiviral state induced by interferon correlated with its ability to
rearrange PML NBs, but not with its ability to disrupt the MRN complex (Ullman et
al., 2007). Ullman then went on to demonstrate that depletion of PML by shRNA
could restore the growth of the E4 Orf3 mutant virus in cells pre-treated with IFN
(Ullman & Hearing, 2008). Interestingly, depletion of Daxx, but not Sp100 also
restored the growth of the E4 Orf3 mutant. Finally, expression of HSV-1 ICP0 and
HCMV IE72, two other viral proteins known to disrupt PML NBs (as discussed
above), restored the growth E4 Orf3 mutant Ad5 in IFN-treated cells (Ullman &
Hearing, 2008). Therefore there is strong evidence that E4 Orf3-mediated disruption
of PML NBs is a mechanism employed by Ad5 to overcome cellular antiviral
activities that are performed by PML NBs or their components.
At later time points during Ad5 infection other viral proteins begin to associate with
PML NBs. Protein IX localises to PML NBs and forms ‘amorphous inclusion
bodies’, and it has been proposed that protein IX may act to maintain the disruption
of PML NBs, caused initially by E4 Orf3, throughout the later phases of infection
when Orf3 expression wanes (Rosa-Calatrava, 2003). Furthermore, impairing the
ability of pIX to form the inclusions resulted in reduced viral yields, suggesting this
to be a mechanism important for the viral life cycle (Rosa-Calatrava, 2003).
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In summary, there is much evidence implicating PML proteins as important
mediators of the IFN response, and a large number of viruses selectively disrupt
PML protein or PML NBs, including Ad5. Taken together, these facts strongly
suggest an anti-viral role of PML proteins, though how PML proteins achieve this
remains incompletely understood. As well as inducing the reorganisation of PML
NBs into tracks, Ad5 infection leads to the production of a novel, as yet unidentified,
species of PML protein through an unknown mechanism. The production of such a
species is likely a reflection of the diversity of PML proteins that may be generated
by differential splicing and post-translational modifications. The functional
significance of the production of this species, as well as PML NB rearrangement, by
Ad5 remains unclear, though these effects may form part of a strategy employed by
Ad5 to overcome antiviral responses.
Study Aims
This study seeks to expand on the knowledge of Ad5-PML interactions, particularly
by identifying PML isoforms that may be altered upon infection. In parallel, the role
of individual PML isoforms in the type I IFN pathway is investigated, with an
ultimate goal of establishing the functional significance of Ad5-induced changes in
the PML population to overcoming innate immune responses. The aims can
therefore be stated as:
1. To investigate changes in the PML protein population induced upon Ad5
infection and to characterise such changes by identifying both the Ad5
proteins and PML isoforms responsible, as well as any relevant post-
translational modifications that may be involved.
2. To examine the roles played by individual PML isoforms in the type I IFN
signalling pathway and, if possible, reconcile this with the changes in PML
imposed by Ad5 infection.
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Chapter 2
Materials and Methods
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2.1 Materials
The following section lists the entire collection of virus strains, cell lines, bacterial
strains and additional materials that were utilised during the course of this study.
Table 2.1 Bacterial strains used during the course of this investigation
Escherichia coli strain Phenotype
TG2 K12, lac-pro supE thi hsdD5 (F’
traD36 proA+B+ laclq lacZ M15)
recA::Tn10
DH5α supE44, ΔlacU169(φ80lacZΔM15), 
hsdR17, recA1, endA1, gyrA96, thi-1,
relA1
Table 2.2 Adenovirus strains used during the course of this investigation
Strain Phenotype
wt300 Wild type (Jones & Shenk, 1978)
inOrf3 E4 frame-shift insertion (300 background) (Huang & Hearing, 1989)
Table 2.3 Cell lines used during the course of this investigation
Cell Line Origin
A549 Human lung carcinoma (Giard, 1973)
HEK293 Human embryonic kidney (Graham et
al., 1977)
HEp2 Human epidermoid carcinoma (Moore
et al., 1955)
U2OS Human osteosarcoma (Ponten, 1967)
MRC5 Normal diploid human lung fibroblasts
(Jacobs J.P., 1970)
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Table 2.4 List of primers used during the course of this study.
Primer name Forward (F)
Reverse (R)
Sequence 5’-3’ Application/
Description
Exon 5 F CCATCAAAGGCCCTTCCTATGGAG PCR
Corresponds to PML exon 5
Exon 1 UTR F AGCTTCTCTTCACGCACTCC PCR
Corresponds to 5’ UTR of
cellular PML mRNA
transcript
Exon 3-7a F CAGGGGAAAGAGGAACGCGTTGTG PCR Mutagenesis
Overlaps PML exon 3/exon 7a
junction
Exon 4-6 F GTTGACCTGGATGTCTCCAATACA PCR Mutagenesis
Overlaps PML exon 4/ exon 6
junction
Exon 6-4 R GGAGACATCCAGGTCAACGTCAAT PCR Mutagenesis
Overlaps PML exon 6/ exon 4
junction
Exon 7a-3 R GCGTTCCTCTTTCCCCTGGGTGAT PCR Mutagenesis
Overlaps PML exon 7a/exon 3
junction
FaltPML F TGCCACCATGGATTACAAGG PCR Mutagenesis
Corresponds FLAG sequence
of pCI-neo PML I-VI
Exon 3 (1) F TGCTGGACATGCACGGTTTC PCR
Corresponds to PML exon 3
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Primer name Forward (F)
Reverse (R)
Sequence 5’-3’ Application/
Description
Exon 3 (2) F CTTGCATCACCCAGGGGAAA PCR
Corresponds to PML exon 3
(McNally et al., 2008)
Orf4 Forward F GGATATCGCCACCATGGTTCTTCCAGCTCTTC
C
PCR
E4 Orf4 coding sequence
Orf4 Reverse R GGGATCCCTACTGTACGGAGTGCGCCG PCR
E4 Orf4 coding sequence
PML I Epitope R GCAAGTGGGGTGGAGACTC RT-PCR
Corresponds to epitope of
anti-PML I monospecific anti-
peptide serum
PML II Epitope R ATCGCACAGCCCCTCGTATC RT-PCR
Corresponds to epitope of
anti-PML II monospecific
anti-peptide serum
SB02 R GTCTGCTCGAAGCATTAAC PCR Mutagenesis
Universal flanking primer
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Table 2.5 List of short interfering RNAs used during the course of this study
siRNA Sense 5’-3’ Antisense 5’-3’ Description
Scramble
siRNA
GAGCCGGACGCCAAAGAAAUU UUUCUUUGGCGUCCGGCUCUU Control siRNA with no sequence
similarity to any Homo sapiens
coding sequence, according to the
Ambion siRNA Target Finder
(Ambion website).
siPML exon 3 GAGCUCAAGUGCGACAUCAUU UGAUGUCGCACUUGAGCUCUU Sequence corresponding to a
region within exon 3 of PML
mRNA
siPML exon 5 CGACAGCCCAGAAGAGGAATT UUCCUCUUCUGGGCUGUCGTT Sequence corresponding to a
region within exon 5 of PML
mRNA
siPML I CGUGAGCUUCAUGGAGCUGUU CAGCUCCAUGAAGCUCACGUU Sequence corresponding to a
region within exon 9 of PML I
mRNA
siPML II CAUCCUGCCCAGCUGCAAAUU UUUGCAGCUGGGCAGGAUGUU Sequence corresponding to a
region within exon 7b of PML II
mRNA
siPML V GUUCAGCCCAGGACUCCUGUU CAGGAGUCCUGGGCUGAACUU Sequence corresponding to a
region within exon 7 of PML V
mRNA
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Table 2.6 Expression plasmids used during the course of this study
Plasmid Description
pCI-neo FLAG-
PML I-VI
Expression plasmid for each of PML isoforms I-VI that are
tagged with a FLAG epitope sequence (MDYKDDDDK)
upstream of the PML translation initiation codon. Gene
expression is initiated by the human cytomegalovirus (CMV)
immediate-early/enhancer region. Constructed by K.J.
Lethbridge and N. Killick (Beech et al., 2005, Guccione et al.,
2004)
pCI-neo FLAG-
PML ΔRBCC I-
VI
As pCI-neo FLAG-PML I-VI, though the sequence from
codon position 1-360 of each PML isoform has been deleted
by one step PCR. The deleted sequence corresponds to exons
1 and 2, and also the majority of exon 3 and therefore removes
the RBCC motif.
pCI-neo FLAG-
PML ΔExon5 I-V 
As pCI-neo FLAG-PML I-V, though the sequence
corresponding to exon 5 of each PML isoform has been
deleted by two-step PCR.
pCI-neo FLAG-
PML I-V
cytoplasmic
As pCI-neo FLAG-PML I-V, though the sequence
corresponding to PML exons 4, 5 and 6 of each PML isoform
has been deleted by two-step PCR
pCI-neo FLAG-
PML II ΔRΔ1 
As pCI-neo FLAG-PML IIΔRBCC, though amino acid 
residues 615 through to 684 of the PML II C-terminal domain
have been deleted (Leppard et al., 2009)
pCI-neo FLAG-
PML II ΔRΔ2 
As pCI-neo FLAG-PML IIΔRBCC, though amino acid 
residues 685 through to 758 of the PML II C-terminal domain
have been deleted (Leppard et al., 2009)
pCI-neo FLAG-
PML II ΔRΔ3 
As pCI-neo FLAG-PML IIΔRBCC, though amino acid 
residues 759 through to 800 of the PML II C-terminal domain
have been deleted (Leppard et al., 2009)
pCI-neo FLAG-
PML II ΔRΔ4 
As pCI-neo FLAG-PML IIΔRBCC, though amino acid 
residues 801 through to 829 of the PML II C-terminal domain
have been deleted (Leppard et al., 2009)
pCMV-IX Ad5 pIX expression plasmid driven by the CMV IE
enhancer/promoter region (Caravokyri & Leppard, 1995).
pcDNA3.1-orf4 E4 Orf4 was amplified from wild-type Ad5 genomic DNA
using PCR, and restriction digested before ligation into the
EcoRV/BamHI site of pcDNA3.1(-).(Invitrogen)
pcDNA3.1-orf3 Ad5 wild-type E4 Orf3 expression plasmid (Hoppe et al.,
2006)
pcDNA3.1-N82A Ad5 E4 Orf3 N82A mutant expression plasmid (Hoppe et al.,
2006)
pRL-TK A low to moderate constitutive expression plasmid encoding
the Renilla reniformis luciferase. Expression is driven by the
HSV thymidine kinase (TK) promoter (Promega E2241).
pISRE-Luc Luciferase reporter plasmid of the Interferon-stimulated
response element (ISRE). Five copies of an ISRE lie
upstream of the firefly luciferase gene. Provided by David
Blackbourn, University of Birmingham. (Stratagene).
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Plasmid Description
pIFNβ-Luc Luciferase reporter plasmid of the Homo sapiens interferon β 
promoter. The promoter lies upstream of the firefly luciferase
gene. Provided by Tony Marriot, University of Warwick.
(King & Goodbourn, 1994).
pcDNA3.1-
HisB::lacZ
β-galactosidase expression plasmid.  Driven by the CMV IE 
promoter region. A poly-histidine region is located upstream
of the lacZ open reading frame (Invitrogen).
pCMV-
22KFLAG
Ad5 L4 22K expression plasmid. A FLAG epitope is
adjoined to the C-terminus of 22K (Morris & Leppard, 2009).
pCMV-
33KFLAG
Ad5 L4 33K expression plasmid. A FLAG epitope is
adjoined to the C-terminus of 33K (Morris & Leppard, 2009).
pCMV-
22/33KFLAG
Ad5 expression plasmid that expresses both L4 22K and L4
33K. A FLAG epitope is adjoined to the C-terminus of 33K
(Morris & Leppard, 2009).
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Table 2.7 List of primary antibodies used during the course of this study
Antibody/
Protein
Detected
Details/Reference Dilution
Western Blotting Immuno-fluorescence
Mouse anti-
FLAG
epitope
Monoclonal
F3165
Sigma-Aldrich
1/100000 1/500
Rabbit anti-
FLAG
epitope
Polyclonal
F7425
Sigma-Aldrich
1/100000 1/500
Mouse anti-
PML
Monoclonal
5E10 (Stuurman et
al., 1992)
1/20 NA
Mouse anti-
PML
Monoclonal
PG-M3
Santa Cruz
Biotechnology
1/250 NA
Rabbit anti-
PML
Polyclonal
Chang (Xu et al.,
2003)
1/64000 NA
Rabbit anti-
PML I
Rabbit mono-
specific
Chang (Xu et al.,
2003)
1/4000 NA
Rabbit anti-
PML II
Rabbit mono-
specific
Chang (Xu et al.,
2003)
1/4000 NA
Rabbit anti-
PML III
Rabbit mono-
specific
Chang (Xu et al.,
2003)
1/4000 NA
Rabbit anti-
IRF3
Polyclonal FL-425
Santa Cruz
Biotechnology
1/500 1/250
Rabbit anti-
PML IV
Rabbit mono-
specific
Chang (Xu et al.,
2003)
1/4000 NA
Rabbit anti-
PML V
Rabbit mono-
specific
Chang (Xu et al.,
2003)
1/4000 NA
Rat anti-E4
Orf3
Monoclonal
6A11
T. Dobner; (Nevels
et al., 1999)
1/500 1/40
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Antibody/
Protein
detected
Details/Reference Dilution
Western
Blotting
Immuno-Fluorescence
Rabbit anti-
p53
Polyclonal FL-393
Santa Cruz
Biotechnology
1/10000 NA
Rabbit anti-
E4 Orf4
Rabbit mono-
specific
(Shtrichman &
Kleinberger, 1998)
1/3000 NA
Rabbit anti-
pIX
Polyclonal
(Caravokyri &
Leppard, 1995)
1/5000 NA
Rabbit anti-
Late
Polyclonal (Farley et
al., 2004)
1/10000 NA
Mouse anti-
GAPDH
Monoclonal AB9484
Abcam
1/10000 NA
Mouse anti-
DBP B6-8
Monoclonal
(Reich et al., 1983)
1/5000 1/200
Table 2.8 List of secondary antibodies used during the course of this study
Antibody Details/Supplier Dilution
Western
Blotting
Immuno-fluorescence
Goat anti-
Mouse
Horseradish peroxidase
conjugate
Sigma-Aldrich
1/100000 NA
Goat anti-
Rabbit
Horseradish peroxidase
conjugate
Santa Cruz
Biotechnology
1/100000 NA
Goat anti-
Rat
Horseradish peroxidase
conjugate
Chemicon International
1/5000 NA
Goat anti-
Mouse
Alexa488
Santa Cruz
Biotechnology
NA 1/500
Goat anti-
Rabbit
Alexa594
Santa Cruz
Biotechnology
NA 1/500
Goat anti-
Rat
Alexa 546
Santa Cruz
Biotechnology
NA 1/500
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Table 2.9 List of suppliers used during the course of this study
Supplier
Address
Ambion 2130 Woodward St.
Austin, TX 78744-1832 USA
Applied Biosystems 2130 Woodward St.
Austin, TX 78744-1832 USA
Fermentas Opelstrasse 9
68789 St. Leon-Rot Germany
Invitrogen 5791 Van Allen Way
Carlsbad, California 92008 USA
Gibco 5791 Van Allen Way
Carlsbad, California 92008 USA
Sigma-Aldrich Sigma-Aldrich Company Ltd.
Dorset, U.K.
Promega Delta House
Southampton Science Park
Southampton, U.K.
Biorad Bio-Rad Laboratories Ltd.
Bio-Rad House
Maxted Road
Hemel Hempstead, U.K.
Greiner Bio-one Greiner Bio-One Ltd. Brunel Way,
Stroudwater Business Park
U.K.
Melford Laboratories Ltd Melford Laboratories Ltd.
Bildeston Road
Ipswich, U.K.
Calbiochem Boulevard Industrial Park
Padge Road, Beeston
Nottingham, U.K.
Santa-Cruz Biotechnology Santa Cruz, Inc.
Bergheimer Str. 89-2
69115 Heidelberg, Germany
Falcon Falcon Laboratories Inc
1305 Pecan St.
Colorado Springs, USA
Eppendorf Endurance House
Vision Park
Chivers Way
U.K.
AFGA Agfa-Gevaert N.V.
Septestraat 27
B-2640 Mortsel Belgium
Fisher scientific Bishop Meadow Road,
Loughborough, Leicestershire, U.K.
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Integrated DNA technologies Integrated DNA Technologies, Inc.
1710 Commercial Park
Coralville, Iowa 52241 USA
GE Healthcare Pollards Wood
Nightingales Lane
Chalfont St Giles U.K.
Fuji St. Martins Business Center, St.
Martins Way, Bedford MK42 0LF,
U.K.
Chemicon International Suite 3 & 5
Building 6
Croxley Green Business Park U.K.
Thermo scientific Thermo Fisher Scientific Inc.
81 Wyman Street
Waltham, MA 02454
Stratagene 11011 N. Torrey Pines Road
La Jolla, CA 92037
Abcam 330 Cambridge Science Park
Cambridge
CB4 0FL, UK
2.2 Methods
2.21 Manipulation of DNA
Polymerase Chain Reaction (PCR)
PCR amplifications were carried out in a total volume of 25µl in 0.5ml
microcentrifuge tubes using an Eppendorf Mastercycler Gradient thermocycler.
Typically 50ng of template DNA was used per reaction. Alongside template DNA,
the reaction mix would consist of 0.4µM of each primer, 0.2µM of each dNTP, 1X
Buffer and 1.25 units Taq polymerase (Fermentas). Unless otherwise stated, the
MgCl2 concentration was kept constant at 2mM and reactions were cycled as
follows: 95oC for 1 min, 29 cycles 94oC for 1 min, 60-66oC for 1 min and 72oC for 2
mins. This was followed by 72oC for 15 mins. The annealing temperature was
varied depending on the primer pair being used in order to reduce non-specific
amplification.
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Colony screen PCR
For screening bacterial colonies for plasmid inserts, PCR reaction mixes were
prepared as described above. As a source of template DNA, bacterial colonies to be
screened were picked with a sterile pipette tip which was then briefly inserted into
the reaction mixture, then scraped onto a master plate. The reaction mixes were
heated to 95oC for 3 mins to ensure bacterial cell lysis, and the reaction was then
performed as described above. After analysis, positive clones were identified and
the corresponding colonies on the master plate were cultured.
Two-step PCR mutagenesis to generate alternative splice variants of PML
isoforms
All PCR mutagenesis performed in this study utilised Pfu polymerase (Fermentas)
rather than Taq polymerase. According to the manufacturer’s instructions, MgSO4
was used instead of MgCl2 as a source of magnesium. 50ng of template DNA was
used in a total reaction volume of 50µl for each primary amplification. The
thermocycle was as follows: 6 cycles of (94oC 1 min, 52oC 1 min, 72oC 5 mins),
followed by 29 cycles of (94oC 1 min, 61.5oC 1 min, 72oC 5 mins) before a final
incubation of 15 mins at 72oC. The sample was then analysed by agarose gel
electrophoresis, and the correct band excised from the gel and purified using a GFX
PCR DNA and gel band purification kit (GE Healthcare) according to the
manufacturer’s instructions.
For the second round of amplification, pairs of products generated during the
primary round of amplification that possessed complementary sequences at their
ends served as a template. 25ng of each template molecule was used to give a total
of 50ng of template DNA per 50µl reaction. The thermocycle was initially
performed in the absence of primers so as to allow the complementary sequences
between template molecules to hybridise and initiate synthesis of full-length
template molecule. The cycle was as follows: 6 cycles of (94oC 1 min, 54oC 1 min,
72oC 5 mins), primers were then added and followed by 29 cycles of (94oC 1 min,
61.5oC 1 min, 72oC 5 mins) and finally 72oC for 15 mins.
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The product from the second round PCR was analysed by agarose gel electrophoresis
and the band corresponding to the correct size was excised and purified using a GFX
PCR DNA and gel band purification kit. The product was then ready for use in
subsequent applications.
Restriction enzyme digestion
Typically up to 1g of plasmid DNA was digested in a total reaction volume of 25-
50l. Restriction enzymes were used according to the manufacturer’s instructions in
the reaction buffer recommended by the manufacturer. In reactions involving
multiple restriction enzymes, the reaction buffer used was the most optimal for all
enzymes. Where this was not possible sequential digestion reactions were
performed, with the DNA being purified after each reaction with a GFX PCR DNA
and gel band purification kit according to the manufacturer’s instructions. Reactions
were inactivated by being heated to 70oC for 10 mins.
Removal of 5’ phosphate groups from DNA
Typically 1µg of linear vector DNA was dephosphorylated with FastAP™
Thermosensitive Alkaline Phosphatase (Fermentas) according to the manufacturer’s
instructions. Phosphatase activity was destroyed by incubating the DNA at 75oC for
10 mins.
DNA ligation
Ligation of DNA molecules was typically performed in a reaction volume of 10-
20l. A 3:1 molar ratio of insert DNA to vector DNA was typically used. T4 DNA
ligase was used according to the manufacturer’s instructions and reactions were
performed in the supplied buffer. Reactions were performed at 16oC for 16h.
Agarose gel electrophoresis of DNA
DNA molecules were typically separated by electrophoresis on 0.7-1.2% (w/v)
agarose in 1X TBE containing 0.5g/ml ethidium bromide. DNA fragments were
loaded onto the gel in 1X loading buffer (5% (w/v) glycerol, 0.04% (w/v)
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bromophenol blue and 0.04% (w/v) xylene cyanol). Electrophoresis was performed
in 1X TBE at 60-120V for 0.5-1h. DNA fragments were visualised under UV light
and imaged using a BioRad Gel/Chemi Doc system and the supplied software.
Extraction of DNA from agarose gels
DNA fragments of interest were visualised with UV then excised from the gel using
a clean scalpel. The DNA was cleaned and extracted from the agarose using a GFX
PCR DNA and gel band extraction kit according to the manufacturer’s instructions.
DNA Sequencing
All DNA sequencing was performed in-house by the Molecular Biology Service at
the University of Warwick using an automated ABI PRISM 3130xl Genetic
Analyser.
2.22 Manipulation of RNA
Extraction of cytoplasmic RNA from cultured HEp-2 cells
Each RNA sample was typically extracted from three 90mm dishes of 80-90%
confluent cells. Each dish was washed twice in 3ml of sterile PBS. Cells were then
scraped off the dish in 5ml of sterile PBS using a sterile cell scraper. The cell
suspension of each dish was then transferred to a 15ml Falcon centrifuge tube. Cells
were then collected by centrifugation (Beckman Coulter AllegraTM X-12R
Centrifuge) at 1300 r.p.m. for 3 mins, and the supernatant was discarded. The pellet
was resuspended in 1.5ml of pre-cooled 1X TBS (50mM Tris, 150mM NaCl,
pH7.6). 75l of 10% NP40 in 1X TBS (Sigma) was added to the cell suspension and
the cells were then vortexed and left on ice for 10 mins. The cytoplasmic fraction
was then prepared by centrifugation at 1500 r.p.m. for 5 mins at 4oC. 100l of
supernatant was then removed for use in SDS-PAGE, and the remaining cytoplasmic
fraction was then dispensed into three 1.5ml micro-centrifuge tubes for RNA
preparation. The pelleted nuclei were then resuspended in 2 ml 1 X TBS, treated
with 100l 10% NP40 and 50l 10% sodium deoxycholate (Sigma), vortexed then
64
centrifuged again at 1500 r.p.m. for 5 mins at 4oC to collect clean nuclei. Nuclei
were then lysed in an appropriate volume of 1X sample buffer for use in SDS-
PAGE.
Each micro centrifuge tube containing the cytoplasmic supernatant was treated with
500l of TRI Reagent (Sigma) and left at room temperature for 1h. 67l of
chloroform was added to each tube and was mixed by inversion. The tubes were
then centrifuged at 13, 200 r.p.m. for 15 mins in a micro centrifuge. The upper,
aqueous phase of each tube was then removed and placed into a fresh 1.5ml micro
centrifuge tube, with care being taken not to disrupt the lower phases. 500l of
isopropanol was then added to each aqueous phase and was placed at –20oC for at
least 1h. When RNA was needed, the tubes were centrifuged at 13200 r.p.m. for 15
mins and the supernatant was discarded. The pellets were then washed with 70%
ethanol and centrifuged at 13200 r.p.m. for 15 mins. The supernatant was discarded
and pellets were left to dry for 15-20 mins in a vacuum dessicator. Pellets were
resuspended in 50l of RNAse-free water and were then immediately used for
analysis.
Reverse-Transcription (RT) of RNA
Typically, 1-5µg of RNA was used per reaction for reverse transcription. Reactions
were performed in a 50µl reaction using SS-Reverse Transcriptase (Fermentas)
according to the manufacturers’ instructions. Reactions were left to proceed for 1h
at 42oC, before being incubated at 70oC for 15 mins to destroy reverse transcriptase
(RT) activity. Finally, 0.5µl RNase H was added to each reaction and incubated at
37oC for 20 mins. Typically 2.5µl of the final reaction volume was used for
subsequent PCR analysis.
2.23 Bacteriological techniques
Throughout this study all methods requiring bacteria utilised E. coli TG2 cells, or
when blue/white screening was required, E. coli DH5α cells.  Bacteria were grown in 
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LB at 37oC and shaken vigorously in a sterile vessel approximately five times the
volume of the liquid culture.
Preparation of competent cells
100ml of pre-warmed LB was inoculated with 2ml of fresh overnight bacterial
culture in LB. The bacteria were then shaken vigorously at 37oC until the OD600
(optical density) of the culture was 0.39. The culture was then placed on ice for 5
mins before centrifugation at 6000r.p.m. for 10 mins at 4oC (Beckman Coulter
AllegraTM X-12R Centrifuge). The supernatant was discarded and the remaining
pellet was resuspended in 40ml transformation buffer I (Tfb I; 10mM RbCl2, 30mM
potassium acetate, 10mM CaCl2, 50mM MnCl2, 15% v/v glycerol and adjusted to
pH5.8). The resuspended pellet was left on ice for 5 mins then centrifuged at
6000r.p.m for 10 mins at 4oC. The supernatant was again discarded the pellet
resuspended in 4ml transformation buffer II (Tfb II; 75mM CaCl2, 10mM RbCl2,
10mM 3[N-morpholino] propanesulphonic acid (MOPS), 15% v/v glycerol, pH 6.5)
then left on ice for 2h. The competent cells were then separated into 100l aliquots
and frozen with dry ice before storage at –70oC.
Transformation of competent bacteria
50ng of plasmid DNA or ligation reaction was added to 100l of thawed competent
E. coli TG2 cells then left on ice for 30 mins. Cells were then subjected to heat
shock for 30s at 42oC and left on ice for 2 mins. 600l of pre-warmed LB was added
and cells were incubated at 37oC with shaking for 1h. Cells were then plated onto
LB plates containing100g/ml ampicillin and left to incubate at 37oC overnight.
Extraction of plasmid DNA from liquid culture
Small quantities of plasmid DNA were typically prepared from 1ml of E. coli TG2
overnight culture in LB supplemented with 100g/ml ampicillin. Plasmid DNA was
extracted using a Sigma-Aldrich GenEluteTM Plasmid Miniprep Kit according to the
manufacturer’s instructions.
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In order to prepare larger quantities of plasmid DNA for use in transfection
experiments a larger culture volume was utilised. 100ml of E. coli TG2 overnight
LB culture supplemented with 100g/ml ampicillin was used, and DNA was
extracted using a Promega PureyieldTM Plasmid Midiprep System according to the
manufacturer’s instructions.
Quantification of nucleic acid
The concentration DNA and RNA samples was quantified by measuring the OD260
using a Nanodrop-ND1000 (Thermo Scientific) and associated software. An
absorbance of 1 is equivalent to 50µg/ml of double-stranded DNA. The purity of
DNA or RNA was indicated by the absorbance ratio of OD260 to OD280, where a ratio
of 1.8 indicates pure DNA, and a ratio of 2 indicates pure RNA.
Blue/white selection of bacterial colonies
Each LB plate containing 100µg/ml ampicillin was aseptically covered with 40µl
20mg/ml X-Gal (Melford Laboratories Ltd.) in dimethylformamide (DMF) and 4µl
isopropyl β-D-1-thiogalactopyranoside (IPTG; Melford Laboratories Ltd.) in H2O
using a glass spreader. The plates were then left to dry at 37oC for 1h, after which
they were ready for inoculation. 24h after inoculation, plates were examined for
white colonies as these were deemed to contain the plasmid carrying the insert of
interest. Positive colonies were transferred to 5ml LB containing 100µg/ml
ampicillin and were incubated overnight in a shaking incubator at 37oC.
2.24 Mammalian cell culture
Maintenance of cell lines
HEp-2, A549 and MRC5 cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% (v/v) heat-inactivated foetal bovine
serum (FBS). HEK293 cells were maintained in DMEM supplemented with 10%
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(v/v) newborn bovine serum (NBS). U2OS cells were maintained in McCoy’s 5A
medium supplemented with 10% FBS.
90mm -irradiated tissue culture dishes were used as the standard culture vessels for
all cells used in the study. Cells were grown in the dishes at 37oC in a 5% CO2
atmosphere until confluent. Cells were then passaged by washing the monolayers
with 3ml versene (0.02% EDTA in PBS), then incubating the cells with 2.5ml
versene, containing 0.02% (v/v) 0.25mg/ml trypsin, for 5 mins. Detached cells were
collected in suspension and added to 0.5ml FBS before centrifugation at 1300 r.p.m.
for 3 mins. The cell pellet was then resuspended in the appropriate growth medium
and seeded into new vessels at the required density.
Transfection, infection and drug treatment of mammalian cells
All cells to be transfected were seeded at the required density into an appropriate
culture vessel 24h prior to transfection. Unless otherwise stated, cells were seeded in
10% serum media in a volume suitable for transfection, preventing the need to
replace the medium prior to addition of DNA or RNA.
Transfection of plasmid DNA
Lipofectamine 2000 (LF2000; Invitrogen) and Turbofect (Fermentas) were used for
liposome-mediated transfection of plasmid DNA throughout this study. For both
transfection reagents, a ratio of 2l reagent for every 1g plasmid DNA was used,
and this was applied to all cell lines used in this study.
All transfections were performed in 12 or 24 well plates. Cells were seeded 24h
before the procedure to allow approximately 90% confluence at the time of
transfection. Transfection reagent-DNA complexes were prepared in pre-warmed,
serum-free OptiMEM to make a volume that corresponded to 100l (24 well) or
200µl (12 well) per well of cells to be transfected. After incubation for 20 mins at
room temperature the complexes were gently pipetted onto the serum media bathing
the cells. The cells were then incubated at 37oC for 6h when, where appropriate, the
medium was replaced with fresh 10% serum medium.
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Transfection of cells by poly (I:C)
Turbofect was found to be an unsuitable reagent for the transfection of cells by poly
(I:C), hence only LF2000 was used for this purpose during the course of this study.
LF2000 was used at a ratio of 2µl per 1µg of poly (I:C), and this was applied to all
cell lines. LF2000/poly (I:C) complexes were prepared in pre-warmed, serum-free
OptiMEM to make a volume equivalent to 100µl or 200µl per well, depending on
the size of the culture plate. The mixture was left to incubate for 20 mins at room
temperature, after which it was gently pipetted into the serum media bathing the
cells. Where appropriate, the medium was replaced with fresh serum media after 8h.
Transfection of cells by short interfering RNA (siRNA)
LF2000 and TriFECTin (Integrated DNA Technologies) were used as lipid reagents
for the transfection of cells with siRNA. 2µl of transfection reagent was used per
well for a 24 well plate. Lipid reagent/siRNA complexes were prepared in pre-
warmed, serum-free optiMEM to make a volume equivalent to 100µl per well. The
mixture was left to incubate for 20 mins at room temperature, after which it was
gently pipetted onto the serum media bathing the cells. For all siRNA experiments,
the medium was replaced with fresh 10% serum medium every 24h after the initial
transfection.
Infection of cells by Adenovirus
Cells were seeded at least 24h prior to infection. The growth media was removed
and cell monolayers were washed once with 0.5ml serum-free medium. Virus stocks
were diluted with serum-free DMEM or McCoy’s 5A medium as appropriate to the
cell type to give the appropriate multiplicity of infection (m.o.i.) of plaque-forming
units per cell. U2OS cells were infected at an m.o.i. of 30 whereas all other cell lines
used in this study were infected at an m.o.i. of 10. The final volume of diluted virus
was typically 100l per well for a 24 well plate and 1ml per 90mm dish. The diluted
virus was added to the cells, which were than kept at 37oC for 1h, being rocked every
15 mins to ensure the medium covered the entire monolayer. After 1h, an
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appropriate volume of pre-warmed serum-containing medium was added to the cells
and left for the duration of the experiment.
Virus stock titration
All virus titrations were performed in duplicate on sub-confluent HEK293 cells.
Cells were seeded onto 6mm plates 24h prior to infection. The growth media was
removed and cell monolayers were washed once with 2ml serum-free DMEM. The
viral stock was diluted with serum-free DMEM to produce a series of 10-fold
dilutions. The dilution range examined was typically 10-5-10-10. 500µl of each
dilution was then added to the cells, which were then kept at 37oC for 1h, being
rocked every 15 mins to ensure the medium covered the entire monolayer. After 1h,
the virus dilutions were aspirated from the cell monolayers, then 4 ml of pre-warmed
agar overlay (Stock: 25ml 2X DMEM –NaHCO3, 2ml NBS, 5ml 7.5% (w/v)
NaHCO3, 18ml 2.8% noble agar) was added to each well. The cells were then kept
at 37oC, and 1ml of pre-warmed agar overlay (Stock: 25ml 2X DMEM –NaHCO3,
0.5ml NBS, 2.5ml 7.5% (w/v) NaHCO3, 18 ml 2.8% noble agar) was added to each
well every 3 days until virus plaques were visible. Upon the appearance of plaques,
2ml of pre-warmed staining overlay (Stock: 25ml 2X DMEM, 0.5ml NBS, 2.5ml
7.5% NaHCO3, 18ml 2.8% noble agar, 5ml 0.1% neutral red) was added to each
well, and plates were wrapped in aluminium foil and placed at 37oC. After 24h,
plaques were counted and the average number of plaques between the two duplicates
was calculated. This value was then used to calculate the titre of the undiluted virus
stock.
Hydroxyurea treatment
A549 or HEp-2 cells were infected with adenovirus as described above. 1h post
infection medium was replaced with 1ml 10% FBS DMEM or 1ml 10% FBS
DMEM containing 10mM hydroxyurea (Sigma-Aldrich). Cells were then incubated
at 37oC for 23h or until the end of the experiment.
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MG132 treatment
A549 or HEp-2 cells were infected by adenovirus as described above. 16h post
infection the medium was replaced with 1ml 10% FBS DMEM or 10% FBS DMEM
containing 50µM MG132 (Sigma-Aldrich). Cells were left to incubate at 37oC for a
further 8h before being harvested.
D-sorbitol treatment
4h prior to harvesting cells were treated with 0.5ml 0.5M D-sorbitol (Sigma-Aldrich)
dissolved in 10% FBS DMEM or mock-treated with fresh 10% FBS DMEM alone.
DMAT treatment
To inhibit casein kinase II (CK2) activity the selective inhibitor DMAT
(Calbiochem) was used. At the appropriate time the medium was removed from
cells and replaced with fresh 10% FBS serum DMEM containing 10µM DMAT
(from 10mM stock in DMSO). Cells were mock treated through the addition of 10%
serum media containing an equivalent volume of DMSO.
2.5 Analysis of protein expression
Harvesting of total cellular protein
To extract cellular protein for SDS PAGE, cell monolayers were washed once with
PBS before incubation with 1X sample buffer (100l used for every 3 x 105 cells
unless otherwise stated) at room temperature for 5 mins. The cell lysates were
collected and boiled for 10 mins and samples were then used immediately or stored
at –70oC.
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SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Denatured protein samples were separated by the method described by Laemmli
(Laemmli, 1970). Gels consisted of a 5% acrylamide stacking gel and a resolving
gel of 8-15% acrylamide (37.5:1 acrylamide:bis-acrylamide, depending on the
molecular size(s) of the protein(s) being investigated. Typically, electrophoresis was
performed for 1.5-2h at 120V in 1X running buffer. All SDS-PAGE performed in
this study utilised the Bio-Rad mini-PROTEAN III systems according to the
manufacturer’s instructions.
Transfer of proteins onto nitrocellulose membranes
Prior to transfer the stacking gel was removed, and the transfer of the separated
proteins from the resolving gel onto nitrocellulose membranes was performed as
previously described (Towbin et al., 1979). Transfers were performed in 1 X
transfer buffer (25mM Tris base, 192mM glycine, 20% methanol) at 350mA for
1.25h at 4oC, or at 80mA for 16h at 4oC using the Bio-Rad Mini Trans-Blot
Electrophoretic Transfer Cell system according to the manufacturer’s instructions.
All transfers utilised HybondTM ECLTM nitrocellulose membrane.
Protein detection by western blotting
Nitrocellulose membranes were incubated for >1h-overnight in 20ml blocking
solution (2% ECLTM Advance blocking agent in PBS containing 0.05% (v/v) Tween-
20). Membranes were then probed with 2.5ml of primary antibody against the
protein of interest diluted in blocking solution, and then incubated 1h at room
temperature on an orbital shaker. The dilution of the primary antibody was
dependent on the protein under investigation (Table 2.7). Membranes were then
washed for 1h on an orbital shaker with PBS containing 0.05% Tween-20, with the
PBS-Tween being replaced every 5 mins. The membranes were then probed with
2.5ml of the appropriate secondary antibody (Table 2.8) diluted in blocking solution
and incubated as before. Membranes were then washed in PBS-Tween for 1h as
before. The blots were developed using ECLTM Advance according to the
manufacturer’s instructions and exposed to Fuji SuperRX X-Ray Film then
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developed using an AGFA Curix60 developer, or imaged using a Biorad Gel/Chemi
Doc system and associated software.
2.6 Luciferase reporter assays
Preparation of cell lysates
All transfections were performed in triplicate on sub-confluent cell monolayers in 24
well plates. Each well was transfected with 500ng total DNA, of which 250ng
consisted of the expression plasmid of interest and 250ng consisted of a combination
of reporter plasmids listed in Table 2.6 in 9:1 ratio of inducible reporter (pIFNβ-Luc, 
pISRE-Luc) to autonomous reporter (pRL-TK, pcDNA3.1-hisB::lacZ). 16h later the
medium was replaced with fresh 10% serum media and cells were transfected with
1µg poly (I:C) per well. Cells were incubated for the appropriate time according to
the experiment before being harvested. Lysis was achieved through the addition of
100l 1X passive lysis buffer (Promega) per well, followed by shaking for 30 mins
at room temperature. Cell lysates were then collected and, where necessary, 5l
samples of each triplicate lysate were pooled together for use in SDS-PAGE and
Western blot analysis. Remaining lysates were stored at -20oC for short-term storage
until analysis.
Dual luciferase assay
10l of each cell lysate was analysed for both firefly and Renilla luciferase activity
in an opaque half-volume 96 well plate (Greiner) using the Dual-Luciferase Reporter
System (Promega) according to the manufacturer’s instructions. Luciferase activity
was measured using a Luminoskan Ascent microplate luminometer and the provided
software (Thermo Fisher Scientific).
Bright-Glo luciferase assay
All assays were performed in an opaque, half-volume 96 well plate (Greiner)
through the addition of 25µl Bright-Glo Luciferase Assay Substrate (Promega) to
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10µl of cell lysate. Luciferase activity was measured using a Luminoskan Ascent
microplate luminometer and the provided software (Thermo fisher Scientific).
β-Galactosidase Assay 
All β-Galactosidase assays were performed in clear 96-well plates (Falcon).  10µl of 
cell lysate was mixed with 86µl Z-buffer (60mM Na2HPO4.7H20, 40mM
NaH2PO4.H20, 1mM KCl and 1mM MgSO4.7H2O) containing 40mM β-
mercaptoethanol and 24mM ONPG (2-nitrophenyl-β-D-galactopyranoside).  The 
lysates were then incubated at 37oC until reaction mixtures became visibly yellow, at
which point reactions were stopped through the addition of 40µl 1M Na2CO3. The
OD405nm was then recorded using a colorimeter (Labsystems Multiskan RC) and
associated software.
Analysis of luciferase assay data
For each sample the Relative Luciferase Activity (RLA) was calculated in order to
normalise luciferase activity to the general transfection efficiency of the cells. This
was achieved by dividing the value of firefly luciferase activity by the activity of the
autonomous reporter (Renilla luciferase or β-Galactosidase) for a given sample.  The 
RLA was calculated independently for control cells left untreated or stimulated with
poly (I:C). All RLAs were then normalised to the respective control, with control
samples having a value of 1. All RLAs were therefore expressed as a ratio to this.
Within an experiment the standard deviation from the mean of the ratios obtained
from each set of triplicates was calculated. Where experiments were repeated a
minimum of three separate times, therefore generating at least nine values, two-tailed
Student’s t-test analysis was performed with two sample unequal variance to test
whether or not the two datasets were significantly different.
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2.25 Immunofluorescence Microscopy
Fixing of cells to cover slips
Cells were seeded at an appropriate density into a 12 well plate containing a single
cover slip per well. At the end-point of the experiment, cells were washed twice
with 0.5ml PBS then 0.5ml of 10% (v/v) formalin in PBS was added to each well
and left at room temperature for 10 mins. Cells were then washed with 0.5ml PBS
prior to the addition of 0.5ml 10% (v/v) NP40 in PBS per well. Cells were incubated
at room temperature for 10 mins then the cells were washed twice with 0.5ml PBS.
Cells were then left in 1ml PBS and stored at 4oC in air-tight conditions for up to two
weeks.
Staining cells
Cells were blocked for 1h in the presence of 0.5ml 1% (w/v) bovine serum albumin
(BSA, Sigma) in PBS, then washed three times with 0.5ml PBS and incubated with
0.25ml primary antibody (Table 2.7) in 1% BSA in PBS for 1h. The primary
antibody was removed, then the cells were washed three times in PBS and 0.25ml of
the appropriate secondary antibody in 1% BSA in PBS was added per well (Table
2.8). Cells were then incubated for 1h in darkness then washed twice with 0.5ml
PBS. If staining by multiple primary antibodies was required then this process was
repeated, but all antibody incubations were performed in darkness. After incubation
with the final secondary antibody, cells were washed twice with 0.5ml PBS then
incubated in darkness with 0.001% (w/v) 4’,6’ –diamidino-2-phenylindole (DAPI) in
PBS for 5 mins. The cover slips were then removed, dried and inverted onto
microscope slides containing 5µl of mounting medium (Vectorshield, Vector
Laboratories Inc.). The edges of the cover slip were then sealed to the slide using
nail varnish.
Immunofluorescence analysis
Microscope images were generated using either a Leica SP2 or SP5 confocal system.
Images were generated by using sequential scanning for multiply stained samples
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using settings which had been optimised to eliminate fluorescence crossover between
channels. Images typically represent a single focal plane, though where indicated
images may consist of a maximal projection through a z-series. Nuclei were
visualised by staining the DNA with DAPI. Images were assembled using the Leica
confocal software.
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Chapter 3
Adenovirus infection alters the population
of PML proteins
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3.1 Introduction
PML protein is the major component of sub-nuclear structures termed PML nuclear
bodies (PML NBs). The major role performed by PML and PML NBs is the subject
of much debate, as PML protein has been implicated in numerous cellular processes,
including anti-viral responses. Much evidence for this role stems from observations
where viruses specifically interact with PML proteins and therefore PML NBs. In
some cases, perturbation of PML NBs has been shown to enhance viral replication
(Chee et al., 2003, Härle et al., 2002, Mossman et al., 2000, Tavalai et al., 2006).
Adenovirus type 5 (Ad5) is one virus which has been shown to alter both PML NBs
and the PML protein population. Infection with Ad5 leads to reorganisation of PML
NBs, and their constituents, from their native spherical appearance into track-like
structures (Carvalho et al., 1995). This observation has been recorded in a number
of cell types and is mediated by the viral E4 Orf3 protein, which interacts
specifically with the unique C terminus of PML II isoform (Hoppe et al., 2006).
PML NB disruption is maintained at later times during infection by the viral
intermediate gene product protein IX (pIX), which sequesters PML into ‘inclusion
bodies’ (Rosa-Calatrava, 2003).
Ad5 infection has also been shown to alter the PML protein population, as infection
with a wild type Ad5 leads to the production of a novel, infection-specific species of
PML that becomes a dominant species within the population by 24 hours post
infection (Leppard & Everett, 1999). This species was not produced upon infection
with a virus lacking the early gene products E4 Orf1-3, and it has subsequently been
found that the viral protein responsible is E4 Orf3 (K. Leppard, unpublished). The
number of higher molecular weight, sumoylated forms of PML has also been
observed to decrease upon infection with Ad5. As yet there is no clear reason why
adenovirus disrupts PML NBs and alters the PML population, though it is
hypothesised that adenovirus targets PML to overcome its antiviral properties and
thus make the cell more conducive to viral replication.
The experiments performed in this chapter explore further the interaction between
Ad5 and the endogenous PML proteins. By using a polyclonal anti-PML antibody
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raised against a GST-PML fusion protein containing the entire N-terminal domain of
PML (Vallian et al., 1998, Xu et al., 2003), it is assumed that the majority of the
PML population of cells could be detected and a comparison made between mock-
infected and infected cells. Emphasis was initially placed on the novel E4 Orf3-
dependent species of PML described above, termed species A throughout the course
of this study, and the extent to which it was produced in various cell lines. During
this work, two other novel infection-specific species of PML were also detected that
were independent of E4 Orf3. The sub-cellular localisation of these infection-
specific species and the requirements for their production were then investigated.
3.2 Infection-specific changes in PML proteins can be detected in
various cell lines
PML species A was previously detected during wild-type Ad5 infection of both
HEp-2 and HeLa cells (Leppard & Everett, 1999), though its presence in other cell
lines has never been investigated. In order to more fully understand the nature of
species A several commonly used cell lines were examined for their capability to
produce this PML species upon Ad5 infection.
HEp-2, HEK293, U2OS and A549 cells were chosen to investigate any infection-
specific changes in the PML population of immortalised cell lines. Normal diploid
MRC5 cells were also investigated as these represent typical cells that are not
immortalised. Such a comparison would ensure that any changes observed were
biologically relevant in the context of a normal diploid cell and not just an artefact of
any transformation processes. Each cell type was mock infected or infected with
wild-type Ad5 strain 300 or, where indicated, E4 Orf3-deficient mutant inOrf3.
Cells were harvested 24 hours post infection (h.p.i.) and the protein content of the
lysates was separated by SDS-PAGE and subjected to Western blotting. The blots
were probed with the polyclonal anti-PML antibody that detected all isoforms of
PML, allowing changes in the entirety of the PML population to be investigated
(Fig. 3.1).
With the exception of U2OS cells, species A was detected in all of the cell lines
tested upon infection with wild-type Ad5. However, its abundance relative to the
PML population varied depending on cell type. Of the cell lines tested, HEp-2 cells
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consistently appeared to express species A to a level comparable with the
endogenous PML population, consistent with the earlier report (Leppard & Everett,
1999). HEK293 cells were also found to produce a significant amount of species A,
though it was not expressed at a level comparable to the major endogenous species
of PML. The presence of species A in MRC5 cells confirmed that the appearance of
this PML form was independent of the transformation state of the cell line.
Between experiments, the level of expression of species A was found to vary even
within a single cell type. In particular A549 cells were capable of producing species
A, but often to only low levels that made detection difficult. For instance, in Fig. 3.1
species A is barely visible in Ad5 300-infected A549 cells. After repeated attempts,
species A was never detected in U2OS cells despite being infected at an increased
multiplicity of infection, suggesting that U2OS cells are intrinsically unable to
support the production of this PML species.
In all the cell lines examined the production of two novel, infection-specific species
of PML was observed (arrows B and C). These species did not clearly co-migrate
with any known species of PML, as determined through over-expression of PML
from cDNA expression plasmids (Beech et al., 2005), and were found to be
independent of the presence of E4 Orf3. Species B in particular was found to be
strongly expressed in all cell lines tested, and indeed was amongst the major bands
detected after infection, particularly in 293 cells. Species C was more variable in its
relative abundance, and was observed to be either strongly (HEK293 cells) or
weakly (MRC5 cells) expressed depending on the cell type being examined.
Thus infection by wild-type adenovirus leads to the production of at least three
infection-specific PML species that can be detected with a polyclonal anti-PML
antibody in most or all of a panel of cell lines, including normal MRC5 cells. Whilst
the appearance of species A was dependent on the viral E4 Orf3 protein, two novel
species B and C were independent of the viral E4 Orf3 protein. Thus these data
indicate that adenovirus infection causes several distinct changes in the cellular PML
population.
Figure 3.1. Adenovirus type 5 infection induces multiple changes in the PML
population. 3 x 105 cells of the type indicated were mock infected or infected
with wild type Ad5 (300) or, where indicated, an E4 Orf3-deficient virus (inOrf3)
at a multiplicity of infection (m.o.i.) of 10pfu/cell, except U2OS cells and MRC5
cells (lanes 3, 5), which were infected at an m.o.i. of 30 pfu/cell. 24 hours post
infection (h.p.i.) all cells were harvested and the protein content of the lysates
was separated by sodium dodecyl sulfate 8% polyacrylamide gel electrophoresis
(SDS-PAGE) and subjected to western blotting. Blots were probed with a
polyclonal anti-PML antibody (Xu et al., 2003) which recognises all isoforms of
PML protein. The infection-specific species of PML are indicated by the arrows
to the right of each blot. Protein sizes are indicated in kDa to the left hand side of
each blot.80
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3.3 Detection of infection-specific species of PML by monoclonal
pan-PML specific antibodies
It was important to ensure that the infection-specific species of PML B and C were
PML related, and not the product of cross-reactivity of the antibody to proteins
unrelated to PML. To address this problem, alternative monoclonal anti-PML
antibodies were employed to investigate the PML population in infected cells. PG-
M3 is a commercially available monoclonal antibody that targets an epitope
overlying the the exon 1/2 boundary of PML. Since all PML isoforms are thought to
possess the RBCC domain encoded by exons 1-3, PG-M3 is an excellent candidate
antibody to use when attempting to detect the entire population of PML species
within a cell. It is however reputed not to detect sumoylated PML well. Species A
has previously been detected in infected cells by the alternative monoclonal anti-
PML antibody 5E10. However, the 5E10 antibody recognises an epitope that has
been mapped to PML exon 5 (Stuurman et al., 1992). Exon 5 lies within the central
domain of PML proteins and is thought to be excluded from both cytoplasmic and a
subset of nuclear PML transcripts by differential splicing (Jensen, 2001). When
using this antibody this information must be taken into account, as it is likely that
5E10 does not detect the entire population of PML proteins.
HEp-2 cells were mock infected or infected with wild type Ad5 300 or E4 Orf3-
deficient mutant inOrf3, and after 24 hours the cells were harvested and multiple
aliquots of extract were separated in parallel by SDS-PAGE and subjected to
Western blotting to generate three replica blots. Each blot was then probed with a
single pan-PML antibody, either a rabbit polyclonal antibody (Xu et al., 2003) or
mouse monoclonal antibodies 5E10 (Stuurman et al., 1992) or PG-M3 (Santa Cruz)
(Fig. 3.2).
PML species A was detected by both the rabbit polyclonal and 5E10 antibodies, but
not by monoclonal antibody PG-M3. PG-M3 did not appear to detect any bands that
correspond with the higher molecular weight endogenous PML I and II isoforms that
were detected by both the polyclonal and 5E10 antibodies (Beech et al., 2005).
As in Fig 3.1, species B was clearly detected by the polyclonal antiserum as it
formed the most dominant species within the PML population. PG-M3 did not
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detect a species of similar molecular weight to B in infected lanes, and resembled the
blotting pattern detected by the 5E10 antibody, which also did not detect a species
which clearly co-migrated with species B. This suggests that these antibodies do not
recognise this particular molecule.
As expected from figure 3.1, the polyclonal antibody detected species C only in the
infected lanes. A band co-migrating with species C was also detected by both 5E10
and PG-M3. However, this band was present in both mock and virus infected lanes,
though in the PG-M3 blot this band was expressed more strongly in virus-infected
lanes, which would be expected for species C. It is therefore possible that PG-M3
but not 5E10 detects species C, while both antibodies also detect an unrelated
molecule or unchanging PML species of a similar molecular weight that is present
equally in uninfected and infected cells.
Both monoclonal antibodies 5E10 and PG-M3 detected an alternative infection-
specific species which did not co-migrate with any of species A, B or C. This
species, labelled X, was not detected by the polyclonal anti-PML antibody but may
represent an additional infection-specific species of PML. However, in order to limit
the scope of this study this species was not examined any further.
It is pertinent to note that none of the single infection-specific species was detected
by all three antibodies utilised. Indeed, each antibody produced a unique banding
pattern of endogenous PML, possibly resulting from a combination of unique
antibody-epitope binding kinetics and various post-translationally modified PML
proteins. Curiously, PG-M3 seemed unable to detect either species A or higher
molecular weight species of endogenous PML that correspond to the migration
positons of PML I and PML II (Beech et al., 2005), though the pattern of lower
molecular weight PML isoforms detected resembled that seen by both the polyclonal
and 5E10 antibodies. This observation makes interpretation somewhat difficult
when using western blotting to examine endogenous levels of PML proteins, and one
must consider that when using a particular anti-PML antibody for western blotting
the true population of PML proteins may not be fully reflected.
Figure 3.2. The infection-specific species of PML can be detected by
multiple anti-PML antibodies. 3 x 105 HEp-2 cells were mock-infected or
infected with Ad5 wild-type 300 or inOrf3 at an m.o.i. of 10 pfu/cell. 24 h.p.i.
cells were harvested and aliquots of extract were separated in parallel by 8%
SDS-PAGE and subjected to western blotting in order to generate three replica
blots. Each blot was probed with a single anti-PML antibody, as indicated
beneath each blot. The arrows to the right hand side indicate the migration
positions of the infection-specific species A, B and C. An additional infection-
specific species is marked as X. Protein sizes are indicated in kDa to the left83
hand side of the blots.
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3.4 All infection-specific species of PML can be depleted using
siRNA targeting PML
No infection-specific species of PML was readily detected by all three antibodies
employed, thus not totally eliminating the possibility that either one or more of these
species could be an artefact of non-specific antibody cross-reactivity. To overcome
this, an alternative technology was utilised with the aim of confirming that the
infection-specific species detected by western blotting were PML-related. siRNA
technology was used to deplete PML proteins in HEp-2 cells prior to subsequent
infection by wild-type adenovirus. A suitable siRNA target within exon 3 of the
PML transcript was designed using appropriate software (Ambion siRNA target
finder). Exon 3 was chosen as a target sequence as it is thought not to be excluded
by differential splicing and is therefore possessed by all isoforms of PML (Jensen,
2001). Software validation was used to ensure that the siRNA target sequence was
not found elsewhere in either the adenovirus genome or the human genome, except
for the PML transcript (NCBI/BLAST).
HEp-2 cells were mock-transfected or transfected with up to 200 picomoles of
siRNA targeting exon 3 of the PML primary transcript. As a negative control, 200
picomoles of a scrambled siRNA with no homology to any gene in the human
genome were used. 48 hours after transfection with siRNA, cells were mock
infected or infected with wild-type Ad5 300, and cells were harvested 24 hours post
infection. Aliquots of the lysates were separated in parallel by SDS-PAGE and
subjected to western blotting to generate two replica blots. One blot was probed
with a polyclonal anti-PML antibody, and the other probed for the housekeeping
gene product glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with a
monoclonal anti-GAPDH antibody. This served as a control for equal protein
loading of the samples and also ensured that any knockdown by PML siRNA was
not due to a global decrease in translation (Fig. 3.3).
The endogenous PML population was successfully depleted in a dose-dependent
manner by transfection of the siRNA targeting PML exon 3, resulting in a significant
reduction in PML protein (lanes 3-7) as compared to cells transfected with a control
siRNA (lane 8). Infection-specific species A, B and C were all observed in the
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iFigure 3.3. The infection-specific species of PML can be depleted by
transfection with PML-specific siRNA. 2 x 105 HEp-2 cells were mock
transfected or transfected with 1, 5, 10, 50 or 200 picomoles of PML siRNA, or
200 picomoles of control scrambled siRNA. 48 hours after transfection, cells
were mock-infected or infected with Ad5 300 at an m.o.i. of 10 pfu/cell. 24 h.p.i.
the cells were harvested and the protein content was separated in parallel by 8%
SDS-PAGE and subjected to western blotting in order to generate two replica
blots. Blots were probed with either a polyclonal anti-PML antibody (Xu et al.,
2003) or a monoclonal anti-GAPDH antibody, which acted as a loading control.
The arrows to the right of the blot mark the migration positions of infection-
specific species A, B and C, and the loading control GAPDH. Protein sizes are
indicated in kDa to the left hand side of the blot.85
ock-transfected, Ad5 300 infected lane (lane 2), though species A in particular was
oorly expressed in this experiment. Pre-treatment with PML siRNA strongly
epleted all of these infection specific species in contrast to transfection with the
ontrol siRNA (lane 8). Protein loading was comparable across the lanes, as
ndicated by the level of GAPDH, thus confirming that PML had been selectively
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knocked down and its depletion was not the result of a general down-regulation of
translation. This, in conjunction with the data presented in figure 3.2, provided
strong evidence that all of species A, B and C are PML species that are produced
upon infection with wild-type Ad5.
Virtually all of the bands present in the control siRNA-transfected cells were
significantly depleted by the PML siRNA. This suggested that the vast majority of
proteins detected by the polyclonal antibody are PML-related, reflecting the complex
diversity of the PML population generated by alternative splicing and various post-
translational modifications.
3.5 Sub-cellular localisation of infection-specific species of PML
The most strongly expressed, and therefore best characterised, PML proteins all
contain a nuclear localisation signal that is encoded in exon 6 of the pml gene
(Jensen, 2001). Consequently, isoforms possessing this sequence localise to the
nucleus and are incorporated into PML nuclear bodies. However, cytoplasmic
variants of PML are known to exist, such as PML VII (Jensen, 2001). These
variants must exclude exon 6 and thus lose the NLS sequence encoded within this
region, though they may still retain the unique exons encoding the carboxyl termini
of specific PML isoforms. Other internal exons such as exon 4 and 5 may also be
excluded from cytoplasmic variants. It is therefore feasible that for every nuclear
isoform PML I-VI, there exists a cytoplasmic splice variant of smaller molecular
weight. Cytoplasmic PML proteins remain relatively poorly understood relative to
their nuclear counterparts.
Infection-specific species C migrates on a polyacrylamide gel to a size that is notably
smaller than the six major nuclear isoforms of PML (Beech et al., 2005). One
explanation for this is that species C represents a splice variant of PML protein that
lacks the internal exons, including exons 6, which define full-length PML proteins.
Such a variant of PML would be expected to show a cytoplasmic localisation within
the cell. To investigate this possibility, the sub-cellular localisation of the infection-
specific species of PML was examined in Ad5-infected A549 cells.
A549 cells were mock-infected or infected with wild-type Ad 5 for 24 hours. After
this time, the cells were separated into the respective nuclear and cytoplasmic
fractions before the addition of denaturing SDS-PAGE loading buffer. Equivalent
amounts of protein from each fraction were then separated by SDS-PAGE and
subjected to western blotting. The blot was probed with a polyclonal anti-PML
antibody in order to detect the infection-specific species of PML (Fig. 4).
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hFigure 3.4. Infection-specific PML species C is abundant in the cytoplasm. 1
x 107 A549 cells were mock infected or infected with Ad5 300 at a multiplicity of
10 pfu/cell. At 24 h.p.i., the cells were fractionated into nuclear (N) and
cytoplasmic (C) fractions, and the protein content was separated by 8 % SDS-
PAGE then subjected to western blotting. The blot was probed with a polyclonal
anti-PML antibody (Xu et al., 2003). The arrows to the right hand side of the
blot indicate the migration positions of the infection-specific species of PML.
Sizes are indicated in kDa to the left hand side of the blot.87
ll the PML proteins detected in the mock-infected cells were predominantly in the
uclear fraction, with barely detectable levels being detected in the cytoplasmic
raction. Higher molecular weight PML proteins are assumed to be full-length and
ence possess exon 6 and the NLS, and therefore are expected to show a nuclear
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localisation. Surprisingly, the lower-molecular weight PML proteins, assumed to be
cytoplasmic variants, also localised to the nuclear fraction. The reason for this is
unclear, but it is possible that some nominally cytoplasmic species of PML are still
incorporated into PML nuclear bodies by both homo- and hetero-oligomerisation of
PML isoforms through coiled-coil mediated interactions, thus maintaining a nuclear
localisation.
Upon infection by Ad5, expression of all three infection-specific species of PML
(arrows A, B, C) could be detected at levels comparable to that of endogenous PML.
Importantly, a distinct difference in banding pattern could be observed between
nuclear and cytoplasmic lanes, ruling out the possibility of spill-over between these
fractions by experimental error. Species A and B were confined solely to the nuclear
fraction of infected cells, possibly suggesting that these represent nuclear species of
PML. However, species C was consistently detected in both the nuclear and
cytoplasmic fractions of infected cells, though it was always found to be more
abundant in the cytoplasmic fraction. This suggests that species C is a cytoplasmic
variant of PML, a scenario made more likely when one considers the relatively small
size of this protein. A small amount of species C could be detected in the nuclear
fraction of infected cells, suggesting that this species may either be free to diffuse
across the nuclear envelope or, more likely, indicates cytoplasmic contamination of
the nuclear fraction.
3.6 Infection-specific PML species are not protected from
proteasome-mediated degradation by Ad5 infection
The complexity of the PML protein population within a cell is reflected by the large
number of bands that may be detected by western blot using a panel of anti-PML
antibodies and correspondingly depleted by PML siRNA (Figs. 3.2 and 3.3). The
underlying cause of this complexity is two-fold; PML is a differentially spliced gene
thought to give rise to at least 11 protein isoforms, and PML proteins are subject to a
number of different post-translational modifications, including sumoylation,
phosphorylation and acetylation (Duprez et al., 1999, Hayakawa et al., 2008,
Hayakawa & Privalsky, 2004, Scaglioni et al., 2008). It is easy to see how various
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isoforms of PML, or indeed various modified states of an isoform, may vary in their
susceptibility to host cell processes. In particular, it is possible that the stability of
PML species may be highly variable, where certain modified PMLs or isoforms may
be less or more stable than other species. It is therefore possible that infection
specific-species A, B and C may represent unusual species of PML that are rapidly
turned over in uninfected cells, yet are specifically stabilised upon infection with
adenovirus. Often, cellular proteins targeted for degradation are sent to the
proteasome, a multi-protein complex, where they are proteolytically cleaved.
Therefore the possible role of the proteasome in the degradation of species A, B and
C in uninfected cells was considered.
A549 and HEp-2 cells were mock-infected or infected with Ad5 wild-type 300 or an
E4 Orf3-deficient virus. 16 hours post-infection cells were mock treated or treated
with MG132, a selective proteasome inhibitor. At 24 h.p.i., all cells were harvested
and the protein content of the lysates was separated by SDS-PAGE and subjected to
western blotting. Blots were probed with either a polyclonal anti-PML antibody, or
a polyclonal anti-p53 antibody. P53 is a cellular protein that is targeted for
proteasome-mediated degradation by the E1B 55K and E4 Orf6 proteins of Ad5
(Querido et al., 2001), and thus should be protected from degradation by the addition
of MG132. Inhibition of the proteasome was achieved, as indicated by the
stabilisation of p53 in both cell types upon the addition of MG132 (Fig 3.5 lower
panels, lanes 4-6, 10-12). The addition of MG132 did not lead to the production of
any species of PML in mock-infected cells of either cell type that co-migrated with
any of species A, B and C from infected cells. This suggests that these do not
represent rare species of PML that are normally subject to rapid proteasome-
mediated degradation in uninfected cells. Compared to other experiments, infection
of both cell types resulted in only low amounts of species C being produced. The
reason for this is unclear, but species C levels are unlikely to vary due to
proteasome-mediated degradation as the addition of MG132 did not result in an
increase in the amount of this species in either of the cell lines examined.
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uFigure 3.5. The infection-specific species of PML are not stabilised in
uninfected cells by a proteasome inhibitor. 3 x 105 A549 cells or HEp-2 cells
were mock infected or infected with Ad5 300 or Ad5 mutant inOrf3 at an m.o.i.
of 10 pfu/cell. 16 h.p.i. cells were mock treated with DMSO, or treated with
DMSO containing MG132 to a final concentration of 50µM. At 24h.p.i. all cells
were harvested the protein content of the lysates was separated in parallel by 8%
SDS-PAGE and subjected to western blotting to generate two replica blots per
cell line. Each blot was probed with either a polyclonal anti-PML antibody (Xu
et al., 2003) or a polyclonal anti-p53 antibody as indicated. The arrows to the
right of the blots indicate the migration positions of infection-specific PML
species A, B and C. Protein sizes are indicated in kDa to the left hand side of the
blots.90
ML species A and B were expressed strongly upon infection of both A549 and
Ep-2 cells, though with notable differences in their relative amounts. Species A
as clearly detected in A549 cells, but its relatively weaker expression was
haracteristic of more minor species of the PML population. This is in contrast to
pecies B, which in A549 cells is the most abundant species of PML present during
nfection. Addition of MG132 led to an increase in the amount of species A to levels
omparable to the major species of PML, though the amount of species B remained
nchanged.
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The opposite pattern was observed in infected HEp-2 cells, where species A in
untreated cells was the most dominant species of PML. This is an observation
similar to that previously reported (Leppard & Everett, 1999). Species A again was
stabilised by the addition of MG132, as indicated by the stronger band in cells
treated with the inhibitor. Species B, however, was a relatively minor species of
PML in untreated infected HEp-2 cells but was stabilised by MG132, resulting in
species B being produced at levels similar to that of species A.
Thus species A, B and C could not be stabilised in uninfected cells by the
proteasome inhibitor, indicating that they are truly infection-specific. In infected
cells species A and B displayed some stabilisation by MG132, suggesting that they
are subject to proteasome-mediated degradation. The apparent difference in their
stability between the two cell types may indicate differences in the cells’ ability to
regulate PML proteins, and may explain the difficulty in detecting species A in A549
cells.
3.7 Infection-specific PML species are not produced in response to
interferon
PML species A, B and C are produced upon infection of cells by adenovirus.
Whereas the appearance of species A is dependent on the viral protein E4 Orf3, it is
unclear whether species B and C are the direct result of a specific viral activity, or
rather a cellular response to virus infection. The best-characterised of such
responses is the interferon response. Type I interferons are cytokines that are
produced via a complex signalling pathway upon infection of a cell by a virus and
exert numerous effects on the cell through both autocrine and paracrine pathways,
resulting in cells adopting a state that is less permissive for both virus infection and
virus replication. PML proteins have been shown to be up-regulated in response to
interferon (Lavau et al., 1995), though it is not known whether interferon alters the
splicing of the PML primary transcript to promote the production of novel variants
of PML. Herpes simplex virus type I infection has previously been shown to result
in the production of such a PML splice variant, and this species could be also
induced through the addition of interferon (McNally et al., 2008). It is therefore
possible that species B and C could be interferon-inducible forms of PML that are
only produced upon infection with Ad5. The effect of interferon on the PML
population, and the possibility that this could account for the infection-specific
species of PML, was therefore examined.
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pFigure 3.6. The infection-specific species of PML are not induced by the
addition of exogenous interferon. 3 x 105 HEp-2 cells were mock infected or
infected with Ad5 300 or Ad5 inOrf3 at an m.o.i. of 10 pfu/cell. In parallel, 3 x
105 uninfected HEp-2 cells were mock-treated or treated with 10, 100 or 1000
units/ml of interferon α in 10% serum media.  All cells were harvested at 24 h.p.i. 
and the protein content of the lysates was separated by 8% SDS-PAGE and
subjected to western blotting. The blot was probed with a polyclonal anti-PML
antibody (Xu et al., 2003). The arrows to the right of the blot indicate the
migration positions of infection-specific species A, B and C as detected in lane 2.
Protein sizes are indicated in kDa to the left hand side of the blot.92
Ep-2 cells were mock infected, or infected with Ad5 wild-type 300 or E4 Orf3-
eficient virus (inOrf3) for 24 hours prior to harvest. In parallel, uninfected HEp-2
ells were mock-treated or treated with increasing amounts of recombinant interferon
 (IFNα) for 24 hours before being harvested.  The protein content of all cells was 
hen separated by SDS-PAGE and subjected to western blotting. The blot was
robed with a polyclonal, anti-PML antibody (Fig.3.6).
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The addition of IFNα to the cells had, as expected, a strong dose-responsive effect, 
as higher concentrations led to more PML proteins being produced. Interferon
treatment increased the amount of the entire PML protein population
proportionately, as no difference in the relative amounts of any species was
observed. The large majority of the species detected by this antibody were increased
in response to interferon, providing evidence that all of the species observed are
PML related. This conclusion agrees also with the data in figure 3.3, where an
siRNA targeting all PML species resulted in a clear loss of the majority of bands on
a western blot, as detected by an anti-PML antibody. Clearly, interferon treatment
did not appear to alter the ratios of species of PML, suggesting that it has little effect
on the splicing of the PML primary transcript. Importantly, no novel species were
produced upon interferon treatment that co-migrated with any of species A, B and C.
This suggests that the infection-specific PML species A, B and C are likely to be
produced as a direct result of Ad5 functions, and do not represent part of a host anti-
viral response mediated by interferon.
3.8 PML species B and C require Ad5 DNA replication for their
production
Production of the infection-specific PML species A has been shown to require the
viral E4 Orf3 protein in order to be produced (Leppard & Everett, 1999). E4 Orf3 is
expressed early in the course of an adenovirus infection, and precedes the onset of
viral DNA replication. The viral determinant for the production of infection-specific
species B and C however remains unknown. In order to further understand species
A, B and C, the role viral DNA replication plays in their production was
investigated. HEp-2 cells and A549 cells were mock infected or infected with Ad5
wild type 300 or E4 Orf3-deficient (inOrf3) adenovirus. At 1 h.p.i., cells were mock
treated or treated with 10mM hydroxyurea. Hydroxyurea is an inhibitor of
ribonucleotide reductase and thus prevents the production of deoxyribonucleotides,
therefore inhibiting DNA synthesis. 24 h.p.i. cells were harvested and the protein
content was separated by SDS-PAGE and western blot. Blots were probed with a
polyclonal anti-PML antibody, or antibodies to various adenovirus proteins (Fig.
3.7).
AFigure 3.7. Production of infection-specific PML species B and C require
Ad5 late phase functions. A 3 x 105 A549 were mock infected or infected with
Ad5 300 or Ad5 inOrf3 at an m.o.i. of 10 pfu/cell. 1h.p.i. the culture medium
was replaced with fresh 10% serum DMEM alone or medium containing 10mM
hyrdoxyurea. All cells were harvested at 24 h.p.i. and the protein content of the
lysates was separated in parallel by 8%, 10% and 15% SDS-PAGE and subjected
to western blotting in order to generate four blots. The blot representeing 8 %
PAGE separation was probed with a polyclonal anti-PML antibody (Xu et al.,
2003). The blots representing 10% PAGE separation was probed with a
polyclonal antibody against late structural proteins of Ad5 (AdJLB), and blots
representing 15% PAGE separation were probed with either a monoclonal anti-
DBP antibody or an anti-E4 Orf3 antibody (6A11). The arrows to the right of the
anti-PML blot indicate the migration position of infection-specific species A, B
and C. Protein sizes are indicated in kDa to the left hand side of each blot. B 3 x
105 HEp-2 cells were treated as in A, though the protein content of the lysates
was separated by 8% SDS-PAGE alone. The blot was probed with a polyclonal
anti-PML antibody. The arrows to the right of the blot indicate the migration
positions of infection-specific species A, B and C. Protein sizes are indicated in
kDa to the left hand side of the blot.94
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The addition of hydroxyurea in A549 clearly inhibited the production of adenoviral
late proteins, which are produced after viral DNA replication, but had no effect on
two early gene products, Orf3 and DBP, suggesting that viral DNA replication had
been sufficiently inhibited (Fig 3.7A, right hand panels). Species A was particularly
poorly expressed in infected A549 cells, even in the absence of hydroxyurea, making
any analysis of this species impossible within this cell type. HEp-2 cells did produce
detectable amounts of species A (Fig. 3.7B), though the amount relative to
endogenous PML appeared to decrease after the addition of hydroxyurea, suggesting
that species A may not be solely dependent on E4 Orf3, and indeed may require an
additional factor produced by DNA replication or subsequently to it.
In both HEp-2 and A549 cells the production of species B and C was completely
inhibited by hydroxyurea, suggesting that these species are produced upon, during or
after viral DNA replication, and directly require a factor produced by this process or
subsequent to it. Without viral DNA replication, Ad5 is unable to produce the
proteins characteristic of the late phase of infection. It is possible that a late phase
protein or proteins of Ad5 may be directly responsible for the production of species
B and C, or else the altered cellular environment of a late phase infection may
generate these new PML forms.
3.9 Investigating viral determinants required for the production of
PML species A, B and C
Each of PML species A, B and C is only produced when infection by Ad5 occurs. In
the case of species A, E4 Orf3 is necessary for its production, though any viral
determinants required for the production of B and C remains unknown. In order to
investigate what viral proteins may be required, a selection of adenoviral proteins
were chosen and exogenously expressed in several cell lines. The effects on the
PML population could then be monitored by use of an anti-PML antibody. The viral
proteins were selected according to their known functions and how these might
influence the PML population through either a post-translational modification or by
altering the splicing pattern of PML mRNA.
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E4 Orf3 and E4 Orf4
Ad5 E4 Orf3 has been shown to be required for the production of species A, as
viruses deficient in this protein do not produce this species. Unlike species B and C,
species A does not require viral DNA replication or any viral late proteins for its
production. However, exogenous expression of E4 Orf3 alone is unable to induce
changes in the PML population of transfected cells (K. Leppard, unpublished). It is
therefore possible that E4 Orf3 functions in concert with an additional Ad5 early
gene protein to alter the PML population. Previous studies have indicated that E1B-
55K and E4 Orf6 are not required for the production of species A (Leppard &
Everett, 1999), so an alternative early gene product was considered in E4 Orf4. This
protein is known to modulate viral transcript splicing through dephosphorylation of
cellular SR proteins, which is achieved by Orf4-induced activation of protein
phosphatase 2A (Kanopka et al., 1998). It was considered that Orf4 may alter post-
translational modifications of PML proteins, and this possibility was therefore
investigated.
Wild-type E4 Orf4 was amplified by PCR from Ad5 genomic DNA and cloned into
the expression vector pcDNA 3.1(-) (see Appendix). In order to confirm expression
of Orf4 from two plasmid clones, HEK 293 cells were mock-transfected or
transfected by either E4 Orf3 or E4 Orf4 expression plasmids. Two different clones
of the Orf4 expression plasmid were used (Cl.1 and Cl.2). Cells were harvested 24
hours later and SDS-PAGE and western blotting was used to analyse the protein
content for PML, Orf3 and Orf4 expression (Fig. 3.8). Strong Orf3 and Orf4
expression was confirmed using antibodies specific to each of these proteins.
Figure 3.8. Expression of E4 Orf3 or Orf4 does not alter the PML protein
population. A 2.5 x 105 HEK293 cells were transfected with 500ng empty vector
(pcDNA3.1 (-), lane 1)) or transfected with 250ng pcDNA3.1-orf3 alongside
250ng empty vector pcDNA3.1 (lane 2). 250ng of two clones of pcDNA3.1-orf4
were used to transfect cells alongside 250ng of empty vector pcDNA3.1 (lanes 3
and 4) or pcDNA3.1-orf3 (lanes 5 and 6). 24 hours later cells were harvested and
the protein content of the lysates was separated by 8% (for PML) or 15% (Orf3,
Orf4) SDS-PAGE and subjected to western blotting. Replica blots were probed
with polyclonal anti-PML (Xu et al., 2003), anti-E4 Orf3 (6A11) or anti-E4 Orf4.
The arrows to the right of lower panels indicate the presence of E4 Orf3 or Orf4
respectively. Proteins sizes are indicated in kDa to the left of the blot. B 2.5 x 105
HEp-2 cells were mock infected or infected with wild-type Ad5 300 at an m.o.i.
of 10 (lanes 1 and 2). In parallel, 2.5 x 105 HEp-2 cells were co-transfected with
250ng pcDNA3.1-orf3 or pcDNA3.1-orf4 alongside 250ng empty vector
pcDNA3.1 (lanes 3 and 4) or pcDNA3.1-orf3 and pcDNA3.1-orf4 together (lane
5). Cells were harvested 24 hours post infection or 24 hours after transfection,
and the protein content of the lysates analysed as in panel A. The infection-
specific species of PML are indicated to the right of the blots by arrows marked
A, B and C. The arrows to the right of the lower panels indicate E4 Orf3 and
Orf4 respectively. Protein sizes are indicated in kDa to the left of the blot.97
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However, expression of these proteins had little effect on the PML population, which
remained unchanged from that of mock-transfected cells.
HEp-2 cells were then mock transfected or transfected with E4 Orf3 or the E4 Orf4
clone 1 plasmid, then harvested 24 hours later. In parallel HEp-2 cells were mock-
infected or infected with wild type Ad5 300, and harvested 24 h.p.i. The protein
content of the lysates was then analysed by SDS-PAGE and western blotting. Orf3
and Orf4 expression was confirmed using the antibodies mentioned above, though
the level of expression in transfected cells was significantly weaker than that seen in
293 cells, probably due to a lower transfection efficiency.
Species A, B and C were detected in the Ad5 300 infected HEp-2 cells, though no
corresponding changes were observed in any of the cells transfected with Orf3, Orf4
or both of these proteins. Thus none of the infection-specific species of PML can be
recreated by exogenous expression of these two proteins.
L4 22K and 33K
A possible mechanism underlying the production of species A, B and C is an
alteration in splicing of the PML primary transcript that is induced by Ad5. Ad5 is
known to use alternative splicing to generate various mRNAs, and has been shown
to encode proteins that can alter the cellular splicing machinery. In particular, the L4
22K and 33K proteins have been shown to act as splicing factors which regulate the
production viral mRNAs (Farley et al., 2004, Morris & Leppard, 2009, Törmänen et
al., 2006). These proteins are produced at the onset of the late phase of infection,
and are good candidates as viral factors responsible for producing infection-specific
changes in the PML population (Fig. 3.9).
HEp-2 cells were mock transfected or transfected with pCMV-22KFLAG, pCMV-
33KFLAG or pCMV-22/33KFLAG, which expresses both L4 22K and L4 33K from
their overlapping reading frames. 24 hours later cells were harvested and the protein
content was analysed by SDS-PAGE and western blotting. An anti-FLAG antibody
was used to confirm expression of the epitope-tagged proteins, and a polyclonal anti-
PML antibody was used to probe the PML protein population.
Expression of 22K and 33K was detected only when expressed from the plasmids
encoding one of these proteins. When expressed in cis alongside 22K, 33K was
poorly expressed in comparison to cells transfected with 22K and 33K in trans. The
22K of pCMV-22/33KFLAG is not FLAG-tagged, and cannot be detected by the
antibody used in this instance. However, expression of 22K or 33K, either alone
o
aFigure 3.9 L4 22K and 33K do not induce the production of any infection-
specific species of PML. 2.5 x 105 HEp-2 cells were mock transfected with
500ng empty vector pCI-neo (lane 1) or transfected with 250ng of empty vector
alongside 250ng L4 22K expression plasmid pCMV-22KFLAG (lane 2) or L4
33K expression plasmid pCMV-33KFLAG (lane 3). Where simultaneous 22K
and 33K expression was required, cells were transfected with 250ng each of
pCMV-22KFLAG and pCMV-33KFLAG (lane 4), or with 500ng of pCMV-
22/33KFLAG (lane 5). 24 hours later cells were harvested, separated by 8%
SDS-PAGE and western blotting in order to generate two replica blots. Each
blot was probed with either a polyclonal anti-PML antibody (Xu et al., 2003)
(upper panel) or a monoclonal anti-FLAG antibody (M2, lower panel). 22K and
33K are indicated by arrows to the right hand side of the blot. Protein sizes are
indicated in kDa to the left hand side.99
r together in trans, did not produce any detectable changes in the PML population,
nd did not lead in the production of species A, B or C. These data therefore suggest
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that 22K and 33K are not the viral proteins responsible for the production of the
infection-specific species of PML.
Protein IX (pIX)
pIX is an intermediate gene product of adenovirus that is thought to stabilise the
capsid of the virus, as well as to act as a transcriptional activator (Lutz et al., 1997,
Rosa-Calatrava et al., 2001). Expression of pIX leads to the appearance of novel
nuclear structures, termed clear amorphous inclusions that do not co-localise with
viral RNA or capsid proteins. PML protein has been shown to be recruited to and
confined within these inclusions (Rosa-Calatrava, 2003), leading the authors to
hypothesise that pIX maintains the disruption of PML protein throughout late
stagesof infection in order to enhance the growth of the virus.
This observation suggested a possible interaction of pIX with the PML population,
and pIX was therefore considered as a candidate protein responsible for the induction
of species B and C. HEp-2 or U2OS cells were mock transfected, or transfected with
either empty vector plasmid or a pIX expression plasmid (pCMV-IX) (Caravokyri &
Leppard, 1995). 24 hours later the cells were harvested and the protein content of
the lysates was subjected to SDS-PAGE and western blotting (Fig. 3.10). pIX
expression in both cell lines was confirmed using an anti-pIX antibody (Caravokyri
& Leppard, 1995), though expression was far weaker in HEp-2 cells. However, no
changes in the PML population were detected using a polyclonal anti-PML antibody
in either cell type. Thus pIX is unlikely to be responsible for the production of
species B and C, though the possibility that it works in concert with other viral
proteins cannot be ruled out.
Figure 3.10 Expression of protein IX does not induce changes in the PML
protein population. 2.5 x 105 HEp-2 (lanes 1-3) or U2OS (lanes 4-6) cells were
mock transfected (lanes 1-4), or transfected with 500ng of empty vector DNA
pCI-neo (lanes 2, 5) or 500ng pCMV-IX (lanes 3 and 6). 24 hours later cells
were harvested and the protein content of the lysates was separated by 8% (PML)
or 15% (pIX) SDS-PAGE and subjected to western blotting. Blots were probed
with a polyclonal anti-PML antibody (Xu et al., 2003)or an anti-pIX antibody.
The arrow to the right of the lower panels marks the migration position of pIX.
Protein sizes are indicated in kDa to the left hand side of the blots.101
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3.10 Discussion
The diversity of the PML protein population of a cell is generated by two principle
mechanisms. Firstly, the PML primary transcript can be differentially spliced to
generate mRNAs encoding at least 11 protein isoforms consisting of both nuclear
and cytoplasmic variants of PML (Jensen, 2001). Second, PML proteins can be
extensively post-translationally modified in a number of ways, including
sumoylation, phosphorylation and acetylation (Hayakawa et al., 2008, Kamitani et
al., 1998, Scaglioni et al., 2006). With these two processes combined, it is easy to
see how a multitude of PML species may be generated within the cell that each
possesses its own unique biochemical properties and functions. Thus, by altering the
constitution of the PML population a cell may adjust to suit various external or
internal stimuli, and these processes may be exploited by adenovirus to make the cell
more conducive to viral replication.
The data presented in this chapter describe changes induced in the PML population
upon infection by adenovirus. Notably, three infection-specific species of PML were
detected upon infection of a variety of cell types. These species were validated as
PML species by the use of three independent anti-PML antibodies and through the
use of siRNA-mediated depletion of PML. One of these species, termed species A,
has previously been described and requires the viral E4 Orf3 protein for its
production. The two other species B and C are previously unrecorded and therefore
represent novel species of PML. The production of these species was independent of
the E4 Orf3 status of the infecting virus, but required viral DNA replication. Species
C is of a lower molecular weight than that of known nuclear PML isoforms, and
accordingly was shown to be localised within the cytoplasm of infected cells. In
uninfected cells, species A, B and C could not be detected even after inhibition of
proteasome-mediated degradation, suggesting that these species are produced only
upon infection by adenovirus. The mechanism employed by adenovirus to generate
these species remains unknown, but it is likely to involve alterations to the processes
mentioned above.
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Infection-specific species A was detected by the polyclonal anti-PML antibody and,
as previously described, by the monoclonal antibody 5E10 (Leppard & Everett,
1999). Species A was not detected by the monoclonal PG-M3 antibody. The reason
for this is unknown, but it was noted that PG-M3 did not detect any bands
corresponding to the migration positions of full-length PML I and PML II and their
sumoylated forms. This may suggest that PG-M3 has difficulty detecting the entire
PML population on a western blot. One possible explanation is that the epitope
targeted by this antibody may be the subject of a post-translational modification in a
subset of PML species, masking them from the antibody. The epitope of PG-M3 lies
15 amino acid residues from the first sumoylation site of PML (Santa Cruz
Biotechnology), and antibody recognition may be disrupted when this particular site
is sumoylated.
The 5E10 antibody did not detect species B and C in infected cells for two possible
reasons. Firstly, they may be post-translationally modified at or in close proximity
to the amino acid sequence recognised by this antibody, thus preventing recognition
by 5E10. Alternatively, they may represent alternative splice variants of PML that
lack exon 5, which encodes the 5E10 epitope (Stuurman et al., 1992), and it is
possible that adenovirus is altering cellular splicing to favour the production of these
species. Species C in particular is likely to arise from a novel differentially spliced
transcript representing a cytoplasmic variant of PML. Indeed species C was found to
be strongly expressed in the cytoplasm of infected A549 cells. Cytoplasmic variants
of PML exclude exon 6 (which contains the NLS) in conjunction with exon 5 alone
or with both exons 4 and 5. Therefore these variants would not possess the epitope
detected by 5E10. Species B, however, showed exclusively nuclear localisation and
is of a molecular weight similar to that of other nuclear PMLs. It may elude
detection by 5E10 because it possesses a post-translational modification within the
epitope, though it is possible that it too lacks exon 5. PML variants are known to
exist that lack exon 5, but retain all the other exons typical of nuclear isoforms
(Jensen, 2001), and these would be nuclear in location.
The PG-M3 antibody did detect infection-specific species that co-migrated with
species C, supporting a PML protein basis for this species. However, it was apparent
that the relative amounts detected varied from the polyclonal anti-PML antibody,
though care has to be taken when comparing relative amounts of a protein detected
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by two different antibodies. The binding kinetics between each antibody and its
respective epitope(s) will differ according to multiple factors, including post-
translational modifications, sample preparation and experimental method.
All of the infection-specific PML species were depleted by siRNA targeting exon 3
of PML, though only species A was detected by the 5E10 antibody which recognises
an epitope encoded within exon 5 of the PML protein. These observations, taken
together with the relatively large size of species A, suggest that it is based on a full-
length nuclear form of PML. Species A was solely confined to the nuclear fraction
of infected cells alongside other larger PMLs. Indeed the migration position of
species A on a PAGE gel corresponds to a molecular weight that is slightly larger
than PML isoforms I and II. Given that E4 Orf3 has been shown to directly interact
with the unique C terminus of PML II (Hoppe et al., 2006), this isoform is the most
likely candidate as the basis of this species. A post-translational modification of
PML II induced by E4 Orf3 may be responsible for the increase in molecular weight
which could account for species A. This possibility is addressed in the following
chapter.
Notably, PML species A was the only species that was not detected in every cell type
examined. After repeated attempts, U2OS cells were found to be incapable of
producing this species, yet still supported the appearance of species B and C. This
suggests either that this cell type possesses an unusual PML population or that it
lacks the required cellular machinery to support the production of species A. U2OS
cells have previously been recorded to possess unusual properties that may be linked
to an aberrant PML population. For example, the HSV-1 early gene product ICP0
has been shown to target PML NBs and cause de-sumoylation, and the subsequent
proteasome-mediated degradation, of PML isoforms (Everett et al., 1998). ICP0
mutants grow poorly in Vero cells, but to levels similar to wild-type in U2OS cells
(Mossman et al., 2000).  Furthermore, while IFNα inhibits ICP0- virus growth, it has
no effect on the growth of the virus in U2OS, suggesting that this cell type is
somehow deficient in the IFN pathway (Mossman et al., 2000). Given that PML
proteins are implicated in the IFN response pathway, it is possible that U2OS cells
lack an isoform of PML normally responsible for exerting an antiviral effect. One
may then speculate that it is this isoform that is usually targeted by Ad5 E4 Orf3,
resulting in the production of species A. In support of this, exogenously-expressed
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ICP0 has been shown to function analogously to E4 Orf3 within the context of an
Ad5 inOrf3 infection (Ullman & Hearing, 2008). However further experimentation
would be required to test this hypothesis. Specifically, it would be of interest to
compare the spectrum of individual PML isoforms in U2OS cells to that of a cell line
capable of producing species A. If U2OS cells were found to be deficient in a
particular PML isoform then this would be a good candidate as the basis of species
A.
None of the infection-specific PML species were induced through the addition of
exogenous IFNα to the culture medium.  As previously described, addition of IFNα 
led to a marked increase in PML protein expression, further supporting the notion
that PML can act as an antiviral effector. Such an increase in PML may pose a
particular problem to Ad5, as increasing amounts of an antiviral protein will inhibit
viral replication. Therefore, Ad5 may possibly alter the PML population to
overcome the antiviral effects of PML, and these alterations exhibit themselves as
the infection-specific species observed. As mentioned above, the two most plausible
mechanisms whereby Ad5 may generate novel PML species is either novel post-
translational modification or by interfering with the splicing process that generates
different PML species. It is worth noting that these two mechanisms are not
mutually exclusive, as a novel splice variant of PML may still be post-translationally
modified exclusively upon virus infection.
The possibility that post-translational modification in the form of proteolytic
cleavage by the adenovirus 23K protease was considered, though comparison of the
amino acid sequence of each of the PML protein isoforms revealed no similarity to
the 23K target site consensus sequence (M/I/L XGG-X or M/I/L XGX-G (Webster et
al., 1989)). This indicated that this protease is not responsible for the production of
the infection-specific species. Nonetheless, this would need to be confirmed
experimentally and does not discount the possibility of a role of cellular proteases
that may be induced upon infection in the production of the infection-specific forms
of PML protein.
The population of PML mRNA transcripts has previously been shown to be altered
during HSV-1 infection. The amount of a cytoplasmic variant of PML, termed PML
Ib, was shown to be disproportionately increased (McNally et al., 2008). This
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species of PML excludes exons 5 and 6, resulting in a frameshift that ultimately
terminates the protein prematurely in exon 7a. While this species was up-regulated
in response to IFN-γ, its ratio relative to the total PML population remained 
unchanged.
Herpes simplex virus type 2 (HSV-2) has recently been shown also to alter the PML
population. The viral ICP27 protein was shown to influence the splicing of the PML
primary transcript to favour production of PML V over PML II (Nojima et al.,
2009). Whether Ad5 exerts similar effects on PML splicing to produce any of the
infection-specific species of PML is unknown.
None of the infection-specific species can be recreated in uninfected cells by
inhibiting proteasome-mediated degradation, supporting the hypothesis that these are
specific changes induced by the virus. The possibility that adenovirus may
selectively target and interact with rare splice variants or post-translationally
modified PML molecules in order to protect them from degradation, can therefore be
discounted. Thus all three of the infection-specific species are likely to be produced
only upon the action of a specific viral protein or proteins, or indirectly via virus
infection-induced effects on the cell. Interestingly, species A and B were somewhat
stabilised by addition of MG132 in A549 and HEp-2 cells respectively. This
indicates that once these species are produced, they are subject to regulation and
proteasome-mediated degradation that may vary according to cell type. This may
explain the relative difficulty in detecting species A within infected A549 cells as
compared with HEp-2 cells, and suggests that the infection-specific species of PML
may be regulated in differential ways depending on the cell type.
The precise viral determinants required for the production of these infection-specific
PML species remains incompletely understood. E4 Orf3 is known to be a viral
factor required for species A, yet is unable to induce this species alone by exogenous
expression. However, this methodology has limitations, the most important of which
is the efficiency of transfection. HEp-2 cells were shown to express Orf3 poorly by
transient transfection when compared to that produced during a viral infection,
indicating a poor transfection efficiency. Poor efficiency reduces the ability to detect
any potential changes in the PML population induced by the protein being over-
expressed, and thus may lead to a false negative result. This problem was somewhat
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overcome by examining the effects of Orf3 expression in HEK293 cells, which are
readily transfectable and expressed Orf3 to high levels. That no change was detected
in either cell type suggests that E4 Orf3 may require an additional viral protein in
order to produce species A. Since the production of species A is not inhibited by the
addition of hydroxyurea and hence does not seem to require any late proteins, it is
likely that the additional protein required is an early or intermediate Ad5 gene
product. Adenovirus is known to use early viral proteins in concert in order to
achieve specific functions, for instance E4 Orf6 and E1B 55K act together to target
p53 for proteasomal degradation (Querido et al., 2001). E4 Orf6 and E1B 55K
deficient viruses are still capable of producing species A, however, and are unlikely
to be the proteins responsible (Leppard & Everett, 1999). In both HEp-2 and
HEK293 cells, no evidence could be found that exogenous expression of Orf3 alone,
or in concert with the early protein E4 Orf4, could alter the PML population.
Therefore it is likely that species A is produced by an action of Orf3 working in
tandem with another unknown viral protein.
Production of PML species B and C was completely inhibited by treatment of
infected cells with hydroxyurea, indicating a late protein or proteins are responsible
for their appearance. However, expression of the splicing factors L4 22K, 33K, or
the intermediate protein pIX, did not result in the production of any species
resembling B or C, though as mentioned above, the success of this methodology is
dependent on obtaining a sufficiently high transfection efficiency, so any role of
these proteins cannot be completely ruled out. Nonetheless, significant expression of
these viral proteins was detected and no corresponding change in the PML
population was observed, suggesting that these proteins do not induce any infection-
specific species of PML alone.
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Chapter 4
Characterisation of the infection-specific
species of PML
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4.1 Introduction
Infection of a number of cell types by Ad5 results in the production of three novel
species of PML protein (Chapter 3), henceforth termed PML- A, -B and -C. The
basis and nature of these species remained unknown and these questions were
therefore addressed by the experiments presented in this chapter. PML-A is
dependent on the viral E4 Orf3 protein and is not produced upon infection of U2OS
cells. In contrast, PML-B and -C are E4 Orf3-independent and are produced in
U2OS cells. Based on these observations, it is likely that the production of species A
is a separate phenomenon from that of PML-B and -C, and therefore the following
experiments were designed with this is mind.
The experiments initially focused on determining the PML isoform basis of each of
PML- A, -B and- C. The primary tool utilised to achieve this was a set of PML
isoform-specific antibodies. These antibodies recognise the unique C terminus of
their respective isoform. The use of antibodies was complemented by studies using
various siRNAs against different PML isoforms. Preliminary studies were then
made to characterise the differences between infection-specific PML species and
those present in uninfected cells. Experiments focused on the two primary
mechanisms that Ad5 might employ to generate novel species of PML; by alternative
splicing or by targeted post-translational modification of existing isoforms.
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4.2 Validation of PML isoform-specific antibodies
The primary transcript of the pml gene is alternatively spliced to give rise to mRNAs
encoding at least 11 protein isoforms. Until recently, anti-PML antibodies have
tended to be pan-isoform specific and therefore detect most, if not all, of the PML
protein isoforms produced by the cell. In order to study individual PML isoforms it
is necessary to utilise antibodies that recognise the unique C-terminal region of the
respective isoforms. Such antibodies were used during the course of this study,
though only antisera to PML isoforms I-V were available (Xu et al., 2005), as the C-
terminal region unique to PML VI is too short for an epitope to produce an isoform-
specific antibody. Prior to experimental use, it was important that each isoform-
specific antibody was confirmed as specific for the relevant PML isoform. In
particular, it was important to verify that the antibodies were specific to one PML
isoform only, and did not cross-react with other PML isoforms.
HEp-2 cells were transiently transfected with one of the expression plasmids pCI-
neoFLAG PML I-VI or empty vector pCI-neoFLAG. 24 hours later the cells were
harvested to generate a set of lysates that possessed an abundance of a single PML
isoform. The protein content of these lysates was separated multiple times in parallel
by SDS PAGE to allow a set of replica blots that could then be subjected to western
blot analysis using either anti-FLAG or one of the isoform-specific anti-PML
antibodies (Fig. 4.1).
The presence of each of the exogenously expressed PML proteins was confirmed by
using the anti-FLAG antibody, as the FLAG epitope is present on the N-terminus of
these proteins (Fig. 4.1). All proteins were expressed, though PML IV expression
was weak. Replica blots, independently probed with each of the isoform-specific
antibodies anti-PML II-V (Fig. 4.1), clearly detected a single band only in the
expected lane that corresponded to the correct size of the respective PML. With
each of these antisera, few non-specific bands were observed in any of the other
lanes, indicating that the antibodies are highly specific and produce little non-
specific background. However, anti-PML II, IV and V detected some bands within
the relevant lane that were of a lower molecular weight than the isoform being
detected. These bands possibly represent degradation products arising from the
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exogenously-expressed protein that still possess the C-terminal epitope of the
isoform in question.
In contrast, the anti-PML I antibody clearly detected numerous bands in all lanes,
though the strongest band seen appeared in the correct lane and was of the expected
size for full-length PML I. The abundance of lower molecular weight proteins in
the PML I lane may be the degradation products of the exogenously expressed PML
Figure 4.1 Validation of PML isoform-specific antibodies. 3 x 105 HEp-2
cells were transfected with 500ng each of expression plasmids pCI-neo FLAG-
PML I-VI or empty vector pCI-neo (mock). 24 hours later cells were lysed and
proteins were separated by 8% SDS-PAGE then subjected to western blotting.
Each lysate was loaded 6 times in parallel to allow the protein content to be
independently probed by each of Anti PML I-V or Anti FLAG (indicated to the
right of each blot). For blots Anti-PML I-V the correct migration position of the
protein being detected is indicated by an arrow. For lanes 36-41 an asterisk is
adjacent to the band that corresponds to the relevant PML protein. Protein sizes
are indicated in kDa to the left-hand side of each blot.
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I protein. This explanation is strengthened when one considers the epitope of the
anti-PML I antiserum, which corresponds to the last 20 amino acids of the C
terminus of PML I. With this extreme C-terminal epitope, it is clear how this
antiserum could detect a multitude of PML I-related fragments that are the result of
various cleavage reactions along the length of this protein.
Relative to the other blots, anti-PML I also produced a relatively strong banding
pattern in lanes other than those representing PML I-transfected cells. This banding
pattern was similar to that of PML-I transfected cells and occurred both in cells
transfected with empty vector (mock) and PML expression plasmids, ruling out
cross-reactivity with other PML isoforms. It is therefore likely that the anti-PML I
antibody was detecting the endogenous PML I and its higher molecular weight,
sumoylated forms (lanes 2-4 and 7), an explanation that is supported by the fact that
PML I is amongst the most strongly expressed PML isoforms (Condemine et al.,
2006). Taken together, it was therefore judged that all of the isoform-specific
antibodies were sufficiently specific for use in subsequent experiments.
Differences were observed in endogenous levels of PML I when PMLs IV, V and VI
were over-expressed (lanes 4-6), as compared to mock-transfected cells. Over-
expression of PML IV caused an increase in sumoylated forms of PML I, whereas
expression of PMLs V and VI caused a decrease in total PML I content. These
observations suggested a possible auto-regulatory role of PML isoforms on the total
PML population, but investigation of this phenomenon was outside the scope of this
study.
4.3 Attempted detection of PML species A using PML isoform-
specific antibodies
Infection-specific PML-A has been shown to be dependent on the presence of the
Ad5 early gene product E4 Orf3. The molecular basis of this novel PML species is
unknown, as it does not co-migrate with any known PML isoforms by SDS-PAGE
separation. In order to identify this species, the validated PML isoform-specific
antibodies were employed to probe lysates from cells infected with either wild-type
or an E4 Orf3-deficient mutant Ad5 (Fig. 4.2).
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In the case of anti-PMLs I, II, IV and V a band of significant intensity was seen in
both infected and mock-infected cells that corresponded to the expected size for that
full-length isoform. It is notable that anti-PML III did not detect a species that co-
migrated with PML III expressed from cDNA. A possible explanation may be that
PML III has been shown to be the most weakly expressed of PML isoforms
(Condemine et al., 2006), making detection of the low levels of endogenous PML III
by this anti-serum particularly difficult.
As expected, infection by Ad5 wild type 300 (lane 2) resulted in the production of a
species of PML detected by the pan-PML antibody of approximately 130kDa in size
(PML-A) that was absent in mock infected cells (lane 1) and mutant inOrf3-infected
cells (lane 3) (Leppard & Everett, 1999). Infection by wild type Ad5 also caused a
reduction in the amount of high-molecular weight, sumoylated PMLs over 130kDa.
It is of note that the pattern of higher molecular weight, SUMOylated PMLs above
130kDa also differed from that in both mock-infected and Ad5 300-infected cells,
suggesting that E4 Orf3 may be in part, but not completely, responsible for the
changes seen in these species during infection by Ad5 300.
None of the isoform-specific anti-sera were able to detect PML-A in this experiment
or three other repeat experiments (data not shown), despite its relative abundance in
the PML population (as indicated by the pan-PML antibody). However, other
infection-specific changes were seen that were independent of E4 Orf3. In
particular, the antisera against PMLs I and II detected significant differences (*,
Fig.4.2) in the cellular PML content between cells that were infected or mock
infected.
Anti-PML I detected changes in both infections (lanes 5 and 6), as there was less
high-molecular weight, SUMOylated PML present above 130kDa in size than mock-
infected cells (lane 4). This is unlikely to be a consequence of Ad5 infection causing
a general decrease in the total amount of PML I, as equal amounts of the unmodified
protein were observed in infected and mock-infected cells (indicated by the arrow).
Second, an infection-specific species that was not dependent on E4 Orf3 is present at
Figure 4.2. PML isoform-specific antibodies do not detect the infection-
specific, E4 Orf3-dependent species of PML. 3 x 105 HEp-2 cells were mock-
infected or infected with either Ad5 wt 300 or E4 Orf3 mutant inOrf3 at an
M.O.I. of 10 p.f.u./cell. Cells were lysed at 24h.p.i. and lysates were separated
by 8% SDS-PAGE then subjected to western blotting. Each lysate was loaded 6
times in parallel to allow the protein content to be independently probed by each
antibody (indicated below each blot). The bold arrow adjacent to the anti-PML
blot indicates the migration position of PML-A. The arrows adjacent to the blots
probed with isoform-specific antibodies indicate the expected migration positions
of the respective full-length PML isoforms that are being detected, as determined
from over-expression of cDNA PML isoform clones. Protein sizes are indicated
in kDa to the left hand side of each blot. The anti-PML antibody used here was
5E10, a monoclonal antibody that recognises an epitope common to all PML
proteins (including PML VI). Asterisks indicate infection specific bands.114
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approximately 60kDa. It is interesting to note that this species was not detected by
the pan-PML monoclonal anti-serum (lanes 1-3). This suggested that this species
may lack exon 5, as the epitope for the 5E10 pan-PML antibody used in this instance
is located within this exon (Stuurman et al., 1992).
The anti-PML II anti-serum detected numerous infection-specific changes in the
PML II population that were independent of E4 Orf3. Strikingly, several apparent
infection-specific PML species were detected (asterisks). These infection-specific
species, although relatively strong, do not appear to be detected by the 5E10
antibody, but do resemble infection-specific species detected by the polyclonal anti-
PML antiserum in HEp-2 cells (Fig. 3.1). It is possible that these species are not
detected by 5E10 because they may lack exon 5, in which lies the epitope for the this
antibody (Stuurman et al., 1992).
4.4 Super-infection of PML-transfected HEp-2 cells
The E4-Orf3 dependent species PML-A was not detected by any of the isoform-
specific anti-sera. One possible explanation for this is that the isoform that forms the
basis of this novel species is post-translationally modified at a site which
corresponds to, or is adjacent to, the epitope of the relevant antibody. It is feasible
that such a modification could ‘mask’ the epitope from the antibody, thereby
preventing detection by western blotting. It could also not be discounted that PML-
A was an extensively post-translationally modified form of PML VI, for which no
specific antibody was available. To investigate these possibilities, an alternative
strategy was devised in which cells were infected that were expressing FLAG-tagged
PML isoforms (Fig. 4.3). The FLAG epitope is located in each case at the N
terminus upstream of the first exon of PML. Thus any post-translational
modifications that these exogenously expressed PML proteins undergo should not
interfere with the detection of the FLAG epitope.
Transfection of HEp-2 cells with empty vector did not prevent the appearance of the
E4 Orf3 dependent species of PML, as it is quite clearly detected by the polyclonal
anti-PML antibody in infected cells (Fig. 4.3, lane 2, arrow). However, although
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expression of FLAG-PMLs I-VI was confirmed in both uninfected and infected cells
(lanes 4-15), in no case was a FLAG-tagged band co-migrating with PML-A clearly
detected in any of the PML-transfected/Ad5-infected cells. Despite this, a subtle
difference was noticed in the banding pattern of PML II-transfected cells upon
infection that could represent the conversion of FLAG-PML II into PML-A (lane 7).
Infection with Ad5 appeared to alter the mobility of the PML II band detected by the
anti-FLAG antibody, and caused the band to migrate to a slightly higher position
than that of uninfected cells (lane 6).
Figure 4.3 PML-A cannot be detected upon super-infection of HEp-2 cells
expressing FLAG-tagged PML proteins. 2.5 x 105 HEp-2 cells were
transfected with 500ng empty vector pCI-neo alone (lanes 1-3), or co-transfected
with 410ng pCI-neo plus 90ng pCI-neoFLAG-PMLI-VI (lanes 4-15). 16 hours
later, cells were mock infected or infected with wild-type Ad5 300 at an m.o.i. of
10. At 16 h.p.i. the medium bathing the cells was replaced with fresh medium
containing 50µM MG132. At 24 h.pi. the cells were harvested and subjected to
8% SDS-PAGE and western blotting. The blot was separated into two pieces,
and probed with either a polyclonal anti-PML antibody (lanes 1 and 2) or a
polyclonal anti-FLAG antibody (F7425, lanes 3-15). Species A, as detected by
the anti-PML antibody, is indicated by an arrow to the right of the anti-PML
blot. Protein sizes are indicated in kDa to the left hand side of the blots.
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This possibly indicated that PML II was undergoing post-translational modification
upon infection with wild-type Ad5. However, it was unclear if a new species of PML
II was genuinely being produced, as a complication of the approach was that
infection by Ad5 tended to result in increased expression of all of the FLAG-tagged
PML isoforms. Therefore it was difficult to determine whether PML II was being
selectively modified, or whether the apparent difference in banding pattern between
infected and uninfected cells was an artefact of differences in expression.
4.5 siRNA mediated knockdown of the E4 Orf3-dependent PML-A
It was previously shown that PML-A was not produced in cells that had been
previously depleted of their total PML content by PML siRNA prior to infection
(Fig. 3.3). In order to identify the PML isoform forming the basis of PML-A, siRNA
was used to deplete the cells of individual PML isoforms before infection with Ad5.
Two previously described isoform-specific siRNAs were employed that target either
PML I or PML II mRNA species (Pavan Kumar et al., 2007). PML I and II were
chosen as the main candidates because they migrate to a similar position as PML-A
by SDS-PAGE and were therefore considered more likely to be the basis of this
species. Also, PML II has been shown to directly interact with the Ad5 E4 Orf3
protein, which is necessary for the production of PML-A (Hoppe et al., 2006,
Leppard et al., 2009, Leppard & Everett, 1999).
Infection by wild-type Ad5 led to the production of infection-specific PML-A in
both mock transfected and control siRNA transfected cells (Fig. 4.4, lanes 2 and 3).
Only a moderate decrease in PML expression was observed upon transfection with
the pan-PML siRNA, but PML-A was clearly depleted in comparison to both mock
transfected and control siRNA transfected cells (lane 4). Upon transfection with
increasing amounts of PML I siRNA, PML-A was unaffected. However, upon
transfection of PML II siRNA PML-A was depleted in a dose-dependent manner,
while total cellular protein levels remained equivalent, as indicated by GAPDH
levels.
Thus knock-down of all PML II species within the cell results in a loss of PML-A,
implying that this species is a novel variant of PML II. PML-A may be a novel
splice variant of PML II that retains the carboxyl terminal region, or it may represent
a novel post-translational modification of this isoform that is induced by infection
with an adenovirus possessing the E4 Orf3 protein.
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(Figure 4.4 PML-A is depleted by siRNA targeting PML II. 2.5 x 105 HEp-2
cells were mock transfected (lanes 1 and 2) or transfected with 200pmol of
control siRNA (lane 3) or pan-PML siRNA (lane 4), or with 0.25, 1, 50 or
200pmol of siRNA targeting PML I (lanes 5 to 9) or PML II (lanes 10 to 14).
48h later cells were mock infected (lane 1) or infected with wild type Ad5 300 at
an m.o.i. of 10 (lanes 2-14). 24 h.p.i. the cells were harvested and the protein
content of the lysates was separated in parallel by 8% SDS-PAGE and western
blotting in order to generate two replica blots. The blots were probed with
monoclonal anti-PML antibody 5E10 or monoclonal anti-GAPDH antibody
(ab9484). The arrow to the right hand side of the blots indicates the migration
position of PML-A. Protein sizes are indicated in kDa to the left hand side of
the blots.118
.6 Can expression of E4 Orf3 complement an inOrf3 infection for
ML-A production?
4 Orf3 directly interacts with a region located in the carboxyl terminus of PML II,
nd it is through this interaction that PML NBs become reorganised into ‘tracks’
Carvalho et al., 1995, Hoppe et al., 2006, Leppard et al., 2009). E4 Orf3 is required
or the production of PML-A, which above has been showed to be related to PML II
Fig. 4.4). Consideration was therefore given to the possibility that PML-A arises as
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a consequence of the direct interaction between PML II and E4 Orf3 (Hoppe et al.,
2006, Leppard et al., 2009). To investigate this, E4 Orf3 mutant N82A was utilised
alongside wild-type E4 Orf3. N82A cannot interact with PML II and hence does not
cause rearrangement of PML NBs (Hoppe et al., 2006). The capability of this and
wild-type E4 Orf3 proteins to cause the appearance of PML-A during infection by an
Ad5 E4 Orf3 mutant, and specifically their ability to complement the Orf3 defect and
allow the production of PML-A was examined in HEp-2 cells (Fig. 4.5).
PML-A was produced upon infection with the wild-type Ad5 (lane 2), but was
absent as expected from inOrf3-infected cells (lane 3). Exogenous expression of
either wild-type or N82A E4 Orf3 alone led to an increase in the amount of PML
detected. This was likely to be an artefact of the exogenous protein expression, as
expression of other proteins unrelated to Orf3 led to similar observations (data not
shown). Upon super-infection of E4 Orf3-transfected cells by inOrf3 infection
specific PML-B and PML-C were produced (lanes 4 and 5), suggesting that the
infections were successful. However, no band was observed that co-migrated with
PML-A. This indicated that the inOrf3 infections had been inefficiently
complemented despite expression of wild-type E4 Orf3. The failure of
complementation may be explained by the relatively poor amounts of E4 Orf3
expressed from transfected cells (lanes 4-7) as compared to a wild-type infection
(lane 2). This is likely to be a consequence of poor transfection efficiency of HEp-2
cells so that few cells in the infected population could be expected to produce PML-
A. In order to overcome this, the same experiment was performed in HEK293 cells
which support high transfection efficiencies. However, transfection followed by
super-infection appeared to cause high levels of cell death and therefore it was not
possible to use this cell type. The question of whether the formation of PML-A by
infection in the presence of Orf3 is linked to PML-II binding cannot therefore be
answered at this time.
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4.7 PML-A is stabilised by the Casein Kinase 2 inhibitor DMAT
The apparent molecular weight, by SDS-PAGE, of PML-A is greater than full-length
PML II, as determined from experiments utilising PML II cDNA (Fig. 4.1). PML-A
may therefore represent a novel post-translationally modified form of PML II that is
produced upon infection by wild-type Ad5. PML proteins are subject to numerous
post-translational modifications (Hayakawa et al., 2008, Kamitani et al., 1998,
Figure 4.5 Can expression of E4 Orf3 complement an inOrf3 infection for
PML-A production? 2.5 x 105 HEp-2 cells were transfected with 500ng of
empty vector pCI-neo (lanes 1-3), pcDNA3.1-orf3 (lanes 4 and 6) or pcDNA3.1-
N82A (lanes 5 and 7). 16 hours later, cells were mock infected, or infected with
Ad5 wild-type 300 or E4 Orf3-deficient mutant inOrf3 at an m.o.i. of 10. Cells
were harvested at 24 h.p.i. and aliquots of the samples were separated in parallel
by 8% and 15% SDS-PAGE and subjected to western blotting. One blot was
probed with a polyclonal anti-PML antibody (upper panel), the other with an
antibody recognising E4 Orf3 (6A11, lower panel). The migration position of
the three infection-specific species of PML and E4 Orf3 are indicated to the right
of the blots. Protein sizes are indicated in kDa to the left of the blots.
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Scaglioni et al., 2006), and it is possible that Ad5, through a function of its E4 Orf3
and an additional viral factor (Fig. 3.8), alters the modification state of PML II. The
small size difference between PML-A and full-length PML II suggested this might
be a phosphorylation event, and thus this possibility was considered.
PML proteins are subject to phosphorylation, the best characterised example of
which involves phosphorylation of serine residue 517 in exon 7a of Δexon5 PML, 
Ser565 in full-length PML, by casein kinase 2 (CK2) (Scaglioni et al., 2006).
Phosphorylation of this residue leads to ubiquitination, and subsequent proteasome-
mediated degradation of PML. Exon 7a is present in all of PMLs I-V, and thus a
modification of Ser517 does not constitute an isoform-specific modification.
However, it was possible that Ad5 was inducing selective phosphorylation of Ser517
of PML II via a mechanism involving E4 Orf3. This was a possibility made more
plausible by the observation that PML-A is stabilised by the addition of MG132, a
proteasome inhibitor (Fig. 3.5). The role of CK2 in the production of species A was
therefore assessed using a CK2-specific inhibitor, DMAT.
HEp-2 cells were mock-infected or infected with Ad5 wild-type 300 or E4 Orf3
mutant inOrf3. 20 h.p.i. the medium was replaced with medium containing sorbitol,
to de-stabilise cellular PML protein, allowing any subsequent stabilisation of PML to
be more easily observed (Scaglioni et al., 2006). At 22 h.p.i. cells were mock-
treated or treated with DMAT, MG132, or DMAT and MG132, before analysis at 24
h.p.i. (Fig. 4.6).
Upon infection with wild-type Ad5, the levels of the major uninfected cell PML
protein decreased significantly, and little PML-A was present (lane 6). The addition
of DMSO appeared to cause a small increase in PML levels (lane 7), though the
addition of DMAT alone or in combination with MG132 (lanes 9 and 10) led to a
stronger increase in both endogenous PML and PML-A. A similar pattern was
observed for inOrf3-infected cells (lanes 11-15).
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The addition of DMAT, particularly when the proteasome was inhibited, did not lead
to a decrease in the amount of PML-A, but rather appeared to enhance its
accumulation. This suggests that the post-translational modification responsible for
species A is not dependent on CK2-mediated phosphorylation. The enhancing effect
of DMAT on PML-A may be caused by a general stabilisation of PML proteins,
which is due to inhibition of proteasome-mediated degradation that is normally
initiated upon phosphorylation of Ser517 by CK2 (Scaglioni et al., 2006).
Figure 4.6 PML-A is not dependent on Casein Kinase II. 3 x 105 HEp-2 cells
were mock-infected or infected by Ad5 wild-type 300 or E4 Orf3-deficient
inOrf3 at an m.o.i. of 10. At 20 h.p.i., the medium bathing the cells was replaced
with fresh 10% FCS DMEM containing sorbitol to a final concentration of 0.5M.
At 22 h.p.i. the medium was replaced with 10% FCS DMEM containing DMSO,
DMAT to a final concentration of 10µM, MG132 to a final concentration of
50µM, or DMAT and MG132. At 24 h.p.i. the cells were harvested and the
samples were analysed by 8% SDS-PAGE and western blotting. The blot was
probed with a polyclonal anti-PML antibody (Xu et al., 2003). The migration
positions of the three infection-specific species of PML are indicated by arrows
to the right of the blot. Protein sizes are indicated in kDa to the left hand side.
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4.8 PML-B and PML-C are not diminished by siRNA targeting
PML exon 5
PML-B and PML -C were previously shown to be depleted in a dose-dependent
manner with siRNA corresponding to exon 3 of PML mRNA (Fig. 3.3). In order to
investigate further the nature of these species, an alternative siRNA was designed
corresponding to exon 5 of the PML transcript. Exon 5, as previously mentioned, is
spliced out of cytoplasmic variants of PML as well as a subset of nuclear variants
(Jensen, 2001). Neither PML-B nor PML-C was detected with the monoclonal
antibody 5E10, the epitope of which corresponds to exon 5. This suggested that
these species lack this exon, and this possibility was investigated using siRNA
technology (Fig. 4.7).
Infection with Ad5 led to the production of all three infection-specific species of
PML (lane 2). The transfection of control siRNA did not alter the abundance of
either the standard PML species or any of the infection-specific species (lanes 3-7).
Upon transfection of PML siRNA targeting exon 5, PML-A was clearly depleted in a
dose-dependent manner alongside higher molecular weight standard PMLs (lanes 8-
12). PML-B and PML-C showed no such depletion and their levels remained
constant across all transfections, indicating equivalent protein loading. Thus, PML-
B and PML-C cannot be depleted by transfection of siRNA targeting PML exon 5,
suggesting that these species lack this exon. This is in accordance with the data
presented in figures 3.2 and 4.1, where antibody 5E10 was unable to detect these
species.
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s4.7 PML- B and PML-C are not depleted by siRNA targeting PML exon 5.
2.5 x 105 HEp-2 cells were mock transfected (lanes 1 and 2) or transfected with
0.25, 1, 10, 50 or 200pmol of control siRNA or siRNA targeting PML exon 5
(Pavan Kumar et al., 2007). 48 hours after transfection cells were mock infected
or infected with wild type Ad5 300 at an m.o.i. of 10 (lanes 2 to 12). 24 h.p.i.
the cells were harvested and the protein content of the lysates was separated by
8% SDS-PAGE and subjected to western blotting. The blot was probed with the
polyclonal anti-PML antibody. PML- A, -B and -C and a novel species are
indicated to the right of the blot by arrows. Protein sizes are indicated in kDa to
the left hand side of the blot.124
.9 PML-C is a variant of PML I
ML-A was diminished upon Ad5 infection of HEp-2 cells previously depleted of
ML II, suggesting this isoform as the basis of this PML species (Fig. 4.4).
owever, the basis of PML-B and PML-C was yet to be determined. Unlike PML-
, PML-B and PML-C lack exon 5, as determined from PML antibody and PML
iRNA studies (Figs. 3.2, 3.3, 4.1 and 4.7).
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In order to determine whether infection-specific PML-B and PML-C carried an
identifiable PML C-terminus, the isoform-specific antibodies described above were
employed in an analysis of infected A549 cells. A549 cells were chosen as this cell
line was repeatedly found to support strong expression of PML-B and PML-C (Fig.
4.8). Infection with Ad5 led to strong expression of both PML-B and PML-C (lane
2), and poor expression of PML-A. After repeated attempts, no infection-specific
band was detected by any of the isoform-specific antisera that co-migrated with
PML-B. However, an infection-specific band detected by anti-PML I was repeatedly
found to co-migrate with PML- C, suggesting that this species may represent a
truncated variant of PML I.
Figure 4.8 PML-C co-migrates with an infection specific species detected by
anti-PML I. 2.5 x 105 A549 cells were mock infected or infected with wild-type
Ad5 300 at an m.o.i. of 10. 24 h.p.i. cells were harvested and the protein content
of the lysates was separated multiple times in parallel by 8% SDS-PAGE and
subjected to western blotting. The blot was cut to produce 6 direct replicates,
each of which was probed with a single antibody. The polyclonal anti-PML
antibody was used to detect all species of PML, and individual isoforms were
detected using anti-PML I-V. PML-B and PML-C are indicated by arrows to the
left of the blot. Protein sizes are indicated in kDa.
126
4.10 Attempted knockdown of PML-C by siRNA targeting PML I
By western blot, PML-C co-migrates with an infection-specific band of PML that is
detected by anti-PML I (Fig 4.8). This suggested that this species may be a truncated
PML I variant that is induced upon infection with Ad5. In an attempt to confirm this
hypothesis, siRNA targeting PML I was used to attempt to deplete PML-C (Fig. 4.9).
Infection with wild-type Ad5 led to the production of all three infection-specific
species of PML (Fig 4.9 A, lane 2), that were unaffected by transfection of control
siRNA (lane 3). Upon infection of cells depleted of PML species containing exon 5,
PML-A was decreased though both PML-B and PML-C remained unaffected as
before (lane 4). As expected, transfection of increasing amounts of siPML I had no
effect on the abundance of PML-A. However, both species B and C also remained
unaffected, suggesting that neither of these species were related to PML I. This is in
contrast to figure 4.8, where species C was detected by the anti-PML I antibody.
It was noted that transfection of siPML I did not lead to any noticeable decrease of
any PML species as detected by the polyclonal anti-PML antibody. Therefore, in
order to determine the efficiency of PML I knock-down, selected samples from
figure 4.9 A were analysed for their PML I content using the anti-PML I antibody
(Fig. 4.9 B). PML I knockdown was observed and was proportionate the use of
increasing amounts of siPML I (lanes 3-7). However, significant amounts
endogenous PML I and PML-C remained even after treatment with the highest
concentration of PML I siRNA. This suggested that either PML I could be
intrinsically more stable than other PML isoforms, and hence more difficult to
deplete, or that the siRNA targeting PML I may be less efficient at depleting its
respective isoform than other PML isoform siRNAs, such as PML II siRNA (Fig.
4.4). Consequently, it was difficult to verify whether the infection-specific species
of PML detected by anti-PML I was the same as infection-specific PML-C.
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AFig 4.9 PML-C is depleted by siRNA targeting PML I. A 2.5 x 105 HEp-2
cells were mock- transfected or transfected with 200pmoles of control siRNA or
siRNA to PML exon 5, or transfected with 0.25, 1, 10, 50 or 200pmoles of
siRNA targeting PML I (Pavan Kumar et al., 2007). 48 hours later cells were
mock infected or infected with wild-type Ad5 300 at an m.o.i. of 10. At 24 h.p.i.
the cells were harvested and the protein content of the lysates was separated by
8% SDS-PAGE and subjected to western blotting. The blot was probed with a
polyclonal anti-PML antibody. PML- A, PML-B and PML-C are indicated by
arrows to the right of the blot. Protein sizes are indicated in kDa on the left hand
side of the blot. B The indicated lysates from A were subjected to 10% SDS-
PAGE and western blotting. The blot was probed with the anti-PML I antiserum.
The arrow to the right of the blot indicates the migration position of PML-C.
Protein sizes are indicated in kDa to the left hand side of the blot..
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truncated form of PML that terminates in exon 7a (McNally et al., 2008), whereas
HSV-2 alters PML splicing to promote the production of PML V over PML II
(Nojima et al., 2009). Infection by Ad5 leads to the production of three novel
species of PML that do not co-migrate with known isoforms, raising the possibility
that Ad5 may also interact with the cellular splicing machinery to favour the
production of novel variants of PML. The population of PML mRNAs in infected
cells was therefore examined. Particular focus was paid to PML-C, as this is smaller
than all of the full-length PML isoforms. It is possible that PML-C is a splice variant
of PML I, as this species can be detected by an anti-PML I antibody. PML-C is also
detected with the pan-PML antibody PG-M3. The epitope for this antibody overlaps
with the exon 1/2 boundary of PML. Taken together, these facts suggest PML-C
must be derived from a novel splice variant. Only PML I and PML II species were
investigated, as anti-sera targeting these isoforms detect numerous lower-molecular
weight bands that migrate to a similar position as PML-C in both HEp2 and A549
cells (figs. 4.2 and 4.8).
HEp-2 cells were mock-infected or infected with Ad5 wild-type 300. At 24 h.p.i. the
cytoplasmic RNA content of the cells was harvested and subjected to reverse-
transcription (RT) into cDNA. Prior to the harvesting of RNA, aliquots of the
nuclear and cytoplasmic fractions of the cells were prepared for protein analysis
using a polyclonal anti-PML antibody. The RT reactions included actin 3’, PML I 3’
and PML II 3’ primers. The PML I and PML II reverse primers were designed so
that they corresponded with the epitopes recognised by their respective isoform-
specific anti-sera. Equivalent amounts of cDNA were then used as template for
subsequent polymerase chain reactions (PCRs). The PML I and PML II reverse
primers were each used in combination with one of four different forward primers
that corresponded to various regions along the PML gene (Fig. 4.10A). One primer
corresponded to the 5’ untranslated region (UTR) of PML, two primers corresponded
to different positions approximately 100 base pairs (bp) apart within exon 3, and one
primer corresponded to exon 5. The 5’ UTR primer was utilised, as in principle, it
allowed the entire length of the PML I or II transcripts to be amplified, including any
internally deleted splice variants of these isoforms. Primers corresponding to exon 3
were used to account for the possibility of splicing out of exon 3 to exon 7a. The
exon 5 forward primer would allow analysis of full-length transcripts of PML I or
PML II. As a positive control, PML I or PML II expression plasmids served as
templates in PCRs containing each of these primer combinations.
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cFigure 4.10 No novel splice variants of PML induced by adenovirus infection
can be detected by RT-PCR. 1 x 107 HEp-2 cells were mock infected or
infected with wild-type Ad5 300 at an m.o.i. of 10. At 24 h.p.i. the cells were
separated into nuclear and cytoplasmic fractions and cytoplasmic RNA was
extracted (see methods). A. Schematic diagram showing the respective positions
of the primers used in the RT-PCR assay. The dashed portion of each mRNA
indicates the 5’ untranslated region (UTR). B. Immediately after fractionation,
the entire nuclear fraction and 100µl of the cytoplasmic were harvested in 1 X
Sample Buffer. For each sample, volumes of the cytoplasmic and nucleoplasmic
fractions corresponding to equal amounts of protein was separated by 8% SDS-
PAGE and subjected to western blotting. The blot was probed with a polyclonal
anti-PML antibody. PML- A, PML-B and PML-C are indicated by arrows to the
right of the blot, and protein sizes are indicated in kDa to the left of the blot. N =
Nuclear fraction, C = Cytoplasmic fraction. C 5µg of total cytoplasmic RNA
used as template for reverse-transcription (RT) using 3’ reverse primers specific
for PML I and actin in the presence (+RT) or absence (-RT) or reverse
transcriptase. 2.5µl of the resulting cDNA was used as template in a polymerase
chain reaction using the actin 5’ and 3’ primers (lanes 9 and 10) or the PML I 3’
primer in combination with each of the 5’ primers indicated (lanes 1-8, 11-14).
50ng of pCI-neoFLAG-PMLI was used as template for the reactions indicated in
lanes 11-14, and served as a positive control. PCR products were mixed with
separated by electrophoresis through a 1% agarose gel containing 0.5µg/ml
ethidium bromide, and imaged under UV light. Full-length PML I PCR products
are indicated to the right of the upper panels, and the DNA size are indicated in
base-pairs (bp) to the left hand side of the panels. D As in C, except the PML I
3’ primer was replaced with the PML II 3’ primer. Full-length PML II products
are indicated to the right hand side of the upper panels, and the DNA size is
indicated in bps to the left hand side of the panels. The excised band is indicated
by an asterisk.131
s indicated in figure 4.10 B, infection of HEp-2 cells with wild-type Ad5 led to the
roduction of all three infection-specific species of PML. As seen in A549 cells (fig
.4), PML species A was confined to the nucleus whereas PML-C was abundant in
he cytoplasmic fraction. PML-B, however, was equally present in both nuclear and
ytoplasmic fractions, which was in contrast to the exclusively nuclear localisation
bserved in A549 cells (Fig 3.4). It was a point of interest that in both uninfected
nd Ad5 infected cells, a higher-molecular weight endogenous species of PML was
lso present in both fractions. The possibility that this was the result of
ontamination between fractions appeared unlikely, as PML-A retained a solely
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nuclear localisation. This suggested that in HEp-2 cells a subset of full-length PML
species are localised in the cytoplasm.
In testing for PML-I related mRNAs, all of the RT-PCR products observed in figure
4.10 C (upper left panel) were ultimately amplified from RNA, as no corresponding
bands were seen in the reactions lacking reverse transcriptase (lower left panel).
Equivalent amounts of actin PCR product were seen in both mock-infected and Ad5
infected cells (lanes 9 and 10), suggesting that equivalent amounts of RNA were
used as template for RT-PCR. A product of expected size was observed for each of
the positive control reactions using PML I 3’ reverse primers (lanes 12-14). The
different sizes of these bands result from the different positions of the 5’ forward
primers. The reaction including the 5’ UTR primer could not produce any PML
product as the 5’ UTR sequence is not present in the PML expression plasmids used
(lane 11).
No infection-specific PML I mRNA variants were detected with any of the primer
combinations used (Fig. 4.10 C, lanes 1-8). The 5’ UTR primer reactions produced
three bands in both uninfected and Ad5 infected cells. As well as not being infection-
specific, these were unlikely to represent PML-B or PML-C mRNA as this particular
primer combination amplified the entire coding region of any PML I transcripts.
Therefore the products observed were too small to account for these infection-
specific species.
The PML reaction containing the PML I reverse primer in combination with the
Exon 3 (1) primer produced a DNA product of a similar size (lane 3) to that observed
in the corresponding positive control reaction (lane 12), though it was not observed
in Ad5-infected cells (lane 4). Interestingly, many smaller bands were observed in
both mock-infected and infected cells when this primer combination was used,
possibly indicating the presence of internally deleted splice variants of PML I (lanes
3 and 4, between 600-800 bp). In contrast, very little product was made when the
Exon 3 (2) primer was used in conjunction with the PML I reverse primer. The
relatively weak amount of product produced from the reactions using the exon 3 (2)
primer may due to an intrinsic property of this primer, as relatively little product was
made in the reaction using pCI-neoFLAGPML I as template as compared with the
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other positive control reactions. Consequently, it was difficult to determine whether
the difference between the products of the two exon 3 5’ primers was significant.
The exon 5 forward primer reaction did not yield any products that corresponded to
full-length PML I (lanes 7 and 8), as indicated by the appropriate positive control
(lane 14), suggesting that primer combination was insufficient or that the majority of
PML I transcripts within the cell lack exon 5. However, an RT-PCR product of
about 250bp was found to disappear upon infection (lanes 7 and 8).
When testing for PML II-related mRNAs, the blank RT-negative controls (Fig. 4.10
D, lower left panel) suggest that the majority of bands observed in figure 4.10 D
(upper left panel) were amplified from cDNA, the exception being a product that was
detected in lane 7 of the RT-negative reaction. Also, the PCR positive controls gave
the expected products (lanes 11-14). The 5’ UTR primer reaction did not produce
any significant products when the PML II 3’ reverse primer was used (lanes 1 and 2).
This suggests that there are no splice variants of PML II with large internal deletions.
In contrast, the exon 3 (1) primer produced a small amount of product corresponding
to full-length PML II (lanes 3, 4 and 12), though the major product was a species too
small to be full-length PML II that became weaker in Ad5-infected cells (indicated
by an asterisk), despite equivalent amounts of actin mRNA being detected (lanes 9
and 10). This band was excised and cloned into a plasmid vector before being
sequenced (see Appendix). Sequence analysis of the clones generated revealed that
this band was not PML related and was the product of non-specific priming. The
exon 3 (2) primer reaction yielded little product (lanes 5 and 6), though the
respective positive control reaction (lane13) also produced relatively little product.
This suggests that the exon 3 (2) primer was not performing optimally under the
conditions used, or that it is intrinsically less efficient than the other primers used.
The exon 5 forward primer reaction produced a product that was larger than full
length PML II, as determined by the positive control reaction (lanes 7, 8 and 14).
This suggested that this species was not a variant of PML II and was a result of non-
specific priming.
Hence no obvious infection-specific species of PML I or PML II mRNA were
detected by RT-PCR, despite several primer combinations being used. This
indicated that Ad5 infection does not initiate the production of alternative splice
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variants of these isoforms, and therefore this could not account for the formation of
PML-B or PML-C. Caution was needed with this interpretation, however, as very
few PCR products were observed that corresponded with full-length PML I or PML
II, meaning that the efficiency of detection might not have been sufficient. Also, the
possibility that PML-B and/or PML-C are novel splice variants derived from an
alternative PML C-terminal isoform not investigated here cannot be discounted.
4.12 Discussion
The E4 Orf3-dependent species of PML, termed PML-A, is depleted in cells
transfected with either siRNA targeting PML isoform II, or siRNA targeting exon 5
of all PML isoforms. This finding suggests that PML-A is a post-translationally
modified variant of full-length PML II that is induced upon infection. However, it
was difficult to verify this finding through other experimental techniques. An
antibody solely targeting PML II was unable to detect PML-A (Fig. 4.2), despite
previously being validated against exogenously-expressed PML II (fig. 4.1). It is
unclear why this antiserum did not detect PML-A. One possibility is that the
infection-specific modification responsible for PML-A interferes with the ability of
the PML II antiserum to recognise its epitope, with the effect of ‘masking’ this
species from the antibody.
However, it was noted that full-length endogenous PML II was also detected poorly
by the PML II antiserum. This was a somewhat surprising result, as PML II,
alongside PML I, was found by Condemine et al to be amongst the most strongly
expressed isoforms (Condemine et al., 2006). In the aforementioned study,
independent isoform-specific antibodies were used and the majority of PML II was
found to be the higher molecular weight, full-length form. This is in contrast to the
data presented here, as the dominant PML II species detected by the isoform-specific
antibody are of a lower molecular weight than full-length PML. This disparity may
be due to intrinsic differences of the cell lines being used, as Condemine used COS
cells, a simian kidney-derived cell line, whereas HEp-2 cells were investigated here.
Nonetheless, HEp-2 cells are thought to express high amounts of endogenous PML
protein (Leppard & Everett, 1999), so it was unexpected that comparatively little
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full-length PML II was detected. It is possible that the anti-PML II antibody used
here is inefficient at detecting endogenous levels of PML II species. Although this
antibody was validated, this was against lysates that were over-expressing PML II,
so it is possible that any inefficiency of this antibody may have been overlooked due
to the increased amount of antigen present.
Replicating the modification responsible for PML-A upon full-length FLAG-tagged
PML II proved difficult, as no clear species co-migrating with PML-A was detected
by the anti-FLAG antibody (Fig. 4.3). The ability to detect PML-A in this way
depends on the proportion of cells that are simultaneously transfected with the
relevant expression plasmid and infected by Ad5. If only a small proportion of cells
meet these criteria then the ability to detect PML-A with an anti-FLAG antibody will
be limited.
The post-translational modification that is responsible for PML-A is unlikely to be
the CK2-mediated phosphorylation previously described by Scaglioni and colleagues
(Scaglioni et al., 2006), as inhibition of CK2 did not reduce the amount of this
species (Fig. 4.6). Instead, inhibition of CK2 led to an increase in the amount of
PML-A, possibly through inhibiting its proteasome-mediated degradation as MG132
had a similar effect (Fig. 4.6). Therefore PML-A may represent an alternative post-
translational modification of PML II that is as yet unknown.
E4 Orf3 rearranges PML NBs via a direct interaction with the carboxyl terminus of
PML II (Hoppe et al., 2006, Leppard et al., 2009), and is necessary, but not
sufficient, for the production of a novel variant of PML II during the course of
infection (Leppard & Everett, 1999). It remains unknown whether these two
phenomena are linked, although it is tempting to speculate that E4 Orf3 exerts both
of these effects through a single interaction with PML II. However, attempts to
address this issue found no evidence that this is the case (Fig. 4.5). Exogenous
expression of E4 Orf3 is sufficient to cause rearrangement of PML NBs, as
determined by confocal microscopy (Hoppe et al., 2006), yet is unable to
complement an Ad5 inOrf3 infection in HEp-2 cells (Fig. 4.5). The approach used
to investigate this, however, is limited by the transfection efficiency of the cells in
question, as it was difficult to obtain a level of E4 Orf3 expression that was
comparable to a wild-type Ad5 infection. Therefore Orf3 expression may not have
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been sufficiently high to fully complement inOrf3, and hence the propensity to
produce, and therefore detect, PML-A would have been limited.
The amount of PML- B was decreased in cells depleted of PML proteins possessing
exon 3 (Fig. 3.3), but not when depletion targeted exon 5 (Fig. 4.7). This, in
combination with the observation that PML-B is not detected with the 5E10
antibody, supports the hypothesis that it is a variant of PML that lacks exon 5. The
nature of any unique C terminus on PML-B remains unknown. No infection-specific
band was detected by PML isoform-specific antibodies that co-migrated with PML-
B in A549 cells (Fig. 4.8). It must be noted that this does not necessarily indicate
that species B is unrelated to PML I-V, as PML-A was depleted by siRNA targeting
PML II yet was not detected by the relevant antiserum. However, PML-B could not
be depleted by siRNA targeting PML I, and no novel splice variants of PML I and II
could be detected in Ad5-infected cells by RT-PCR. Based on these observations in
this chapter, PML-B is unlikely to be a variant of PML I, and is probably related to
one of the remaining PML isoforms (II-VI). Further experimentation would be
required to confirm this.
As predicted, the production of PML-C was unaffected by the depletion of PMLs
possessing exon 5 (Fig. 4.7). PML-C is, in any case, unlikely to possess exon 5 as it
is of a molecular weight that is too small to be any full-length PML isoform and is a
cytoplasmic variant. Indeed, a band co-migrating with PML-C was detected in
infected cells by the PML I antibody, suggesting that it may be related to PML I
(Fig. 4.8). Attempts to deplete endogenous PML I and PML-C using siRNA
targeting PML I were successful and led to modest decreases in PML I expression,
as determined by detection with the anti-PML I antibody. In contrast, detection with
the pan-PML polyclonal antibody did not display any such decrease in these PML
species. This may be because, by SDS-PAGE, both PML I and PML-C co-migrate
with other PML isoforms that are also detected by this antibody. Since other
isoforms should remain unaffected by siRNA targeting PML I, the depletion of PML
I and PML-C may therefore be more difficult to detect. For instance, PML II co-
migrates to a similar position to PML I. Also, in HEp-2 cells, the anti-PML II
antibody detected an infection-specific band of a similar size to PML-C (third
asterisk down, Fig. 4.2), indicating that this band may also be heterogenous with
regard to PML protein content.
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It must be noted, however, that both endogenous PML I and PML-C expression
could not totally be abolished. PML I is the most strongly expressed PML isoform
(Condemine et al., 2006) , perhaps explaining why this was the case. It may also be
particularly slowly turned-over in the cell, making siRNA-mediated depletion more
difficult. The siRNA targeting PML I could also be less efficient at achieving
knock-down, in which case a stronger knock-down effect may be obtained by using
an alternative PML I siRNA either alone or in conjunction with the PML I siRNA
used in this study.
Despite using a combination of primer sets, no infection-specific PML I or PML II
transcripts could be detected that could account for PML-C, suggesting that Ad5
infection does not result in the production of novel splice variants of these PMLs.
This is in conflict with other data presented (Figs. 3.2 and 4.8), as PML-C can be
detected by both the pan-PML PG-M3 antibody and the anti-PML I antibody. The
epitope recognised by PG-M3 lies over the exon 1/exon 2 junction of PML, whereas
the anti-PML I epitope lies in the last 20 amino acids of the C terminal end of PML
I. This suggests that, if PML-C is related to PML I then it must be a legitimate
internal splice variant of this isoform, and not the product of a cleavage reaction of a
larger species. There is reason to suggest that the RT-PCR assay presented in this
chapter was of insufficient sensitivity to detect any infection-specific transcripts of
PML. Very few bands were observed that would correspond to full-length PML I or
II mRNAs which might be expected to be at least as abundant as any novel mRNAs.
This indicates that PML mRNA was inefficiently amplified, resulting in very small
amounts of product being produced. For further investigation, it may be necessary to
utilise a visualisation technique more sensitive than ethidium bromide staining when
detecting PCR amplification products from total PML I and PML II RNA species.
For example, southern blotting using probes directed against PML I and II could be
used.
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Chapter 5
Optimisation of interferon reporter assays
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5.1 Introduction
PML protein exists as a collection of at least seven amino-terminally related
isoforms that differ from one another in their carboxyl terminal domains by up to
300 amino acids. Therefore individual PML isoforms are likely to possess functions
that are separate from the rest of the PML protein population. This is likely to
account for the fact that, despite intensive investigation, a definitive role of PML
proteins remains elusive.
There are several lines of evidence to suggest that one function of PML proteins is to
exert an antiviral activity. First, the pml gene is directly inducible by type I
interferon α (Lavau et al., 1995), a major agonist of the innate antiviral response of
cells. Type I interferons are produced upon stimulation of a signalling pathway by
double-stranded RNA (dsRNA) or other molecular signatures of pathogens. dsRNA
is often a product of viral replication, and interferons act by inducing the expression
of a range of proteins that limit viral replication (Takaoka & Yanai, 2006). Second,
a number of different viruses actively target and disrupt PML protein and PML NBs
by either relocalising PML protein or targeting it for proteasome-mediated
degradation (Carvalho et al., 1995, Doucas et al., 1996, Everett et al., 1998). Mutant
viruses unable to make the normal interactions with PML NBs are often more
sensitive to interferon treatment than wild-type viruses (Mossman et al., 2000,
Ullman et al., 2007).
During the course of this investigation the role of PML proteins in the interferon
pathway was examined through the use of reporter gene assays. Two firefly
luciferase reporter plasmids, driven by either the interferon β promoter or an 
interferon-stimulated response element (ISRE), allowed analysis of different stages
of the IFN response. The IFNβ promoter is activated by a signalling cascade that is
induced upon the detection of double-stranded RNA (dsRNA) within the cell. IFNβ
is produced and secreted from cells, where it acts in an autocrine or paracrine
manner to induce a further signalling cascade that ultimately results in the activation
of ISRE-driven interferon-stimulated genes (ISGs).
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In order to study the role of PMLs in the IFN response it was necessary to optimise
both reporter assays. In particular, it was first necessary to identify a cell line that
could support both IFNβ and ISRE reporter activation through the addition of poly
(I:C), which is an analogue of dsRNA and induces cells to produce IFNβ. Through
this action, poly (I:C) may then stimulate ISRE-driven genes in an indirect manner.
The work presented in this chapter outlines the efforts that were made to identifying
a suitable cell line as a basis of IFN reporter assays. Particular emphasis was placed
on cell lines that had been shown to support the Ad5-induced changes in the PML
protein population (Chapters 3, 4).
5.2 HEp-2 cells do not support activation of the interferon β 
promoter
HEp-2 cells were first analysed to determine whether they could support induction of
the IFNβ reporter plasmid by poly (I:C).  Cells were transfected with an IFNβ 
promoter reporter plasmid and 24 hours later the cells were mock-transfected or
transfected with poly (I:C). Cells were harvested at various times, and the lysates
analysed for firefly luciferase activity (Fig. 5.1).
Transfection with poly (I:C) did not cause a significant increase in reporter activity
over basal levels at any of the time points tested. This suggested that the HEp-2 cells
were unable to respond to poly (I:C). Overall, the general IFNβ reporter activity of
the lysates decreased as the incubation time with poly (I:C) increased. The reason
for this is unclear, though it may reflect a general stress response to transfection, as
both treated and untreated cells displayed this pattern.
In order to confirm this result, HEp-2 cells were compared with A549 and Vero cells
in parallel for their ability to support IFNβ promoter activation. A549 cells have
previously been shown to support IFNβ-promoter reporter assays (Hayman et al.,
2007).
Figure 5.1 Time-course of IFNβ activity in HEp-2 cells. 2.5 x 105 HEp-2 cells
were transfected in triplicate with 500ng of IFN β reporter plasmid pIFNβ-Luc.
24 hours later cells were mock-transfected or transfected with 1µg poly (I:C).
Cells were incubated with poly (I:C) for 4, 8, 16 or 24 hours prior to harvest.
50µl of each lysate was then assayed for firefly luciferase activity. The light
intensity was recorded using a luminometer and appropriate software. Luciferase
activity is expressed as arbitrary Relative Light Units (RLU). Error bars indicate
the standard deviation from the mean of three replicate samples. Blue bars:
mock-transfected cells. Red bars: poly (I:C)-transfected cells.141
Figure 5.2 The IFNβ reporter is not stimulated by poly (I:C) in HEp-2 cells.
2.5 x 105 A549, HEp-2 or Vero cells were transfected in triplicate with 500ng of
IFN β reporter plasmid pIFNβ-Luc. 24 hours later cells were mock-transfected or
transfected with 1µg poly (I:C). All cells were harvested 24 hours later and
lysates were analysed for luciferase activity. All values for each cell line were
normalised to the mean value of the mock-treated samples of the respective cell
line to generate the Relative Luciferase Activity (RLA), which is expressed here
as a ratio relative to mock-transfected cells. Blue bars: mock-transfected cells.
Red bars: poly (I:C)-transfected cells. Error bars indicate the standard deviation
from the mean value of three replicate samples. A. A comparison of all cell lines
tested. B. The same values as represented in A. on a smaller scale.142
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Upon incubation with poly (I:C), luciferase activity increased by approximately 30
fold in Vero cells (Fig. 5.2A).  This suggested that the IFNβ reporter was strongly 
induced, and so confirmed that the assay system was working. The reporter was also
induced in A549 cells, though the level of induction was low compared to Vero cells,
(Fig. 5.2B).  In contrast, in HEp-2 cells the IFNβ promoter did not show any 
induction. This suggested that HEp-2 cells are unable to respond to poly (I:C), and
therefore were discarded as a candidate cell line for subsequent assays. Vero cells
were also not utilised any further as they are not a human cell line, and have also
been suggested to be deficient in IFN production, which is assumed to be due to a
defect in or absence of the IFNβ gene  (Emeny & Morgan, 1979). 
5.3 A549 cells do not respond to exogenous interferon α 
A549 cells were shown to support to the induction of the IFNβ reporter by poly
(I:C), placing them as a candidate cell line for reporter assay experimentation (Fig.
5.2). Therefore, their ability to support the induction of the ISRE reporter plasmid
was examined to determine whether downstream aspects of the IFN signalling
cascade were also functional in these cells (Fig. 5.3A). When performing reporter
assays based on transient transfection methodologies it is important to control for
variation in the transfection efficiency. Reporter readings are quantitative and will
largely depend on the number of cells successfully transfected with the respective
reporter plasmid. To account for this, a control reporter plasmid is used alongside
the experimental reporter plasmid. The control reporter activity is autonomous and
should not be influenced by any of the experimental variables. In order to control for
transfection efficiency, an autonomous Renilla luciferase reporter plasmid, driven by
the HSV thymidine kinase (TK) promoter, was used alongside the ISRE reporter
plasmid.
Transfection with poly (I:C) stimulated only a two-fold increase in ISRE reporter
activity, though poly (I:C) is not a direct stimulant of the ISRE and this may explain
why the level of induction was poor.  Surprisingly, the addition of IFN α to the cells  
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The pISRE-Luc reporter plasmid responds poorly to the addition
us IFN α in A549 cells.  A. 2.5 x 105 A549 cells were co-transfected
e with 270ng pISRE-Luc alongside 30ng Renilla luciferase reporter
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(intended as a positive control) did not lead to an increase in reporter activity.  IFN α 
is a direct stimulant of the ISRE and its addition would be expected to strongly
induce the ISRE reporter. To examine this observation further, the ability of A549
cells to respond to increasing concentrations of IFN α was compared to that of an 
alternative cell line, 293 cells (Fig. 5.3B). 293 cells showed a strong activation of
the ISRE by IFNα, which was dose-responsive. No induction was seen at 10 Units
IFN α /ml, but at concentrations of 100 and 1000 U/ml the ISRE reporter was 
induced by 7-fold and >25-fold respectively. This strong induction was in contrast
to that observed in A549 cells, where no increase in reporter activity was observed at
any of the concentrations of IFN α tested. These results indicated that A549 cells are
incapable of responding to exogenous IFN α.  Although both the IFNβ and ISRE
reporter plasmids responded to poly (I:C) in A549 cells, the levels of induction by
poly (I:C) were considered too poor to warrant further use of this cell line.
5.4 U2OS cells support both IFNβ and ISRE promoter activation 
The focus of investigation then shifted to an alternative cell line, U2OS cells, which
are derived from human osteosarcoma. In these cells, both reporters were strongly
induced by the addition of poly (I:C) (Fig.5.4A). IFNβ reporter activity was
stimulated by approximately 7-fold, whereas the ISRE reporter was stimulated by
approximately 12-fold. However, after 24h incubation with poly (I:C) a large
amount of cell death was observed. This suggested that the experiment needed to be
further optimised to reduce toxicity to the cells. Therefore to address this, the same
experiment was repeated, but all cells were harvested 8 hours after transfection with
poly (I:C) (Fig. 5.4B). Relatively little cell death was observed after 8 hours
incubation time with poly (I:C), yet the activity of both the IFNβ and ISRE reporters
was induced, by 6-fold and 8-fold respectively.
The difference in the amount of stimulation of these reporters reflects the fact that
they represent different stages of the interferon pathway. Therefore it was not to be
expected that the fold-inductions would necessarily be similar to one another. U2OS
cells could therefore support the stimulation of both reporter plasmids by poly (I:C),
and were therefore utilised in initial reporter studies.
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BFigure 5.4 U2OS cells support activation of both pIFNβ-Luc and pISRE-Luc 
reporters. A. 2.5 x 105 U2OS cells were co-transfected in triplicate with 250ng
empty vector pCI-neo, 25ng pRL-TK (Renilla luciferase reporter) and 225ng
pIFNβ-Luc or 225ng pISRE-Luc.  16 hours later cells were mock-transfected or 
transfected with 1µg of poly (I:C). Cells were harvested 24 hours later and the
firefly and Renilla luciferase activities of the lysates were assayed. Firefly
luciferase activity was normalised to Renilla luciferase activity in order to
generate an RLA, which was expressed as a ratio relative to mock-transfected
cells.  Blue bars represent pIFNβ-Luc reporter activity, red bars indicate pISRE-
Luc reporter activity. Error bars indicate the standard deviation of three replicate
samples from the mean value. B. as in A. but cells were harvested 8 hours after
transfection with poly (I:C).A.5 The effect of PML protein exp
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BFigure 5.5 Expression of PML proteins influences pISRE-Luc reporter
activity. A. 2.5 x 105 U2OS cells were co-transfected in triplicate with 225ng
pISRE-Luc, 25ng pRL-TK and 250ng empty vector pCI-neo or pCI-neo FLAG-
PML I-VI. 16 hours later cells were mock-transfected or transfected with 1µg
poly (I:C). All cells were harvested 8 hours later and both the firefly and Renilla
luciferase activity of the lysates was assayed. Firefly luciferase activity was
normalised to Renilla luciferase activity to generate an RLA, which was
expressed as a ratio relative to mock transfected cells. B. Samples from the
replicate extracts used for assay in A. were pooled together and prepared for
SDS-PAGE by the addition of sample buffer. Samples were separated by 8%
SDS-PAGE and subjected to western blotting. A mouse anti-FLAG antibody
was used to detect all exogenously-expressed PML proteins. Lanes 1-7 represent
cells that were transfected with poly (I:C), lanes 8-14 represent mock-transfected
cells. Protein sizes are indicated in kDa to the left hand side of the blot.A147
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considerably reduced. It is unclear whether this was a result of translational shut-off,
a known effect of the interferon response (Randall & Goodbourn, 2008), or due to
cell death. PMLs II and III showed particular sensitivity to poly (I:C), as their
expression was significantly reduced (lanes 2 and 4) compared to untreated cells
(lanes 10 and 11).
Expression of PMLs I, II, III and IV had little effect on the basal activity of the ISRE
reporter when compared to cells transfected with empty vector (Fig. 5.5A). In
contrast, PMLs V and VI both exerted strong inhibitory effects on the basal activity
of the ISRE reporter, as activity was reduced to approximately 40% and 60% of the
control respectively. All these basal activities were however low compared to the
activity of the reporter upon poly (I:C) stimulation (approximately 46-fold activation
in this experiment). Upon stimulation with poly (I:C), all PML isoforms inhibited
the activity of the ISRE reporter. Expression of PMLs III-VI was particularly
inhibitory, as ISRE reporter activity was reduced to less than 40% of that in the poly
(I:C)-stimulated control.
These data would suggest that expression of all full-length PML proteins, especially
PML V and VI, inhibits the ability of the cell to mount an effective interferon
response when challenged with dsRNA. However, the activity of the Renilla
reporter was found also to vary depending on the PML protein being expressed, and
whether cells had been treated with poly (I:C) (Table 5.1). PML II, IV, V and VI
were found to increase Renilla luciferase activity by up to five fold, whereas poly
(I:C) treatment decreased luciferase expression by 3- to 4-fold. There were two
possible explanations for this observation. It was possible that the reporter plasmids,
when mixed with PML III-VI expression plasmids, had a much higher transfection
efficiency than when mixed with any of the other plasmids tested, though this
seemed unlikely. Instead, it was more likely that the Renilla control plasmid was
being influenced by expression of various PML proteins. There was also a
systematic decrease in Renilla luciferase activity upon poly (I:C) treatment. One
possible explanation for this could be that the Renilla luciferase-expressing cells
were being killed off. However, no corresponding cell death was observed within
the culture, so this possibility was unlikely. Again, it could not be discounted that
Renilla luciferase activity was being influenced by external factors, although it was
Expression
vector Sample
pISRE-Luc
activity
(RLU)
pRL-TK
Activity
(RLU) Ratio Average
Mock 1 0.0575 0.7689 0.0748
Empty vector 2 0.0964 1.2970 0.0743 0.0749
3 0.0931 1.2320 0.0756
4 0.1608 2.1050 0.0764
PML I 5 0.1383 2.0630 0.0670 0.0718
6 0.1123 1.5590 0.0720
7 0.0882 1.0990 0.0803
PML II 8 0.0909 0.9986 0.0910 0.0936
9 0.1286 1.1730 0.1096
10 0.2497 3.1350 0.0796
PML III 11 0.2819 3.3840 0.0833 0.0800
12 0.2100 2.7300 0.0769
13 0.3369 4.7390 0.0711
PML IV 14 0.4293 5.2350 0.0820 0.0779
15 0.4253 5.2870 0.0804
16 0.1172 3.5020 0.0335
PML V 17 0.1189 3.5510 0.0335 0.0341
18 0.1008 2.8440 0.0354
19 0.1250 2.7120 0.0461
PML VI 20 0.1599 3.0080 0.0532 0.0503
21 0.1168 2.2590 0.0517
Poly (I:C) 22 0.2154 0.2791 0.7718
Empty vector 23 0.2440 0.3823 0.6382 0.7001
24 0.2792 0.4044 0.6904
25 0.2341 0.6067 0.3859
PML I 26 0.1878 0.5218 0.3599 0.3988
27 0.1564 0.3470 0.4507
28 0.1465 0.3062 0.4784
PML II 29 0.1512 0.3396 0.4452 0.4688
30 0.1616 0.3348 0.4827
31 0.1924 0.7822 0.2460
PML III 32 0.3016 1.2250 0.2462 0.2563
33 0.1767 0.6388 0.2766
34 0.2023 1.0840 0.1866
PML IV 35 0.2533 1.1940 0.2121 0.2007
36 0.2400 1.1810 0.2032
37 0.0860 0.3439 0.2501
PML V 38 0.2771 1.1370 0.2437 0.2672
39 0.2263 0.7351 0.3078
40 0.2038 0.8595 0.2371
PML VI 41 0.0925 0.5789 0.1598 0.1527
42 0.1347 0.6098 0.2209Table 5.1 The pRL-TK reporter plasmid is influenced by external stimuli.
The luciferase values are those from the experiment represented in figure 5.5.
RLU – Relative light units149
plausible that the decrease in activity reflected a general shutoff of translation by the
IFN response. Therefore Renilla expression could not be safely used as a
transfection control.
5.6 HEK293 cells support both IFNB and ISRE reporter assays
HEK293 cells were analysed for their ability to activate both IFNβ and ISRE
reporters when stimulated with poly (I:C). These cells had shown a strong response
to exogenous IFNα (Fig. 5.3). CMV-β-Gal was used as a control for transfection
efficiency, since its activity was less sensitive than pRL-TK to external variables.Figure 5.6 HEK 293 cells support both IFNβ and ISRE reporter assays. 2.5
x105 HEK293 cells were co-transfected in triplicate with 250ng pCI-neo, 25ng
pcDNA3.1-HisB::lacZ and 225ng pLuc-IFNβ or 225ng pLuc-ISRE. 16 hours
later cells were mock-transfected or transfected with 1µg poly (I:C). All cells
were harvested 8 hours later, and the firefly luciferase and β-galactosidase activity
of the lysates were measured. Luciferase activity was normalised to β-
galactosidase activity to generate an RLA for each sample. RLAs are expressed
as a ratio to mock-transfected cells. Error bars indicate the standard deviation of
three replicate samples from the mean value. Blue bars: mock-transfected cells.
Red bars: poly (I:C)-transfected cells.150
Reporter Treatment Sample
Luciferase
reporter
activity
(RLU)
Adjusted
β-Gal 
activity
(OD405nm) Ratio Average
IFNβ-
Luc 1 0.013 0.139 0.091
Mock 2 0.012 0.115 0.108 0.116
3 0.013 0.088 0.148
4 0.145 0.060 2.408
Poly (I:C) 5 0.116 0.072 1.604 2.140
6 0.153 0.066 2.300
ISRE-
Luc 7 0.054 0.130 0.417
Mock 8 0.053 0.075 0.701 0.616
9 0.048 0.065 0.729
10 0.383 0.053 7.175
Poly (I:C) 11 0.437 0.038 11.387 8.686
12 0.348 0.046 7.494Table 5.2 HEK 293 cells support both IFNβ and ISRE reporter assays.
Values shown are from the experiment represented in figure 5.7. RLU: Relative
light units. β-galactosidase activity is represented as the optical density at a
wavelength of 405nm, and is adjusted to exclude the cellular background.151
Transfection of cells with poly (I:C) led to 18-fold and 15-fold increases in IFNβ and
ISRE reporter activities, respectively (Fig. 5.6). Most of the induction observed was
due to a direct increase in luciferase reporter activity, as β-galactosidase activity only
varied by approximately 2-fold between mock-treated and poly (I:C)-treated cells
(Table 5.2). This was in contrast to the 4-fold decrease in pRL-TK activity observed
upon poly (I:C) treatment of U2OS cells (Table 5.1). This indicated that the β-
galactosidase reporter was not significantly influenced by poly (I:C) treatment and
could be deemed as a reliable indicator of transfection efficiency.
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5.7 Discussion
The assays performed in this chapter were designed to identify a cell line that would
respond effectively to the IFN inducer, poly (I:C). They were based upon transient
transfection methodology, and therefore their success is highly dependent on the
transfection efficiency of the cell line being used. If a cell line has a poor efficiency
of transfection then general reporter activity across the cell population will be low.
Consideration must also be taken that the stimulant used in these assays, poly (I:C)
was also delivered to cells by transient transfection. Therefore, within a population
of cells of poor transfection efficiency only a tiny subset of cells would be
transfected with both the necessary reporter and the poly (I:C) required to induce it.
In such a scenario only a small, if any, increase in reporter activity would be
recorded. This could possibly explain why the IFNβ reporter responded relatively
poorly to poly (I:C) in both HEp-2 and A549 cells (Fig. 5.2).
U2OS cells were initially found to support significant increases in both IFNβ and
ISRE reporter activity, in contrast to that of either HEp-2 or A549 cells. However,
upon closer inspection, much of the apparent induction seen was due to decreasing
Renilla luciferase activity after poly (I:C) treatment that was over 5-fold in some
cases; this created an increase in corrected ISRE activity. Cell death could not
account for this decrease, though could have reflected host cell translational shutoff
induced by the IFN response. Renilla luciferase activity was also found to vary
depending on the PML protein being expressed, suggesting that it was not
independent of the experimental variables. Subsequent analysis of 293 cells, where a
β-galactosidase reporter was used as a transfection control, revealed that poly (I:C)
treatment again decreased control reporter activity, though in this case the decrease
was typically only <2-fold. Uncorrected IFNβ and ISRE reporter activity, however,
gave strong responses to poly (I:C), suggesting that the relative induction was not
strongly dependent on decreasing β-gal reporter activity in response to poly (I:C).
Furthermore, the β-gal reporter was found not to be strongly affected by PML
protein expression (Chapter 6), suggesting that it is truly independent of the
experimental variables.
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The mechanism underlying the differences between Renilla luciferase activity is
unclear, though one possibility is that the autonomous HSV-TK promoter used to
drive this reporter was being selectively down-regulated upon poly (I:C) treatment.
The β-galactosidase reporter, in contrast, utilised a CMV immediate early promoter
and therefore would not be subjected to the same regulatory mechanisms. Such a
scenario could also explain why the Renilla luciferase activity was altered upon
expression of various PML proteins.
As well as affecting translation, interferon has also been shown to exert anti-tumour
properties (Gresser & Belardelli, 2002), and to enhance the p53 apoptotic response
(Takaoka et al., 2003) . This has implications when performing IFN reporter assays
in immortalised cell lines, as normal IFN responses may be intrinsically impaired.
For example, Vero cells are known to lack the ability to produce IFN α due to a
mutation in the IFN β promoter (Emeny & Morgan, 1979).  It is therefore not 
inconceivable that the poor response to poly (I:C) observed in the majority of cell
lines tested here may be due to deficiencies in the IFN signalling pathway upstream
of IFNβ promoter activation. Indeed, U2OS cells have been suggested to possess
deficiencies in IFN signalling (Mossman et al., 2000), which may be a contributing
factor to their poor response to poly (I:C).
Aberrant IFN signalling pathways may also be responsible for the apparent lack of
reporter induction by poly (I:C) in both A549 and HEp-2 cells. In particular, A549
cells were unable to induce ISRE reporter activity in the presence of exogenous IFN
α., though they did support induction of the IFNβ promoter by poly (I:C).
Altogether, this suggested that A549 cells may possess deficiencies in IFN signalling
downstream of IFNβ production.  It is of interest that a small induction of the ISRE 
reporter was observed in A549 cells upon transfection with poly (I:C), indicating that
the cells may still respond to endogenously-produced IFNβ, but have lost the ability 
to respond to exogenous IFNα. In contrast, the IFNβ reporter did not show any
induction upon transfection of HEp-2 cells with poly (I:C). This would indicate a
failure of IFN signalling upstream of IFNβ induction. However, further work would
be required to confirm these hypotheses.
HEK293 cells are an immortalised cell line, yet both IFNβ and ISRE activity
increased markedly upon stimulation with poly (I:C). Unlike A549 cells, 293 cells
154
also responded in a dose-dependent manner to the addition of exogenous IFN α,
indicating that the IFN signalling pathway is functional within these cells. 293 cells
are routinely reported to give very high transfection efficiencies, and in accordance
with this, they also supported relatively strong expression of exogenous proteins, as
observed in Fig. 3.8A. Altogether, this suggests that 293 cells are an ideal cell line
for an analysis of the effect of different PML proteins on the IFN response that
utilises reporter assays.
155
Chapter 6
Investigation of the roles of individual
PML isoforms in type I IFN signalling
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6.1 Introduction
PML proteins have been extensively implicated in exerting anti-viral activity against
a number of viruses. Furthermore, they have also been implicated in the interferon
response, though no clear role of PML proteins in this pathway has been defined.
Therefore, the experiments presented in this chapter were designed to address this
utilising the reporter assay system set up in HEK293 cells, as described in Chapter 5.
The assays performed all utilised the IFNβ promoter reporter plasmid, which is 
activated by both IRF3 and IRF7. This reporter is therefore activated upon induction
of MDA5/RIG-1, TLR and JAK/STAT signalling pathways by cytosolic dsRNA.
The primary aim of the experiments was to identify any functions that individual
PML isoforms might perform in the IFNβ signalling pathway.  The principle 
approach was to over-express both full-length and selected truncated PML variants
and to examine the effect on reporter activity. These studies were complemented
with studies utilising siRNA-mediated depletion of various PML species, and studies
using Ad5 E4 Orf3 to perturb the PML protein population.
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6.2 Over-expression of full-length PML IV, V and VI alters the
activity of the IFNβ promoter 
To investigate any potential role of PML proteins in the interferon response, IFNβ 
promoter reporter assays were performed in cells over-expressing each of six full-
length PML isoforms (Fig. 6.1A). Essentially uniform expression of all PML
proteins was achieved, as indicated by western blotting (Fig. 6.1B), though in each
case a slight decrease in expression was observed in poly (I:C) treated cells (lanes 9-
14) when compared to the equivalent untreated cells (lanes 2-7). The reason for this
was unclear, though it may have been due to small amounts of cell death induced by
poly (I:C). The decrease was unlikely to be due to the effects of host translational
shutoff, a known function of interferon (Haller et al., 2006), as the control β-
galactosidase reporter activity in these cells remained comparable to cells untreated
with poly (I:C).
Expression of PMLs I-III, V or VI did not exert any significant effect on basal IFNβ 
reporter activity in the absence of stimulation by poly (I:C), as compared to the
appropriate control. (Fig. 6.1A, blue bars). In stark contrast, expression of PML IV
led to a significant increase in IFNβ promoter activity, suggesting a regulatory role 
of this isoform in the IFN response.
Upon stimulation with poly (I:C), IFNβ promoter activity in control cells was 
stimulated by an average of 15-fold across the three assays. This stimulation was
similar to that in cells over-expressing PMLs I-III. Unexpectedly, expression of
PML IV did not further enhance the activity of the IFNβ promoter in response to 
poly (I:C), in contrast to its effect in the absence of stimulation, perhaps suggesting
that its capability to enhance reporter activity in the already activated state was
saturated.  Expression of both PML V and VI, however, significantly inhibited IFNβ 
promoter activity to approximately 50% and 60% of the control respectively,
suggesting that these isoforms may play negative roles in IFN signalling.
Thus, altering the balance of PML isoforms by exogenous expression of full-length
PML proteins clearly exerts differential effects on the activity of the IFNβ promoter 
depending on the isoform in question, suggesting that the unique C-termini of these
proteins may perform different functions within the IFN response.
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Figure 6.1 Expression of full-length PML proteins alters expression of the IFNβ 
reporter. A HEK293 cells were co-transfected in triplicate with pIFNβ-luc plus 
pcDNA3.1hisB::lacZ and pCI-neo or pCI-neo FLAG-PML I-VI. 16 hours later cells
were mock-transfected or transfected with poly (I:C). 8 hours later cell lysates were
assayed for both β-galactosidase and luciferase activity.  Luciferase activity was 
normalised to β-galactosidase activity to generate the relative luciferase activity (RLA), 
which was expressed as a ratio to that of pCI-neo control transfected cells. The data
presented are the average of three separate experiments (i.e. 9 values). Student’s T-test
analysis was performed on PML-transfected cell data against the equivalent control data.
An asterisk above a bar indicates a significant difference from the control (pCI-neo). * -
P <0.05, ** - P<0.005, *** - P<0.001. B. Samples of the three replicate lysates from
each assay performed in A were pooled together and separated by 8% SDS-PAGE and
subjected to western blotting. Blots were probed with a rabbit anti-FLAG antibody.
Protein sizes are indicated in kDa on the left side of each blot.
B
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6.3 PML ΔRBCC isoforms exert different effects on the IFNβ 
promoter to that of their full-length counterparts
The RBCC domain is found in all described PML proteins, and allows homo- and
hetero-oligomerisation between various PML isoforms through interactions via the
coiled-coil motif (Fig. 1.2). Therefore, exogenous expression of any full-length
PML isoform may indirectly affect the activity of other endogenous isoforms
through this interaction. This is a consideration that needs to be accounted for when
studying the function of individual PML isoforms. Although individual expression
of full-length PMLs IV, V and VI altered the activity of the IFNβ reporter in 
different ways (Fig. 6.1), it cannot be discounted that some of the effects observed
were mediated through interactions with other endogenous PML isoforms. To try to
separate out the effects of the unique C-terminal regions of PML from such indirect
effects, PML isoform mutants lacking the N-terminal 361 residues, and therefore the
RBCC motif, were utilised in experiments similar to those with full-length PMLs in
Fig. 6.1.  These ΔRBCC mutants do not localise to PML NBs and show a diffuse 
nuclear localisation (Leppard et al., 2009).
Consistent expression of PML I-VIΔRBCC was observed in all but one of the four 
assays performed (Fig 6.2B), no expression being observed for PMLs III, V and VI
in assay 4. Consequently, the reporter activity of these samples was discarded from
the analysis in Fig. 6.2A. Unlike full-length PMLs, no decrease in expression upon
poly (I:C) treatment was observed. Also, in contrast to the full-length PMLs,
expression of PML IΔRBCC and PML IIΔRBCC led to significant increases in the 
basal activity of the IFNβ promoter (Fig. 6.2A).  PML II ΔRBCC consistently 
exerted the strongest activating effect, increasing reporter activity approximately 1.6-
fold.  In contrast to its full-length counterpart, PML IV ΔRBCC did not significantly 
increase activity of the IFNβ promoter.  Taken together, these assays suggest that the 
RBCC domain is required for the positive activity of PML IV.  PML V ΔRBCC 
expression led to a significant decrease in IFNβ promoter basal activity, an effect 
that was also not observed upon expression of full-length PML V (Fig. 6.1A).
BAFigure 6.2 PML ΔRBCC isoforms have different effects on the IFNβ 
reporter to full-length PML proteins. A. As Fig. 6.1 panel A except PML
ΔRBCC plasmids were used and four independent experiments were done.  The 
data presented are the average of either three (PML III, V and VI) or four
(Control, PML I, II and IV) separate experiments. Student’s T-test analysis was
performed on PML-transfected cell data against the equivalent control cell data.
An asterisk above a bar indicates a significant difference from the control (pCI-
neo). * - P <0.05, ** - P<0.005. B. Samples of the three replicate lysates within
each assay performed in A. were pooled together and separated by 8% SDS-
PAGE and subjected to western blotting. Blots were probed with a rabbit anti-
FLAG antibody. Protein sizes are indicated in kDa on the left side of each blot.160
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In accordance with data from full-length PMLs, none of ΔRBCC mutant PMLs I, III-
VI significantly enhanced the activity of the IFNβ promoter during stimulation by 
poly (I:C).  Expression of PML II ΔRBCC, however, caused a significant (1.5-fold) 
increase in activity, and indeed was the only PML species found to enhance
promoter activity in response to poly (I:C). In line with their full-length
counterparts, both PML VΔRBCC and VIΔRBCC significantly inhibited poly (I:C)-
mediated stimulation of promoter activity, to 50% and 70% of the control
respectively. This suggested that the C-terminal domains of these isoforms are
sufficient to mediate their inhibitory actions.
6.3 Depletion of various PML species alters the activity of the IFNβ 
promoter
The data presented in Figures 6.1 and 6.2 collectively indicated a role of specific
PML proteins in regulating the IFNβ promoter.  However, these studies utilised 
transient over-expression methodology and the use of PML ΔRBCC mutants that are 
not known to occur naturally. It was therefore possible that the effects that were
observed on the activity of the IFNβ promoter were due to stress responses to high-
concentrations of exogenously-expressed protein or to the presence of unnatural
proteins (ΔRBCC mutant PMLs).  To address this, cells were depleted of various 
endogenous PML species using siRNA technology prior to being assayed for IFNβ 
promoter activity.
Initially, knockdown of total PML was tested. Two different siRNAs targeting all
PML isoforms were used independently in order to account for the possibility that
internally-deleted PML proteins could differ from full-length PML proteins in their
ability to influence IFNβ promoter activity.  siRNA targeting PML exon 3 would 
deplete all known PML mRNA species, including those encoding cytoplasmic
variants or internally truncated species that arise from skipping of exons 4, 5 and/or
6. siRNA targeting PML exon 5 would deplete mRNA encoding nuclear PML
proteins that retain this exon, though it should be noted that nuclear variants of PML
protein can exist that lack exon 5 (Jensen, 2001) (Fig. 6.3A). Isoform-specific
knockdown was also developed for PML isoforms I, II and V, since these had been
implicated in IFNβ promoter regulation (Figs. 6.1 and 6.2).   
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Successful knockdown of the total PML protein content of cells was achieved in all
three assays performed using the siRNAs targeting PML exon 3 and exon 5 (Fig. 6.3
C). No obvious difference was apparent between the PML species depleted by
siRNA targeting exon 3 or exon 5 although, with the exception of assay 2, the pan-
PML anti-serum only detected a major PML species of approximately 120kDa that
was depleted by both exon 3 and exon 5 siRNA. It was therefore impossible to
determine the extent of knockdown of different PML isoforms. Subsequent attempts
to detect PML I, II and V protein levels in these lysates using isoform-specific anti-
sera also proved extremely difficult, and therefore their knockdown was investigated
separately (see section 6.4).
Depletion of PML proteins possessing exon 3 resulted in a significant decrease in
basal IFNβ promoter activity, to levels of approximately 50% to that of the control 
(Fig. 6.3B). Depletion of PML proteins containing exon 5, however, had the
opposite effect, as it led to a significant increase in IFNβ promoter activity (~1.3 
fold). Depletion with either siPML I or siPML II also led to significant inhibition of
the IFNβ promoter, to levels equivalent to 80% and 40% of the control respectively.  
In contrast, depletion with siPML V had no significant effect. Upon stimulation with
poly (I:C), only depletion using siPML II significantly affected the activity of the
IFNβ promoter, where stimulation was again reduced to approximately 40% of 
control cells, a result that fits with the observed increase in activity caused by over-
expressing PMLIIΔRBCC  depletion with siPML V had no effect. This contrasts 
with the effect of PML V over-expression, which inhibited reporter activity after
treatment with poly (I:C) (Figs. 6.1 and 6.2).
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sFigure 6.3 Depletion of various PML species exhibits different effects on the
IFNβ reporter.  A. Diagram showing the positions of PML siRNA. PML
mRNA lacking exon5 or exons 4, 5 and 6 will not be depleted by siPML exon5,
though will be depleted by siPML exon 3. B. HEK293 cells were transfected in
triplicate with 150pmol of control siRNA, or siRNA targeting PML exon 3, PML
exon 5, PML I, PML II or PML V. 32 hours later cells were co-transfected in
triplicate with the reporter plasmids and pCI-neo control. 16 hours later cells
were mock-transfected or transfected with poly (I:C). 8 hours later the cell
lysates were assayed for reporter activity, and data analysed as before (Fig. 6.1,
panel A). The data presented are the average of three separate experiments.
Student’s T-test analysis was performed on siPML knockdown data against
control siRNA cell data. An asterisk above a bar indicates a significant
difference from the control (pCI-neo). * - P <0.05, ** - P<0.005, *** - P<0.001.
B. Three replicate lysates from each assay performed in A. were pooled together
and separated by 8% SDS-PAGE and subjected to western blotting. Blots were
probed with a polyclonal anti-PML antibody. Protein sizes are indicated in kDa
on the left side of each blot. The arrows to the right hand side of the blots164
.4 siRNA-mediated depletion of PMLs I, II and V in 293 cells.
estern blot analysis of 293 cell lysates prepared for reporter assay analysis
evealed low levels of PML protein, as detected by a pan-PML antibody (Fig. 6.3B),
s compared with those seen in chapters 3 and 4. This was likely to be a
onsequence of using lysates prepared in Passive Lysis buffer (PLB), suitable for
nzyme activity assays, for SDS-PAGE. These lysates will be more dilute than
ysates prepared directly in SDS gel sample buffer. Also, because it lacks ionic
etergent, PLB is unlikely to solubilise the entire PML content of the cell, hence
aking subsequent detection difficult. This was indeed the case for another nuclear
atrix-associated protein, E4 Orf3, which is demonstrated in figure 6.8B.
n order to confirm that PML I, II and V were being successfully knocked-down by
iRNA in HEK293 cells, the extent of depletion of these isoforms in cells lysed
irectly in sample buffer was investigated. After 48 hours of incubation with
iRNA, PML I species were not visibly depleted (Fig. 6.4, lanes 2-5). This suggests
hat either PML I is intrinsically difficult to knock-down due to a high degree of
tability, or the siRNA used to deplete this isoform is inefficient. In contrast,
indicate successful depletion of the major PML species.
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endogenous PML V was clearly detected by its respective anti-serum (lane 11), and
was depleted by siPML V in a dose dependent manner (lanes 12-15).
Depletion with siPML II led to a decrease in the amount of the major species of PML
detected with a pan-PML antibody (Fig. 6.3B, arrow). This band was consistent
with the migration position of PML I and II, as determined previously by exogenous
over-expression of PML (Fig. 4.1), and therefore suggested PML II was being
successfully depleted. However, analysis of siPML II-mediated depletion with an
anti-PML II antibody was inconclusive, as no endogenous PML II was observed in
the control lane with which to draw comparison (Fig. 6.4, lane 6). One possible
explanation for this discrepancy is that 293 cells possess low levels of endogenous
full-length PML II, which may below the level of detection by anti-PML II.
Interestingly, this mirrored an observation previously noticed in HEp-2 cells (Fig.
4.2).
An alternative strategy was devised to assess PML I and II knockdown in HEK293
cells. siRNA knockdown of each of these isoforms was performed on cells over-
expressing the isoform in question (Fig. 6.5). Again, PML I knockdown was found
to be very poor, with only a modest decrease in expression at the highest
concentration of siPML I used as compared to siControl-transfected cells (Fig. 6.5A,
lane 6). In contrast, PML II was found to be strongly depleted at all the siPML II
concentrations used, but not by the control siRNA (Fig. 6.5B). This suggested that
either PML II is more rapidly turned over, and hence more readily depleted than
PML I, or that siPML II is highly efficient. Therefore, after 48 hours of incubation
with the relevant siRNA, PML II and V can be successfully depleted by siRNA.
PML I, however, only exhibits very modest knock-down by siRNA at the
concentration used in the reporter assays described in Fig. 6.3. Although the number
of cells and the concentrations of siRNA used were the same as for the assay
described in Fig. 6.3A, the incubation time with siRNA was 8 hours shorter in this
experiment. Therefore the knockdown of PML during the assays performed in Fig.
6.3A is likely to have been greater than that observed in Figs. 6.4 and 6.5. It may be
concluded however, that PML I knock-down was considerably weaker than knock-
down of PML II and PML V.
Figure 6.4 Attempted depletion of endogenous PMLs I, II and V in HEK293
cells. 2.5 x 105 HEK293 cells were transfected with 1, 5, 50 or 150pmol siRNA
targeting PML I, II or V, or 150pmol of control siRNA. 48 hours later cells were
harvested and the lysates separated by 8% SDS-PAGE and subjected to western
blotting. The blots were probed with either anti-PML I, anti-PML II or anti-PML
V antibodies. The migration positions of PML I and PML V are indicated by
arrows to the right of the respective blots. Full-length PML II would be similar
in size to PML I. Protein sizes are indicated in kDa to the left of each blot.
A BFigure 6.5 Knockdown of exogenously-expressed FLAG-PML I and II in
HEK293 cells. A. HEK293 cells were mock-transfected or co-transfected with
450ng pCI-neo plus 50ng pCI-neo FLAG-PML I. 16 hours later cells were
transfected with 1, 5, 50 or 150pmol control siRNA or PML I siRNA. 48 hours
later cells were harvested and the lysates were separated by 8% SDS-PAGE and
subjected to western blotting. The blot was probed with an anti-PML I antibody.
The migration position of PML I is indicated to the right hand side of the blot,
and protein sizes are indicated in kDa on the left. B. As panel A, except FLAG-
PML II, PML II siRNA and anti-PML166
II were used instead.
167
6.5 Cytoplasmic and ΔExon 5 PML II do not enhance IFNβ 
promoter activity
The data presented in Figures 6.1, 6.2 and 6.3 suggested that PML II plays a role in
regulating the activity of the IFNβ promoter.  Expression of a ΔRBCC mutant PML 
II enhanced IFNβ activity, whereas depletion of all endogenous PML II species led 
to a significant decrease in activity. However, expressing additional full-length PML
II exerted no effect on the IFNβ promoter, raising the possibility that a splice variant 
of PML II rather than full-length PML II may be responsible for enhancing IFNβ 
promoter activity. Therefore, cDNAs encoding natural alternative splice variants of
PML II were created and their effect on the IFNβ promoter was investigated.  cDNA 
clones for two naturally occurring PML splice variants (Jensen, 2001) were
constructed by PCR mutagenesis using full-length PML II or, as a control, full-
length PML I as the parent molecule. Exons 4, 5 and 6 were excluded from both
PML I and PML II to create cytoplasmic variants of these isoforms (see Appendix).
In parallel, clones of PML I and PML II were generated that just lacked exon 5 (see
Appendix). Exclusion of these exons in both types of construct left the resulting
sequence in frame, and hence the PML I and PML II C-termini were maintained.
Upon transfection of these new plasmids alongside the previously analysed full-
length and ΔRBCC isoforms, uniform expression was observed of all PML I and 
PML II species (Fig. 6.6C). In the absence of stimulation with poly (I:C), all PML I
variants significantly enhanced IFNβ promoter activity to similar extents (Fig. 6.6 A, 
B).  This result accords with the previous data for PML I ΔRBCC (Fig. 6.2) but 
contrasts with that for full-length PML I (Fig. 6.1), in which only a slight and not
significant increase was seen.  As seen in earlier experiments, PML II ΔRBCC but 
not full-length PML II significantly enhanced IFNβ promoter activity. The 
cytoplasmic variant of PML II mimicked this activity, and appeared to exert an even
stronger effect.  However, PML IIΔexon5 behaved similarly to full-length PML II.   
Upon stimulation with poly (I:C), neither the cytoplasmic PML I variant nor PML I
Δexon5 significantly enhanced or decreased IFNβ promoter activity, again 
resembling in activity both full-length and PML IΔRBCC.  As demonstrated above, 
PML IIΔRBCC again significantly enhanced reporter activity, while full-length PML  
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response of the IFNβ reporter to poly (I:C).  A. HEK293 cells were co-
transfected in triplicate with the reporter plasmids and pCI-neo FLAG-PML I-II,
pCI-neo FLAG-PML ΔRBCC I-II or pCI-neo FLAG-PML I-II cytoplasmic.  16 
hours later cells were mock-transfected or transfected with poly (I:C). All cells
were harvested 8 hours later and lysates were assayed for both luciferase and β-
galactosidase activity.  Luciferase activity was normalised to β-galactosidase 
activity to obtain the RLA, which was expressed as a ratio to that of the Mock
control. The data presented are the average of three separate experiments.
Student’s T-test was performed on data from PML-transfected cells against pCI-
neo-transfected (control) cells. An asterisk above a bar indicates a significant
difference from the mock control. **- P <0.005, *** - P<0.0005, **** -
P<0.0001. B. As A, except FLAG-PML I Δexon5 and IIΔexon5 were used 
instead of the cytoplasmic constructs, and the data presented are the average of
two separate experiments. Error bars indicate the standard deviation from the
mean of at least five replicates. C. Replicate lysates from the assays shown in A
and B were pooled together and separated by 8% SDS-PAGE and subjected to
western blotting. Blots were probed with a rabbit anti-FLAG antibody. Protein169
I did not.  However, neither cytoplasmic PML II nor PML IIΔexon5 species 
ignificantly altered reporter activity. Therefore, during poly (I:C) stimulation of the
FNβ promoter, cytoplasmic and Δexon5 variants of both PML I and PML II behave 
n similar ways to their full-length counterparts, and the enhancing activity of PML
I ΔRBCC on IFNβ promoter activity does not mimic the properties of either of these 
aturally occurring variants.
.6 The sub-cellular localisation of PML I and II splice variants
pon poly (I:C) stimulation
ML IIΔRBCC was the only PML-related molecule found to enhance IFNβ 
romoter activity during stimulation with poly (I:C), but the mechanism by which
his molecule achieved this remained unclear. This protein has been shown to have a
iffuse nuclear localisation (Leppard et al., 2009). It was therefore of interest to
etermine whether PML IIΔRBCC underwent any re-localisation during poly (I:C) 
timulation which could contribute to its positive activity on the IFNβ reporter.  To 
est this, PML IIΔRBCC was over-expressed and visualised in HEK293 cells 
ndergoing stimulation of an IFN response by poly (I:C), and its location was
sizes are indicated in kDa to the left hand side of each blot.
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compared to that of a variety of other PML I and PML II proteins expressed from
cDNA constructs (Fig. 6.7). In order to identify cells responding to poly (I:C) and
hence undergoing an IFN response, cells were co-stained with an anti-IRF3
antibody. During an IFN response, IRF3 migrates to and accumulates in the nucleus,
where it acts as a transcription factor (Haller et al., 2006) (Fig. 1.1). Therefore, cells
that had been transfected with the PML construct and poly (I:C) could be
distinguished from the rest of the population.
As expected, in the absence of poly (I:C) stimulation, IRF3 displayed a diffuse
cytoplasmic staining pattern and was excluded from the nucleus (Fig. 6.7A). Upon
poly (I:C) treatment, nuclear localisation of IRF3 was observed, however,
surprisingly, this was only seen in a small fraction of cells. This suggested a
relatively low transfection efficiency of poly (I:C), which is contrary to the normal
experience in HEK293 cells, which are generally considered to be highly supportive
of transient transfection (Parham et al., 1998).
As expected, full-length PML I localised to PML NBs (Beech et al., 2005), and this
localisation was unaffected in cells undergoing an IFN response, as indicated by the
nuclear localisation of IRF3 (Fig. 6.7B).  PML IΔRBCC displayed a diffuse nuclear 
localisation (Fig 6.7C), as described previously (Leppard et al., 2009). This pattern
of localisation was also unaffected by induction of the IFN response. Of the novel
forms of PML I, PML IΔexon5 localised to PML NBs, but a subset of cells were also 
found to display alternative localisation patterns around the nuclear membrane and
within the cytoplasm (Fig. 6.7D). This was not wholly unexpected, as PML I
contains a nuclear export sequence (NES) allowing it migrate to the cytoplasm
(Jensen, 2001), but the same was not seen for full-length PML I, which contains the
same NES. However none of these alternative patterns were exclusive to poly (I:C)-
transfected cells, indicating that the localisation is not influenced by the IFN
response (Fig. 6.7D). Cytoplasmic PML I was restricted to the cytoplasm and hence
did not associate with PML NBs (Fig. 6.7E). As with the other PML I constructs,
induction of the IFN response did not alter its localisation (Fig. 6.7E), further
suggesting that PML I is inert regarding the IFN response.
In contrast to full-length PML I, full-length PML II did not co-localise with PML
NBs in the absence of poly (I:C), but instead localised to the periphery of the nucleus
(Fig. 6.7F). This was unexpected, as previous studies have shown that exogenously
expressed PML II localises to PML NBs in other cell types (Beech et al., 2005).
This pattern of localisation was independent on the IFN response, as it was similarly
observed in poly (I:C)-transfected cells (Fig. 6.7F). Similar patterns of full-length
PML II staining have been observed in other cell types in a proportion of cells,
particularly those with high levels of expression (K. Leppard, personal
communication). PML IIΔexon5 staining resembled that of full-length PML II in 
that it did not form PML NBs, but instead associated with the periphery of the
nucleus (Fig. 6.7H). No cells were found that exhibited strong nuclear staining of
IRF3 alongside PML IIΔexon5 expression, making it impossible to determine 
whether its localisation is altered during an IFN response (Fig. 6.7H).A171
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PML I and PML II species during an IFN response. HEK293 cells were
transfected with empty vector pCI-neo or variants of either PML I or PML II.
16 hours later cells were mock transfected or transfected with poly (I:C), and
then fixed and stained 4 hours later. The cells were then treated with primary
antibodies to IRF3 and the FLAG epitope, and then treated with the appropriate
fluorophore-conjugated secondary antibodies. Nuclei were visualised by DAPI
staining. For each of A-I, the upper row of images represent control cells
untreated with poly (I:C), while the lower row represent poly (I:C) treated cells.
All images are single slices on the Z-axis, and are representative of the cell
population. Scale bar - 10µM. A. pCI-neo control; B. pCI-neo FLAG-PML I;
C. pCI-neo FLAG PML IΔRBCC; D. pCI-neo FLAG-PML IΔexon5;  E. pCI-
neo FLAG-PML I cytoplasmic; F. pCI-neo FLAG-PML II; G. pCI-neo
FLAG-PML IIΔRBCC;.  H. pCI-neo FLAG-PML IIΔExon5;  I. pCI-neo174
toplasmic PML II displayed a distinct cytoplasmic localisation in untreated cells
ig. 6.7I). Upon poly (I:C) treatment, however, cytoplasmic PML II localisation
s altered as it displayed a nuclear localisation pattern. It must be noted though
t this nuclear localisation also occurred in cells displaying cytoplasmic IRF3
alisation, suggesting that an induction of the IFN response was not responsible.
ternatively, more cells may be responding to poly (I:C) than are displaying
ominent nuclear IRF3 staining (see below), in which case this location change
uld be relevant.  As with PML IΔRBCC, PML IIΔRBCC displayed a diffuse 
clear localisation in both the presence and absence of poly (I:C) (Fig. 6.7G). This
ggested that the localisation of PML II ΔRBCC is unchanged during an IFN 
FLAG-PML II cytoplasmic.
response, and therefore is not associated with its positive effect of IFNβ promoter 
activity.
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pFig. 6.8 The co-transfection efficiency of poly (I:C) with PML I and PML II
plasmids. The images obtained from the experiment described in Fig. 6.7 were
subjected to quantification analysis. Only cells treated with poly (I:C) were
analysed. Cells from fields of view chosen at random were scored for individual
and simultaneous nuclear IRF3 localisation and exogenous PML expression.
Numbers are expressed as a percentage of the total number of cells present, as
counted by DAPI-stained nuclei. For each plasmid, a minimum of 130 cells were175
he proportion of cells exhibiting both expression of FLAG-PML and a nuclear
RF3 localisation was very low, making analysis of the experiment very difficult;
uantification revealed this was no more than 2% of cells (Fig. 6.8). The
ransfection efficiency of the PML expression plasmids varied between 5% and 30%,
epending on the plasmid used (Fig. 6.8). Poly (I:C) transfection was found to be
ore consistent, as the proportion of cells displaying nuclear IRF typically varied
etween 5% and 10%. This was surprisingly lower than anticipated, and prompted a
ubsequent time-course analysis of IRF3 localisation in HEK293 cells following
oly (I:C) treatment (Fig. 6.9).
counted in total.
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BFigure 6.9 Time course of IRF3 nuclear localisation upon stimulation with
poly (I:C). A. HEK293 cells were mock transfected or transfected with poly
(I:C). The cells were fixed at the indicated time points post-transfection. Cells
were probed with an anti-IRF3 antibody and appropriate fluorophore-conjugated
secondary antibody, then stained with DAPI. Images represent a single slice
through the Z-axis. Scale bar - 50µm. B. Cells from fields of view (A.) chosen at
random were scored for nuclear localisation of IRF3, and are expressed as a177
pproximately 2.5% of cells display a nuclear IRF3 localisation after two hours of
ncubation with poly (I:C). As expected, this proportion increased upon longer
ncubation times, reaching 14% after 8 hours of incubation. Note that the proportion
f 7.5% observed after 4 hours’ incubation is similar to that observed in the
xperiment quantified in Fig. 6.8, which also used 4 hours incubation time. This
rovided evidence that the prior transfection of plasmid DNA, such as that used in
ig. 6.7 as well as in the reporter assays described in this chapter, does not interfere
ith the induction of the IFN response by poly (I:C). Also, the consistency between
xperiments indicated that this was a reliable figure which could be applied to the
eporter assays described in this chapter, which utilised HEK293 cells and an 8 hour
ncubation time with poly (I:C). The figure of 14% after eight hours incubation with
oly (I:C) was still lower than anticipated, given the propensity of HEK293 cells to
upport transfection. It must be noted, however, that this method involved the visual
etection of IRF3 within the nucleus, and it is therefore possible that low levels of
uclear IRF3 accumulation would not be scored. This would result in an under-
stimation of the percentage of cells transfected with poly (I:C).
percentage of the total number of cells counted (n).
6.7 Endogenous PML II localises to PML NBs in HEK293 cells
In the experiment described in Fig. 6.7, full-length, ΔRBCC and cytoplasmic PML II 
tended to localise to the periphery of the nuclear membrane, rather than in PML
NBs. This was both unexpected and in contrast to that observed in PML I-
transfected cells, which localised to PML NBs. In U2OS cells, exogenously-
expressed PML II localised to PML NBs (Beech et al., 2005). It must be noted that a
subset of cells with high-levels of exogenous over-expression of PML II displayed
localisation patterns similar to that observed in Fig. 6.7 (K. Leppard, personal
communication). However, in HEK293 cells, no cells displayed exogenously-
expressed PML II association with PML NBs, which therefore prompted an
investigation to determine the localisation of endogenous PML II in this cell line
(Fig. 6.10).Figure 6.10 Endogenous PML II localises to PML NBs in HEK293 cells.
HEK293 cells were fixed 24 hours after seeding and probed with pan-PML or
anti-PML II antibodies, and an appropriate fluorophore-conjugated secondary
antibody. Nuclei were visualised by DAPI staining. The images represent178
maximum projections of images made in the Z-axis.
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Upon staining with a pan-PML antibody, HEK293 cells displayed normal PML NB
structures. Staining with an anti-PML II antibody revealed that this isoform shared a
similar localisation. There was no evidence of localisation to the nuclear membrane.
These results therefore suggest that exogenously-expressed PML II variants
possessing an RBCC domain display an atypical pattern of localisation in HEK293
cells, probably associated with the high levels of expression achieved in transient
assays.
It was therefore clear that the localisation of PML IIΔRBCC during an IFN response 
remained unchanged, and therefore a change in localisation was unable to account
for its positive effect on the activity of the IFNβ promoter.  
6.8 Analysis of PML IIΔRBCC C-terminal mutants 
It has previously been described that the Ad5 E4 Orf3 protein initiates rearrangement
of PML NBs into tracks via a direct interaction with the C-terminus of PML II
(Hoppe et al., 2006, Leppard et al., 2009). Furthermore, E4 Orf3 has been shown to
be essential for efficient virus growth during an interferon response (Ullman et al.,
2007), and to overcome an intrinsic antiviral activity of PML protein (Ullman &
Hearing, 2008). Given the results just described which suggest a role for PML II in
the activation of the IFNβ promoter, these findings raised the possibility that E4 Orf3 
could interfere with this activity of PML II through its documented interaction with
this isoform.  In order to investigate this, four clones of PMLIIΔRBCC that each 
carry unique deletions in the carboxyl terminus, termed IIΔRΔ1-4, were utilised in 
IFNβ promoter reporter assays.  Orf3 directly interacts with the region deleted in 
IIΔRΔ1, and will therefore only bind IIΔRΔ2-4 (Leppard et al., 2009).
The effect of each IIΔRΔ mutant was compared to ‘wild-type’ IIΔRBCC in the 
presence or absence of Orf3 (Fig. 6.11).  Expression of PML IIΔRBCC and its 
mutants IIΔR1-4 was detected in all of the relevant assays (Fig. 6.11B-E), though 
IIΔR3 and IIΔR4 expression was always found to be considerably lower than that of  
 AFigure 6.11.  PML II mutants ΔRΔ1 and ΔRΔ2 are unable to enhance IFNβ 
promoter activity after stimulation with poly (I:C). A. 2.5 x 105 HEK293
cells were co-transfected in triplicate with 25ng pcDNA3.1-HisB::lacZ, 225ng
pIFNβ-Luc and 125ng pcDNA3.1-Orf3 alone or with pCI-neo FLAG-PML
ΔRBCC II, pCI-neo FLAG-PMLII ΔRΔ1-4.  All DNA mixes were made to a 
total of 500ng with pCI-neo. 16 hours later cells were transfected with 1µg poly
(I:C). All cells were harvested 8 hours later and lysates were assayed for both
luciferase and β-galactosidase activity.  Luciferase activity was normalised to β-
galactosidase activity to obtain the RLA, which was expressed as a ratio to that
of the control. The data presented represent the activity of poly (I:C)-treated
cells only, and are the average of at least three separate experiments. For the
control+Orf3 and ΔRBCC PML II, Student’s T-test was performed against the 
control –Orf3.  ΔRBCC PML II+Orf3 was compared to ΔRBCC PML II-Orf3. 
For ΔR1-4 +/- Orf3, Student’s T-test analysis was performed against IIΔRBCC 
+/- Orf3. * - P <0.05, ** - P <0.005, ***-P <0.001. Green bars – activity in the
absence of Orf3. Purple bars – activity in the presence of Orf3. B-E. Replicate
extracts from each assay used in A. were pooled together and prepared for SDS-
PAGE by the addition of sample buffer. Samples were separated by 15% SDS-
PAGE and subjected to western blotting. Blots were probed with either rabbit
anti-FLAG or rat anti-Orf3 antibodies. Where appropriate, Orf3 expression is
indicated with an arrow to the right of the blot. Protein sizes are indicated in180
kDa to the left of each blot.
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IIΔR1 and IIΔR2 (Fig. 6.11D and E).  E4 Orf3 expression was found to be highly 
variable across the assays. This was a consequence of the lysis procedure, which
was inefficient at solubilising all cellular material. However, the use of passive lysis
buffer was necessary in order to perform luciferase assays. In later experiments, this
was addressed by using sample lysis buffer on an additional replicate of each DNA
treatment (Fig. 6.12B). Under conditions where Orf3 was not detected in the lysates
used for reporter analysis, it was readily detected in a complete lysate, indicating
adequate levels of Orf3 expression were occurring. Therefore, Orf3 expression
across all these assays was assumed to be successful.
Consistent with earlier results, PML IIΔRBCC significantly enhanced IFNβ 
promoter activity in response to poly (I:C) to almost twice of that of the control (Fig.
6.7A).  In contrast, Orf3 expression alone significantly inhibited IFNβ promoter 
activity during poly (I:C) stimulation, which suggested that Orf3 expression was
successful and was acting to inhibit the IFN response pathway. However, Orf3
expression did not significantly reduce the potentiation due to PML IIΔRBCC, as 
IFNβ promoter activity when PML IIΔRBCC and Orf3 were expressed together 
remained comparable to that observed when IIΔRBCC was expressed in the absence 
of Orf3.
The effect of each of IIΔR1-4 was compared to that of ‘wild-type’ PML IIΔRBCC.  
In the absence of Orf3, only IIΔR3 and IIΔR4 enhanced IFNβ promoter activity to 
levels comparable with PML IIΔRBCC.  Indeed, their effects did not significantly 
differ from that of the intact C-terminal domain. Upon IIΔRΔ1 and IIΔRΔ2 
expression, however, IFNβ promoter activity was significantly lower compared to 
PML IIΔRBCC.  Co-expression of Orf3 with IIΔR1-4 caused a significant decrease 
in IFNβ promoter activity, in contrast to the limited effect which it had on activity in 
the presence of PML IIΔRBCC.  Orf3 expression with IIΔR1 and IIΔR2 reduced 
activity of the IFNβ promoter to levels similar to Orf3 alone, which was to be 
expected as these mutants alone did not enhance IFNβ promoter activity.  Orf3 
expression alongside IIΔR3 and IIΔR4 reduced IFNβ promoter activity to levels 
similar to that of the control in the absence of E4 Orf3.
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6.9 E4 Orf3 inhibits the ability of PML IIΔRBCC to enhance the 
IFNβ promoter 
The data presented in Fig. 6.7 suggested that Orf3 could inhibit the potentiating
activity of PML IIΔRΔ3 and IIΔRΔ4 on the IFNβ promoter, though surprisingly 
PML IIΔRBCC activity was not significantly affected by the presence of E4 Orf3.  
Since the hypothesised mechanism of Orf3 action here is via its binding to the PML
II C-terminal domain, one possible reason for this may be that the level of Orf3
expression achieved in these experiments was insufficient to inactivate the over-
expressed PML.  To test this possibility, the activity of PML IIΔRBCC on IFNβ 
promoter activation was analysed in the presence of increasing amounts of Orf3 (Fig.
6.12).  Expression of PML IIΔRBCC was consistent across all samples, as 
determined by western blotting (Fig. 6.12). E4 Orf3 was previously found to be
poorly solubilised in the buffer used for luciferase analysis (Fig. 6.11), and so one
transfection replicate of each Orf3 plasmid input was lysed directly in sample buffer
to allow accurate analysis of Orf3 expression levels. As expected, E4 Orf3
expression was detected at levels corresponding to the amount of input DNA (lanes
11-13).
During poly (I:C) stimulation, expression of PML IIΔRBCC enhanced reporter 
activity by ~1.5-fold, consistent with earlier experiments. Moreover this
enhancement was reduced by expression of E4 Orf3 in a dose-responsive manner. At
an Orf3:PML II DNA ratio of 3:1, IFNβ promoter activity was reduced to control 
levels.  However, at a ratio of 5:1, the activity of the IFNβ promoter was reduced to 
less than 80% of the control. Therefore this suggested that E4 Orf3 expression can
inhibit the stimulation of the IFNβ promoter caused by expression of PML 
IIΔRBCC.
ABFigure 6.12.  Expression of wild-type E4 Orf3 inhibits the ability of ΔRBCC PML II 
to activate the IFNβ reporter.  A. HEK293 cells were co-transfected in triplicate with
25ng pcDNA3.1-HisB::lacZ, 225ng pIFNβ-Luc, 125ng pCI-neo FLAG-PML ΔRBCC II 
and 125ng, 375ng or 625ng pcDNA3.1-Orf3. Each transfection mix was made up to 1µg
total DNA with the appropriate amount of pCI-neo. 16 hours later cells were mock-
transfected or transfected with 1µg poly (I:C). 8 hours later all cells were harvested and
the lysates were assayed for both luciferase and β-galactosidase activity.  The RLA was 
calculated as before and expressed as a ratio to the RLA of control cells (pCI-neo). Error
bars indicate the standard deviation from the mean of three replicate values. B.
Replicate lysates from the assay represented in A. were pooled together. One replicate
well was lysed directly in Sample Buffer. Lysates were separated by 8% (FLAG) and
15% (Orf3) SDS-PAGE and subjected to western blotting. The blots were probed with
either a rabbit anti-FLAG or rat anti-E4 Orf3 antibody. Protein sizes are indicated in184
kDa to the left of each blot.
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6.10 Expression of wild-type E4 Orf3, but not the N82A mutant, is
sufficient to inhibit IFNβ promoter activity. 
Expression of wild-type E4 Orf3 overcame the enhancing activity of PML IIΔRBCC 
on the IFNβ promoter, and at higher concentrations decreased promoter activity to 
less than that of the control (Fig. 6.12). This raises the possibility that E4 Orf3 might
also inhibit IFNβ promoter activity in the absence of PML IIΔRBCC.  One possible 
mechanism whereby Orf3 could achieve this is by interacting with, and inhibiting,
endogenous PML II species that are required for normal IFNβ promoter function.  
Such a model would fit the observation that depletion of all PML II-related species
by siRNA significantly reduced the responsiveness of the promoter to poly (I:C)
(Fig. 6.3). To test this model, the abilities of wild-type E4 Orf3 and E4 Orf3 mutant
N82A to modulate IFNβ promoter activity were compared in the absence of 
exogenous PML. N82A does not interact with PML II, and thus cannot rearrange
PML NBs (Hoppe et al., 2006). Interestingly, N82A does not appear to possess the
same antagonistic properties of E4 Orf3 on the IFN response (Ullman et al., 2007),
suggesting that the interaction with PML II may be important for this particular
function.
Expression of both wild-type and N82A E4 Orf3 increased in a dose-dependent
manner (Fig. 6.13), and expression levels of the two proteins at equivalent DNA
inputs were similar. Increasing expression of wild-type E4 Orf3 further reduced the
low basal activity of the IFNβ promoter to approximately 60% of the control.  
Expression of the N82A mutant, however, did not exhibit any dose-dependent effects
on IFNβ promoter activity.  During stimulation with poly (I:C), expression of wild-
type E4 Orf3 again inhibited the activity of the IFNβ promoter in a dose-responsive 
manner, with promoter activity reduced to 50% of the control at the highest amount
of Orf3 used. N82A, despite similar expression levels to wild-type E4 Orf3, did not
affect the activity of the stimulated promoter in a dose-dependent manner.  IFNβ 
promoter activity in the presence of N82A remained broadly comparable with that of
the control, suggesting that this mutant exerts no effects on the promoter.
ABFigure 6.13. Wild-type E4 Orf3, but not the N82A mutant, inhibits the
activity of the IFNβ reporter.  A. 2.5 x 105 HEK293 cells were co-transfected in
triplicate with 25ng pcDNA3.1-HisB::lacZ, 225ng pIFNβ-Luc and 150ng, 300ng, 
450ng, 600ng or 750ng pcDNA3.1-Orf3, or pcDNA3.1-N82A. Each transfection
mix was made up to 1µg total DNA with the appropriate amount of pCI-neo. 16
hours later cells were mock-transfected or transfected with 1µg poly (I:C). 8
hours later all cells were harvested and the lysates were assayed for both
luciferase and β-galactosidase activity.  The RLA was calculated as before and 
expressed as a ratio to the RLA of control cells (pCI-neo). Error bars indicate the
standard deviation from the mean of three replicate values. B. One replicate well
from the assay represented in A. was lysed directly in Sample Buffer. Lysates
were separated by 15% SDS-PAGE and subjected to western blotting. The blot
was probed with a rat anti-E4 Orf3 antibody. Protein sizes are indicated in kDa186
to the left of the blot.
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6.11 Discussion
The data presented in this chapter provide evidence that various PML isoforms play
roles in modulating the activity of the IFNβ promoter.   A somewhat surprising 
finding was that, depending on the isoform being expressed, IFNβ promoter activity 
could be enhanced or inhibited by over-expression of PML protein. This was
apparent when full-length PML isoforms were expressed (Fig. 6.1). Expression of
PML IV significantly enhanced the basal activity of the promoter. PML IV has been
shown to bind the tumour suppressor p53 via a direct interaction in its C-terminus
and subsequently to recruit it to PML NBs, where activating modifications of p53
are promoted (Bischof et al., 2002, Fogal et al., 2000). p53 is also an IFN-inducible
gene, and has been proposed to exert antiviral activities of its own via the IFN
pathway (Porta et al., 2004). It is possible therefore that p53 recruitment to PML
NBs by PML IV could support the normal induction of the IFNβ promoter.  This 
could explain why PML IVΔRBCC failed to exert a similar effect, as it is unable to 
localise to PML NBs and, unlike full-length PML IV, cannot activate a p53-
responsive promoter (K. Leppard, personal communication). In contrast to these
effects on basal IFNβ promoter activity, neither full-length nor PML IVΔRBCC 
enhanced IFNβ promoter activity during stimulation by poly (I:C), suggesting that 
the capability of this isoform to the enhance IFNβ promoter activity is saturated 
under a normal IFN response. It would be interesting to ascertain whether depletion
of PML IV by siRNA can reciprocally inhibit IFNβ promoter activity. 
One must use caution when considering changes in the basal values of IFNβ 
promoter reporter activity brought about by over-expression of exogenous proteins.
By implication, these values are very low in cells not stimulated by poly (I:C), and
hence only slight variations in activity will cause a large change in relative activity
which may not be genuine effects. For instance, in Figs. 6.1 and 6.2 expression of
PML I and PML IΔRBCC respectively had no effect on basal IFNβ reporter activity, 
though in Fig. 6.6A expression of these proteins led to small (<1.4 fold) but
significant increases in activity. Such discrepancies highlight the inconsistency of
basal reporter activity, and indicate that interpretation of any changes may be
somewhat unreliable. It is far more prudent to concentrate on IFNβ reporter activity 
during poly (I:C) stimulation, where reporter values are much larger and hence any
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variations are more likely to be significant. It should be noted that in Figs. 6.1, 6.2
and 6.6, over-expression of PML I and PML IΔRBCC had no effect on IFNβ 
promoter activity during stimulation.
Expression of both full-length and ΔRBCC versions of PML V and PML VI 
significantly inhibited IFNβ promoter activity during activation by poly (I:C).  The 
fact that full-length and ΔRBCC forms were equivalent in this respect suggests that 
the ability to localise to PML NBs is dispensable for these actions. One model to
explain these activities is that the C-terminal domains of these isoforms can bind and
sequester factors involved in activating the IFNβ promoter, and hence limit the 
activation observed when they are over-expressed. Depletion of PML V by siRNA
did not lead to a corresponding increase in IFNβ promoter activity, supporting the 
notion that over-expression of PML V sequesters a factor involved in IFNβ promoter 
induction that is not limiting for IFNβ activation under normal levels of PML 
expression.
Of all the PML isoforms tested, only over-expression of PML II-related species was
sufficient to enhance the activity of the IFNβ promoter during poly (I:C) stimulation.  
Over-expression of PML IIΔRBCC, but not-full-length PML II, caused a significant 
increase in promoter activity. Since no naturally occurring species of PML II
lacking the RBCC domain have been described, the physiological significance of this
result is hard to determine. One possibility is that full-length PML II negatively
regulates the activity of an activator of the IFNβ promoter, perhaps binding it via its
C-terminus and with inhibition requiring the RBCC domain, and PMLIIΔRBCC
merely acts as a dominant negative. If this were the case, one would expect
depletion of endogenous PML II to enhance IFNβ promoter activity. However, upon
depletion with siPML II siRNA, a significant and substantial decrease in promoter
activity was observed during poly (I:C) stimulation. This provides evidence that an
endogenous PML II-related species plays a role in activating the IFNβ response, and 
suggests that PMLIIΔRBCC may not act as a dominant negative but instead plays an
active role in regulating IFNβ promoter activity that mimics the properties of a
natural PML II variant. It should be noted, however, that the isoform-specific
siRNA targets all mRNAs containing the target exon, regardless of whether this exon
is ultimately translated. For example, a PML II mRNA containing a stop codon
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upstream of exon 7b could not produce a PML II-related protein, yet would still be
depleted by PML II siRNA.
The exact nature of the PML II-related species that is required for normal IFNβ 
promoter activity remains unknown. Expression of either cytoplasmic or PML II
Δexon 5, two known splice variants of full-length PML II (Jensen, 2001), could not 
replicate the activity of PML IIΔRBCC during poly (I:C) treatment.  In contrast to 
other constructs, PML IIΔRBCC exhibits a diffuse nuclear localisation, possibly 
allowing it to freely interact with soluble nucleoplasmic factors. The localisation of
PML IIΔRBCC was unaltered during poly (I:C) stimulation, ruling out the 
possibility that the positive activity of this molecule on IFNβ reporter activity is due 
to an increased ability to mobilise during an IFN response.
The localisation pattern of full-length and PML II Δexon5 were remarkably similar, 
in that they all tended to associate with the nuclear periphery. This was unexpected,
as exogenously-expressed full-length PML II has previously been confirmed to
associate with PML NBs (Beech et al., 2005), raising the possibility that PML II
localisation in HEK293 cells was unusual. Analysis of endogenous PML II in this
cell type, however, revealed it to be largely confined to PML NBs similar to other
cell types. It is therefore possible that the unusual localisation of exogenous full-
length and PML IIΔexon5 in HEK293 cells is due to an artefact of the experimental 
method, most likely the level of over-expression. The precise mechanism underlying
this remains elusive, as exogenously-expressed full-length PML I and PML IΔexon5 
were still able to form PML NBs. Another unexpected result was the apparent
nuclear localisation of the ‘cytoplasmic’ PML II upon poly (I:C) stimulation, which
was also observed in HEp-2 cells (see Appendix), though in this case cytoplasmic
PML II clearly localised to PML NBs and the cells were not treated with poly (I:C).
A similar phenomenon was seen with a cytoplasmic PML III construct (see
Appendix), but not with cytoplasmic constructs of PML I, IV and V. This suggests
that PML II and PML III possess additional sequences within their unique C-
terminal domains that can promote nuclear accumulation, at least in some cell types.
Pan-isoform depletion of PML proteins using siRNA targeting exons 3 and 5 did not
lead to a decrease in IFNβ activity after stimulation with poly (I:C), in contrast to 
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what was observed upon PML II-depletion. There are two possible explanations why
this is the case. Knockdown of total PML protein by targeting exon 3 or exon 5 may
deplete PMLs that perform both inhibitory and positive roles during promoter
activation, with the net effect being no difference in promoter activity. This is
supported by the data presented in this chapter that specific PML proteins do indeed
exert both positive and negative effects on the promoter. Alternatively, the PML II
species responsible for enhancing IFNβ promoter activity may lack both exons 3 and 
5 and therefore evade knock-down. Although there is no direct evidence for such a
truncated variant of PML II, anti-PML II anti-serum detects many lower-molecular
weight bands by western blot (Fig. 4.2), suggesting that such molecules may exist.
However, further experimentation would be required to determine that this is the
case.
Examination of four PML II ΔRBCC deletion mutants found that only two of these 
constructs were able to activate the IFNβ promoter.  Neither IIΔRΔ1 nor IIΔRΔ2 
could significantly enhance promoter activity, whereas mutants IIΔRΔ3 and IIΔRΔ4 
displayed similar activity to that of the ‘wild-type’ PML IIΔRBCC.  This suggests 
that the regions deleted in IIΔRΔ1 and IIΔRΔ2 are responsible for enhancing the 
activity of the promoter.  Since the IIΔR1 deletion covers the region that serves as a 
target for E4 Orf3 binding (Leppard et al., 2009), this provides a possible
mechanism whereby Orf3 may inhibit the activity of any PML II-related species by
direct binding competition with the natural interaction partner of this region of PML
II. However, E4 Orf3 is able to bind the IIΔRΔ2 mutant, yet this construct also lacks 
the ability to enhance IFNβ promoter activity.   The region absent in the IIΔRΔ2 
mutant interacts with at least one as yet unidentified protein (K. Leppard,
unpublished observations), which could possibly be required to enhance IFNβ 
promoter activity. Further work would be required to identify the precise regions
absent in IIΔRΔ1 and IIΔRΔ2 that are required for enhancing IFNβ promoter 
activity.
When cells were transfected with equivalent amounts of PML IIΔRBCC and Orf3 
DNA, Orf3 expression was too low to significantly overcome the PML IIΔRBCC-
mediated enhancement of IFNβ activity (Fig. 6.11).  However, the same amount of 
Orf3 was able to successfully inhibit the activating ability of both the IIΔRΔ3 and 
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IIΔRΔ4 deletions.  This may be explained by two observations.  First, although 
expression of IIΔRΔ3 and IIΔRΔ4 could not be directly compared to IIΔRBCC 
expression, they were consistently expressed at much lower levels than IIΔRΔ1 and 
IIΔRΔ2 (Fig. 6.11D-E).  Therefore, their biological effects may have been more 
readily overcome by limited amounts of Orf3 expression than those of highly-
expressed IIΔRBCC.  Second, both IIΔRΔ3 and IIΔRΔ4 were shown to co-
precipitate Orf3 more strongly than IIΔRBCC, IIΔRΔ1 or IIΔRΔ2 (Leppard et al.,
2009). This suggests that these constructs may more readily bind Orf3 and therefore
be inhibited by it more effectively than IIΔRBCC. 
Many viruses have been demonstrated to encode proteins that mitigate the interferon
response (Haller et al., 2006, Levy & Garcia-Sastre, 2001, Randall & Goodbourn,
2008). In some cases, the proteins responsible have also been demonstrated to alter
PML protein and PML NBs (Everett et al., 1998, Mossman et al., 2000, Ullman et
al., 2007). The Ad5 E4 Orf3 protein has been implicated in overcoming the cellular
IFN response, and also disrupts PML NBs through a direct interaction with PML II
(Hoppe et al., 2006, Leppard et al., 2009, Ullman & Hearing, 2008, Ullman et al.,
2007). Here it has been demonstrated that exogenous expression of wild-type E4
Orf3 inhibits IFNβ promoter activity in a dose-responsive manner.  Furthermore, 
expression of an Orf3 mutant unable to interact with PML II, N82A, does not exhibit
similar activity. Expression of Orf3 is also sufficient to overcome the enhancement
in IFNβ promoter activity upon expression of PML IIΔRBCC.  This suggests that the 
Orf3-PML II interaction, and subsequent PML NB disruption, may be a viral
mechanism employed to negate the positive influence on the IFN response of any
PML II-related species present within the cell. However, further experimentation
would be required to confirm this, as the Orf3 N82A mutant also lacks functions
other than the PML-binding capability of wild-type Orf3 (Stracker et al., 2002).
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Chapter 7
Final Discussion
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It has long been established that Ad5 causes disruption to PML NBs by
redistributing PML protein into nuclear ‘tracks’ (Carvalho et al., 1995). This
phenomenon is dependent on the direct interaction between the viral E4 Orf3 protein
and the carboxyl terminal domain of PML II (Hoppe et al., 2006). Ad5 infection
also results in the production of a novel species of PML protein, termed PML-A
throughout this investigation (Leppard & Everett, 1999). Like PML NB
redistribution, the production of PML-A is dependent on the viral E4 Orf3 protein.
PML proteins have been extensively implicated in exerting antiviral effects, though
the mechanism by which they achieve this is incompletely understood. Furthermore,
very little is known about the roles of individual PML isoforms in established
antiviral pathways. This study sought to understand further the relationship between
Ad5 and PML protein by examining the the changes in the PML protein population
induced upon infection. Also, the roles of individual PML isoforms in the type I IFN
response were investigated, with the ultimate goal of linking Ad5-induced changes in
the PML protein population to the modulation of the IFN response.
It was hypothesised that PML-A would be related to one of the known PML protein
isoforms, though initial attempts at identifying PML-A using isoform-specific
antibodies proved to be unsuccessful. However, PML-A was successfully depleted
by siRNA targeting PML isoform II, indicating that it shares the same C-terminal
domain as this isoform. This was not entirely unexpected because, as described
above, E4 Orf3 directly interacts with the C-terminal domain of PML II (Hoppe et
al., 2006, Leppard et al., 2009). The significance of PML-A and its role in Ad5
infection remains unclear.
E4 Orf3 is responsible for both the production of PML-A and the rearrangement of
PML NBs, with both phenomena involving PML II. This initially suggested that
these observations could be directly related and possibly dependent on one another.
However, over-expression of E4 Orf3, even at relatively high levels, did not result in
the production of PML-A in HEK293 nor HEp-2 cells (Fig. 3.8A). In contrast,
previous studies have demonstrated that E4 Orf3 expression alone is sufficient to
induce rearrangement of PML NBs (Carvalho et al., 1995, Hoppe et al., 2006).
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Taken together, these observations indicate that the production of PML-A may
require a viral or cellular infection-specific factor in addition to E4 Orf3.
As well as its depletion by siRNA targeting PML II, PML-A was also successfully
depleted independently by siRNAs targeting PML exon 3 or exon 5. These
observations indicate that PML-A is derived from an mRNA that possesses all of
these exons, showing it to be related to full-length PML II. Indeed, by SDS-PAGE,
PML-A migrates to a position that corresponds to a molecular weight that is slightly
larger than endogenous PML II. The most likely explanation for this size
discrepancy is post-translational modification of PML II that is induced upon
infection with an E4 Orf3-competent Ad5, leading to the accumulation of PML-A.
As yet, there are no known post-translational modifications to PML that are isoform-
specific. However, PML-A shows a distinct similarity in size to a phosphorylated,
mitosis-specific form of PML that was described by Everett and colleagues (Everett
et al., 1999), prompting the consideration of PML-A as a phosphorylated form of
PML II. The possibility that PML-A is a phosphorylated variant of PML II led to the
question as to whether additional viral proteins are involved in its production.
However, upon co-expression of E4 Orf3 with E4 Orf4, a protein known to affect
cellular phosphatase activity, no changes in the PML population were detected.
Therefore Orf4 is unlikely to be the cooperating factor with Orf3 responsible for the
production of PML-A, and the nature of this factor remains unknown. It is possible
that alternative viral proteins which were not examined in this study could be jointly
responsible with E4 Orf3 for the production of PML-A. Alternatively, the additional
factor required for PML-A may instead be a cellular protein that is induced or
activated during viral infection.
The possibility that alternative post-translational modifications, such as sumoylation,
may play a role in PML-A production cannot be discounted. For instance, infection
with wild-type Ad5 leads to the loss of higher molecular weight, sumoylated forms
of PML (Leppard & Everett, 1999). This activity, like the presence of PML-A,
positively correlates with the presence of E4 Orf3. The appearance of PML-A has
been shown to precede the loss of sumoylated PMLs, suggesting that it may be the
cause of this phenomenon (Leppard & Everett, 1999). In this study, U2OS cells,
which are incapable of supporting the production of PML-A, display no such loss of
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sumoylated PML species (Fig. 3.1). This observation further suggests that the loss
of sumoylated PML and the production of PML-A may be directly related.
The mechanism whereby this link between PML-A and desumoylation could be
achieved is unclear, though there are several described examples where
phosphorylation can regulate the sumoylation status of a PML protein. For instance,
early studies showed that treatment with phosphatase inhibitors led to a decrease in
sumoylated PML species (Muller et al., 1998), suggesting that phosphorylation may
inhibit sumoylation. Interestingly, the appearance of the mitosis-specific PML
species also correlates with the loss of higher molecular weight PML species
(Everett et al., 1999). These observations bear striking similarities to the
circumstances under which PML-A occurs, and may imply that it can also be
produced in uninfected cells, though only under certain circumstances. It is tempting
to speculate that E4 Orf3 acts in conjunction with an additional protein to hijack a
cellular pathway, perhaps the same one responsible for the mitosis-specific species
of PML, which results in a phosphorylation on PML II which subsequently initiates
desumoylation of PML proteins. This model would fit with previous observations,
as PML-A is produced prior to the loss of sumoylated PML species (Leppard &
Everett, 1999). It is unclear, however, how phosphorylation of PML II alone could
mediate desumoylation of other PML isoforms.
Alongside PML-A, two other infection-specific PML species were detected (PML-B
and PML-C). These species were previously unreported and, unlike PML-A, were
produced upon infection with either wild-type or E4 Orf3-deficient Ad5, indicating
that the production of PML-B and PML-C does not require E4 Orf3. Both of these
PML forms are produced after the onset of DNA replication, suggesting that a viral
late protein is responsible for their production. Over-expression of pIX, a viral
protein previously been shown to interact with PML at late time points of infection
(Rosa-Calatrava, 2003), or the L4 22K and 33K proteins, which regulate late mRNA
formation post-transcriptionally, did not lead to any alterations in the PML
population. This suggests that these proteins are not responsible for the production
of PML-B and -C, though it cannot be discounted that one of them may act in
conjunction with other viral proteins to produce PML-B and PML-C. However, as
with PML-A, the factor responsible for the production of PML-B and PML-C may
also be a cellular protein that is induced by viral infection.
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The precise nature of PML-B and PML-C remains elusive. Both are depleted by
siRNA targeting exon 3 of PML, but not by siRNA targeting exon 5. This is in
contrast to PML-A, which was depleted by both siRNAs. This indicates that these
proteins are encoded by mRNAs that lack exon 5. PML-B was not detected by any
PML isoform-specific antibodies, and could not be depleted with siRNA targeting
PML I. RT-PCR analysis of PML I and PML II mRNA did not reveal any infection-
specific mRNA that could account for PML-B. It is possible that PML-B may
represent a splice variant or an infection-specific post-translational modification of
one of PML III-VI.
An infection-specific band co-migrating with PML-C was detected using an anti-
PML I antibody, and this protein was correspondingly depleted by siRNA targeting
PML I. This strongly indicates PML-C to be a PML I-related molecule, though its
low molecular weight and sub-cellular localisation indicate it to be a cytoplasmic
variant of PML I. However, RT-PCR analysis of mRNA from Ad5-infected cells
did not yield any infection-specific product that was PML I-related. This suggests
that PML-C may not be an infection-specific splice variant of PML I but instead may
represent a novel Ad5-induced post-translational modification of an existing PML I
splice variant.
In order to understand the functions of PML-A, -B and –C it will first be necessary
to identify and characterise these species in terms of their PML exon composition as
well as any post-translational modifications that distinguish them from the rest of the
PML population. Once understood, these species may then be artificially recreated
and their roles in the cell may be elucidated. For instance, in the case of PML-A,
mass spectrometry could be used to identify the post-translational modification that
is likely to be responsible for its appearance. This, however, would require it to be
successfully identified out the entire cellular protein content, and given the variable
levels of PML-A production observed during the course of this study, this approach
could be problematic. Ideally, targeted mutations to residues within PML protein
that are known to be post-translationally modified could be used to identify the
modification of PML II that is responsible for PML-A. Again, this approach would
not be without difficulty, as the post-translational modification responsible for PML-
A could not be replicated on exogenously-expressed PML II, an essential
prerequisite for such an approach (Fig. 4.3).
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For PML-B and PML-C, a more thorough analysis of PML mRNA splice variants
during infection may reveal the nature of these proteins. The RT-PCR analysis
performed in this study focused on PML I and PML II-related mRNA only, so it
remains possible, for instance, that PML-B may be derived from a splice variant of
one of PMLs III-V. PML-C on the other hand, is related to PML I though its exact
composition remains unknown. More detailed analysis of PML I splice variants
during infection, perhaps incorporating more sensitive methods of specific PCR
product detection, may reveal an infection-specific splice variant mRNA responsible
for PML-C. If RT-PCR analysis yields no such infection-specific PML mRNAs,
then mass spectrometry could reveal the nature of PML-B and PML-C. Both of
these PML species were relatively strongly expressed and, especially in the case of
PML-C, are likely to be more soluble than PML-A. This could allow the
identification of these proteins by this methodology somewhat more easily than
would be the case for PML-A, which was the least abundant of the infection-specific
species.
As mentioned above, PML proteins have been proposed to possess antiviral
activities, though the nature of their action remains largely unknown. This study
sought to shed light on this issue by investigating the effects of altering the balance
of individual PML isoforms during a type I interferon response. The data generated
suggest that the role of PML proteins in type I interferon signalling is complex, as
IFNβ promoter activity was decreased or enhanced depending on the PML isoform 
being altered. For instance, over-expression of PML V and PML VI was sufficient
to significantly decrease the activity of the IFNβ promoter after stimulation with the 
dsRNA analogue poly (I:C). On the other hand, expression of PML IV led to a
significant 2-fold increase in basal reporter activity. However, out of all of the PML
isoform constructs tested, only expression of PML IIΔRBCC was found to 
significantly enhance IFNβ promoter reporter activity during stimulation with poly 
(I:C). This was in contrast to expression of full-length PML II, which had no
significant effect on reporter activity.  It may be argued that PML IIΔRBCC 
represents an unnatural protein, and that its positive effect on IFNβ promoter reporter 
activity is due to a non-specific cellular stress response to the presence of a
misfolded or damaged protein.  However, ΔRBCC variants of PML I, III-VI did not 
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display such an effect, and in the case of PML VΔRBCC and VIΔRBCC, actually 
inhibited IFNβ promoter activity, making the above scenario unlikely.   
An alternative explanation may be that PML IIΔRBCC acts as a dominant negative 
over full-length PML II, inhibiting the normal function of endogenous protein. For
instance, the lack of the RBCC domain may render PMLIIΔRBCC biochemically 
inactive, but free to interact with any proteins that normally bind to the C-terminal
domain of PML II.  In such a scenario, over-expressed PMLIIΔRBCC could out-
compete full-length PML II in binding proteins that are normally regulated by this
isoform, resulting in a loss of regulation. If, for example, such a protein was a
regulator of the type I IFN response, over-expression of PML IIΔRBCC could 
conceivably alter the activity of the IFNβ promoter.  On the other hand, over-
expression of full-length PML II would not necessarily have a significant effect, as
under normal conditions this supposed regulatory mechanism may already be
saturated.  In order to determine the nature of PML IIΔRBCC-mediated 
enhancement, a construct of this molecule could be made that was resistant to
knockdown by PML II siRNA.  If PML IIΔRBCC possesses its own activating 
ability, then the siRNA-resistant mutant would still enhance promoter activity in
cells depleted of endogenous PML II.  However, if PML IIΔRBCC acts as a 
dominant negative then its ability to enhance IFNβ promoter activity in such cells 
would be diminished.
The study of PML IIΔRBCC-mediated enhancement of IFNβ promoter activity was 
complemented through protein depletion studies. Depletion with siRNA targeting
exon 7b, which encodes the PML II-specific C-terminal domain, led to a
considerable decrease in IFNβ promoter activity upon stimulation with poly (I:C) 
that was not observed during depletion of PML I or PML V. This provides direct
evidence of a role for an endogenous PML II-related protein in type I IFN signalling,
though the nature of the protein responsible remains unclear. Depletion of total
endogenous PML with siRNAs targeting exon 3 or exon 5 did not lead to any such
decrease in IFNβ activity.  It is possible that, given the apparently opposing effects 
of PML II, PML V and VI on IFNβ activity, pan-isoform PML knock-down leads to 
no net effect on IFNβ promoter activity.  Alternatively, the PML II-related species 
responsible for enhancing IFNβ promoter activity may lack both exons 3 and 5.  It 
must be noted, however, that no such variant of any PML isoform has been recorded.
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Like full-length PML II, expression of internally spliced PML II variants known to
occur naturally (PML IIΔexon5 and cytoplasmic PML II) did not replicate the 
enhancing effect of PML IIΔRBCC on IFNβ promoter activity.  This suggests that 
none of these variants of PML II are responsible for its positive effect on IFNβ 
promoter activity. However, exogenously expressed full-length PML II and PML
IIΔexon5 displayed an atypical localisation pattern in HEK293 cells, when compared 
to that of endogenous PML II. Therefore it cannot be discounted that, in HEK293
cells at least, exogenously-expressed PML II does not function in the same way as
endogenous PML II. In such a case, any effect of endogenous PML II on the activity
of the IFNβ promoter may not be replicated by expression of exogenous PML II.  
This offers a possible explanation for why expression of full-length PML II did not
enhance IFNβ promoter activity in HEK293 cells.  It would be interesting to 
compare the effect of PML II expression on IFNβ promoter activity in alternative 
cell types where the localisation of exogenous PML II mirrors that of endogenous
PML II.
Depletion of the total PML content with siRNA targeting exon 3 or exon 5 led to a
decrease in PML protein expression, yet had no significant effect on stimulated IFNβ 
reporter activity. Although not demonstrated in this investigation, previous studies
have demonstrated that knock-down of the cellular PML content leads to a decrease
in the size and number of PML NBs (Ullman & Hearing, 2008). Thus, the absence
of an effect of PML depletion on IFNβ promoter activity suggests that the structural 
integrity of PML NBs is not required for IFN signalling. This is interesting for two
reasons. First, as described in Section 1.3.5, a number of viruses disrupt PML NBs
and initiate their dispersal. Such observations have been taken to indicate that PML
NBs exert antiviral effects. The data presented in this study would suggest that such
effects may not be directly related to blocking the IFN response to virus infection.
Second, PMLIIΔRBCC was the only molecule used in this study that could enhance 
IFNβ promoter activity during stimulation with poly (I:C).  PML IIΔRBCC does not 
localise to PML NBs, but instead displays a diffuse nuclear localisation. Therefore it
is possible that the endogenous PML II-related species responsible for enhancing
IFNβ promoter activity may also not associate with PML NBs.  Although there is no 
direct evidence to suggest such a PML II molecule exists, the anti-PML II antibody
does detect numerous lower-molecular weight species in HEp-2 cells (Fig. 4.2).
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Depletion with siRNA targeting PML II could determine whether these are genuine
PML II-related molecules or artefacts of antibody cross-reactivity.
Analysis of four PML IIΔRBCC C-terminal deletion mutants identified two regions, 
defined by the Δ1 and Δ2 deletions, which were required for PML IIΔRBCC to 
enhance the response of the IFNβ promoter to poly (I:C).  It is therefore possible that 
the sequences deleted in these mutants may contain binding sites for other proteins
that are involved in IFN signalling.  For instance, IIΔRΔ2 binds an as-yet 
unidentified protein (K. Leppard, personal communication) which could be such a
factor.  E4 Orf3 has been shown to bind a site deleted in IIΔRΔ1 (Leppard et al.,
2009), providing at least two possible mechanisms whereby E4 Orf3 might
overcome the enhancing effect of PML IIΔRBCC on the IFNβ promoter.  E4 Orf3 
binding to PML IIΔRBCC may disrupt its binding to the unknown factor described 
above, thereby preventing an interaction that may be necessary for enhancing IFNβ 
promoter activity. Alternatively, E4 Orf3 may directly out-compete any cellular
factors for binding to PML IIΔRBCC, with the ultimate result of limiting its ability 
to enhance promoter activity.
It is likely that any such mechanism would also apply to an endogenous PML II-
related species involved in IFNβ promoter activation.  Indeed, expression of the E4 
Orf3 mutant N82A, which is unable to bind PML II, in the absence of exogenously-
expressed PML II had no significant effect on IFNβ promoter activity while wild-
type E4 Orf3 expression led to a decrease in promoter activity in a dose-responsive
manner. The N82A mutant, however, is also deficient in reorganisation of the MRN
complex. Whereas there is evidence that suggests Ad5-mediated reorganisation of
the MRN complex is not required for overcoming the IFN response (Ullman et al.,
2007), this possibility was not tested directly during this study. Therefore, it would
be of interest to determine if an Ad5 Orf3 mutant that is unable to bind PML II, yet
still retains the ability to reorganise the MRN complex, could replicate the results
presented in this study.
The effects of wild-type E4 Orf3 on IFNβ promoter activity, alongside the evidence 
presented that supports a role for PML II in IFN signalling, imply that E4 Orf3 may
act on an endogenous PML II species in a manner that reduces the response of this
promoter to inducers such as poly(I:C). It is likely that this activity of E4 Orf3
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would apply during Ad5 infection, and may indicate a mechanism whereby Ad5 can
‘dampen’ the IFN response. In order to confirm this, further work comparing the
effect on IFNβ promoter activity of wild-type Ad5 and E4 Orf3-deficient Ad5 would 
be required. According to the data presented in this study, infection with an E4
Orf3-deficient virus would be predicted to lead to an increase in IFNβ promoter 
activity that is greater than that caused by infection with the wild type virus.
A possible model that accounts for the observations made in this study is presented
in Figure 7.1.  PML IIΔRBCC may mimic the activity of a natural nucleoplasmic, 
PML II-related molecule by increasing the nucleoplasmic concentration of a
regulatory factor involved in type I IFN signalling, with the ultimate result of
increasing IFNβ promoter activity. siRNA targeting PML II would deplete the cell
of this enhancing nucleoplasmic species, resulting in a loss of IFNβ promoter 
induction. Full-length PMLII-mediated localisation of this regulatory factor to PML
NBs, however, sequesters it and renders it inactive. An interaction between Ad5 E4
Orf3 and the nucleoplasmic PML II species or PML IIΔRBCC could then prevent 
their binding to the regulatory factor, thus biasing its distribution to sequestration
and so inhibiting IFNβ promoter activity. 
This model makes several predictions which require confirmation experimentally.
For instance, the model assumes that the endogenous PML II species responsible for
enhancing IFNβ promoter activity is not full-length PML II, but instead a novel, 
nucleoplasmic version of this protein that is required for the full induction of the
IFNβ promoter under normal circumstances.  The model also assumes that such a 
species may compete with full-length PML II for binding to a protein that performs
regulatory functions in the IFN response, with the nucleoplasmic localisation of this
protein resulting in a positive effect on IFNβ promoter activity.   
It is currently impossible to determine the stage in IFN signalling whereby the
nucleoplasmic PML II-related species acts to enhance IFNβ promoter activity.  For 
example, it is possible that it directly affects the availability of a component of the
enhanceosome that directs expression from the IFNβ promoter, such as NF-κB or 
AP-1. Alternatively, this nucleoplasmic PML II-related species may interact with
and modulate the activity of factors involved in sensing dsRNA or signalling
proteins upstream of IFNβ induction. PML proteins are known to interact with such
ft
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cFigure 7.1 A model of PML II-related regulation of the IFNβ promoter. This
diagram outlines a possible mechanism of action of nucleoplasmic PML II-
related species in IFN signalling. A hypothetical nucleoplasmic PML II-related
species interacts with a regulatory protein involved in IFN signalling and
promotes its nucleoplasmic localisation, resulting in induction of the IFNβ 
promoter.  Addition of PML IIΔRBCC promotes further the nucleoplasmic 
localisation of this regulatory protein, whereas addition of E4 Orf3 results in the
sequestration of PML IIΔRBCC and the nucleoplasmic species of PML II, with 
the ultimate effect of preventing IFNβ promoter induction. 202
actors. For instance it is known that that PMLs I, II and IV can reduce the
ranscriptional activity of phosphorylated STAT-1, resulting in a decrease in IFNγ 
ignalling (Choi et al., 2006). In the case of PML IV, the C-terminal domain was
equired for the interaction with STAT-1. Thus, it is conceivable that the endogenous
ML II-related species can also interact with such a factor through its unique C-
erminal domain, but instead promote its activity, resulting in an increase in type I
FN signalling. It would therefore be of particular interest to identify cellular
nteraction partners with the C-terminal domain of PML II, as this may provide a
lue to the stage of IFN signalling at which the PML II-related molecule may act.
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As stated above, the C-terminal domain of PML II is known to directly interact with
at least one unidentified cellular protein. Once this protein is identified it would be
possible to examine other cellular interaction partners of this protein, including any
variants of PML II, by co-immunoprecipitation. This could therefore be used as a
possible strategy to test for the presence of the hypothesised alternative form of PML
II that is responsible for enhancing IFNβ promoter activity.
It remains unclear whether E4 Orf3-induced rearrangement of PML NBs, or indeed
the production of PML-A, is related to the ability of Orf3 to inhibit IFNβ promoter 
activity. As shown by Ullman and colleagues, PML rearrangement correlates with
the ability of Ad5 to replicate during an IFN response (Ullman et al., 2007).
However, it is difficult to distinguish between E4 Orf3-induced rearrangement of
PML and its effects on endogenous PML II species. Therefore it is possible that
PML rearrangement is not a necessity for replication during an IFN response, but
rather it is an interaction of Orf3 with the nucleoplasmic form of PML II implied by
this study that is required.
One may speculate that the E4 Orf3-dependent modification of PML II responsible
for PML-A is part of a mechanism of Ad5 to overcome the antiviral effect of PML
II. As described above, PML-A is likely to be related to full-length PML II,
expression of which exerted no effect of IFNβ promoter activity. However, it is
possible that the modification responsible for PML-A also occurs on an undetected
variant of PML II-related protein that does perform a role regulating IFNβ promoter 
activity. In such a case, modification of this species may result in a loss of ability to
promote IFNβ activity.  Further experimentation would be required to establish if 
this is the case, though it does provide a particularly interesting avenue of
investigation. For example, once the modification responsible for PML-A is
elucidated it would be possible to examine the effects of this species on the IFN
response. This approach could similarly be applied to PML-B and PML-C, though
both of these proteins are E4 Orf3-independent and their production is thus unlikely
to represent a mechanism for overcoming PML II-mediated enhancement of the
IFNβ promoter.  Given the involvement of PML proteins in processes important to 
the cell and the virus, such as the cell cycle, it is possible that these infection-specific
species promote viral replication in other ways.
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It is clear that the relationship between Ad5 and PML proteins is incompletely
understood. This study has provided evidence that Ad5 induces additional changes
in the PML protein population within infected cells that were previously unrecorded.
It has also provided strong evidence that a PML II-related molecule is important in
regulating the type I IFN response, and that Ad5 may selectively target this isoform
in order to overcome innate immune responses. However, it remains to be
established if these changes in the PML population lead directly to alterations in the
ability of PML proteins to regulate the type I IFN response.
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Appendix
Appendix A
Construction of an Ad5 E4 Orf4 expression plasmid
E4 orf4 was amplified from wild-type Ad5 genomic DNA by PCR using primers that
corresponded to 20 base-pairs at the 5’ and 3’ ends of the open reading frame. In
order to facilitate subsequent cloning, the forward and reverse primers incorporated
EcoRI and BamHI restriction sites respectively. The forward primer also
incorporated a Kozak sequence around the AUG initiation codon to allow efficient
translation of Orf4 after insertion into the vector plasmid (Kozak, 1987). PCR
products were separated by agarose gel electrophoresis in order to confirm that Orf4
had been successfully amplified (Fig A1 A). A band corresponding to the expected
size (341bp) of the correct PCR product was excised and ligated into pcDNA3.1(-).
The ligation products were used to transform E. coli DH5α, and successfully 
transformed colonies were selected by ampicillin selection. 10 colonies were picked
and screened for the correct Orf4 plasmid by colony screen PCR using the primers
described above. PCR products were separated by agarose gel electrophoresis, and
all were found to possess an insert of the correct size (Fig. A1 B). Clones 2 and 8
were selected and confirmed to express E4 Orf4 (Fig. 3.8).A BFigure A1. Generation of an E4 Orf4 expression plasmid. A. Orf4 was
amplified by PCR from wild-type Ad5 genomic DNA, and PCR products were
separated by 0.7% agarose gel electrophoresis. A negative control PCR was used
to account for the possibility of contamination. DNA size in base-pairs is
indicated to the left. B The PCR product in A was excised and ligated into
pcDNA3.1 (-). Ligation mixes were used to transform E. coli DH5α, and 
subsequent colonies were screened by PCR. PCR products were then separated
by 0.7% agarose gel electrophoresis. DNA size is indicated in base pairs to the
left.206
Appendix B
Sequencing of RT-PCR products
The RT-PCR product under investigation (Section 4.11) was excised and ligated into
a pGEM-T Easy vector (Promega). The ligation mix was used to transform DH5α E.
coli, which were subsequently plated on selective media and subjected to blue/white
selection. After incubation, positive colonies were picked and screened by PCR
using PML exon 3 5’ and PML II 3’ primers (Table 2.4). At least 4 different PCR
products were detected (3, 4, 5, 8, 9, and 10 being similar to 1) (Fig. A2), and one of
each was sequenced using a T7 primer that corresponded to the sequence upstream
of the multiple cloning site in pGEM-T Easy. Sequences were compared against the
NCBI BLAST database; none of the inserts was found to be related to PML.
BLAST results:
1 - Homo sapiens oxoglutarate (alpha-ketoglutarat
(lipoamide)
2- Homo sapiens RNA, 18S ribosomal 1 (RN18S1
6 - Homo sapiens transketolase (TKT), transcript v
7 - Homo sapiens chaperone, ABC1 activity of
(CABC1)Figure A2 Identification of
RT-PCR products. The RT-
PCR product under
investigation (section 4.11) was
cloned into pDEM-T Easy and
used to transform DH5α E. coli.
Subsequent colonies were
screened by PCR, and products
were separated by 0.7% agarose
gel electrophoresis. DNA size
is indicated in base-pairs to the
left.207
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), ribosomal RNA
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Appendix C
Construction of cytoplasmic PML I-V expression plasmids
A two step PCR methodology using pCI-neo FLAG-PML I as the initial template
was implemented. In the first round a combination of four primers was used to
amplify two regions of PML, which would later serve as templates for the second
round (Fig. A3).Figure A3. Diagram outlining the PCR strategy employed to generate
cPML expression plasmids. The first round of PCR generates 2 overlapping
products (A and B), which can then reciprocally act as primers in the second
round of reactions to generate product C. Addition of 5’ and 3’ terminal primers
further amplifies product C. Product C contains the required exon3-7a splice
junction, and can be cloned into the appropriate plasmid using the described
restriction sites.208
Second round PCR products were d
neo FLAG PML I-V that had previ
ligation mixes were then used t
screened for the correct insert by P
FLAG-PML I-Vcytoplasmic plasm
exogenous PML localisation was exFigure A4. Generation of cytoplasmic
PML expression plasmids. According to
the strategy outlined in A3, products A and
B were generated in the first round of PCR
using the primers indicated above each gel.
Products were separated by 0.7% agarose
gel electrophoresis, and excised before
being used as template for the second
round. PCR products were separated by
0.7% agarose gel electrophoresis, and
product C was subsequently excised.
Products are indicated by arrows, and DNA
size is indicated in base pairs.209
igested with MluI and SalI, then ligated into pCI-
ously been cut with MluI and SalI (Fig. A4). The
o transform DH5α E. coli, and colonies were
CR, and confirmed by DNA sequencing. pCI-neo
ids were then used to transfect HEp-2 cells, and
amined using an anti-FLAG antibody (Fig. A5).
Figure A5. Localisation of cPML I-V. HEp-2 cells were mock-transfected or
transfected with full-length FLAG-tagged PML I and PML IV, or FLAG-tagged
cytoplasmic PML I-V expression plasmids. 24 hours later cells were fixed and
probed with rabbit anti-FLAG and an anti-rabbit fluorophore-conjugated
secondary antibody. Nuclei were stained with DAPI. Images represent
maximum projections of images made in the Z-axis.210
Appendix D
Construction of Δexon5 PML I-VI expression plasmids 
A two step PCR methodology using pCI-neo FLAG-PML I as the initial template
was implemented. In the first round a combination of four primers were used to
amplify two regions of PML, which would later serve as templates for the second
round (Fig. A6).Figure A6. Diagram outlining the PCR strategy employed to generate
cPML expression plasmids. The first round of PCR generates 2 overlapping
products (X and Y), which can then reciprocally act as primers in the second
round of reactions to generate product Z. Addition of 5’ and 3’ terminal primers
further amplifies product Z. Product Z contains the required exon 4-6 splice
junction, and can be cloned into the appropriate plasmid using the described
restriction sites.211
Second round PCR products were digeste
neo FLAG PML I-V that had previously
ligation mixes were then used to transform
for the correct insert by PCR, and confirmFigure A7.  Generation of Δexon 5 
PML expression plasmids. According
to the strategy outlined in A6, products
X and Y were generated in the first
round of PCR using the primers
indicated above each gel. Products
were separated by 0.7% agarose gel
electrophoresis, and excised before
being used as template for the second
round. PCR products were separated by
0.7% agarose gel electrophoresis, and
product Z was subsequently excised.
Products are indicated by arrows, and
DNA size is indicated in base pairs.212
d with MluI and SalI, then ligated into pCI-
been cut with MluI and SalI (Fig. A7). The
 DH5α E. coli, and colonies were screened
ed by DNA sequencing.
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Appendix E
Plasmid maps of IFN reporter plasmids used during the course of this study
pIFN-LUC
6458 bps
1000
2000
3000
4000
5000
6000
Luciferase
IFN-ßPromoter
'SV40An
amp
SV40TpolyAsite
SV40t IVS
214
215
Bibliography
Ablasser, A., Bauernfeind, F., Hartmann, G., Latz, E., Fitzgerald, K. A. & Hornung, V.
(2009). RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA
polymerase III-transcribed RNA intermediate. Nat Immunol 10, 1065-1072.
Adamson, A. L. & Kenney, S. (2001). Epstein-Barr Virus Immediate-Early Protein BZLF1
Is SUMO-1 Modified and Disrupts Promyelocytic Leukemia Bodies. J. Virol. 75,
2388-2399.
Akira, S., Uematsu, S. & Takeuchi, O. (2006). Pathogen Recognition and Innate
Immunity. Cell 124, 783-801.
Alsheich-Bartok, O., Haupt, S., Alkalay-Snir, I., Saito, S., Appella, E. & Haupt, Y.
(2008). PML enhances the regulation of p53 by CK1 in response to DNA damage.
Oncogene 27, 3653-3661.
Beech, S. J., Lethbridge, K. J., Killick, N., McGlincy, N. & Leppard, K. N. (2005).
Isoforms of the promyelocytic leukemia protein differ in their effects on ND10
organization. Experimental Cell Research 307, 109-117.
Bellodi, C., Kindle, K., Bernassola, F., Cossarizza, A., Dinsdale, D., Melino, G., Heery,
D. & Salomoni, P. (2006). A cytoplasmic PML mutant inhibits p53 function. Cell
Cycle 5, 2688-2692.
Berk, A. J. (2005). Recent lessons in gene expression, cell cycle control, and cell biology
from adenovirus. Oncogene 24, 7673-7685.
Berk, A. J. (2007). Fields Virology, Fifth Edition, 5th edn, pp. 2355-2394. Edited by D. M.
Knipe & P. M. Howley: Lippincott Williams & Wilkins.
Bernardi, R. & Pandolfi, P. P. (2007). Structure, dynamics and functions of promyelocytic
leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8, 1006-1016.
Bernardi, R., Scaglioni, P. P., Bergmann, S., Horn, H. F., Vousden, K. H. & Pandolfi,
P. P. (2004). PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
Nat Cell Biol 6, 665-672.
Bischof, O., Kirsh, O., Pearson, M., Itahana, K., Pelicci, P. G. & Dejean, A. (2002).
Deconstructing PML-induced premature senescence. The EMBO Journal 21, 3358-
3369.
Bischof, O., Nacerddine, K. & Dejean, A. (2005). Human Papillomavirus Oncoprotein E7
Targets the Promyelocytic Leukemia Protein and Circumvents Cellular Senescence
via the Rb and p53 Tumor Suppressor Pathways. Mol. Cell. Biol. 25, 1013-1024.
Bishop, C. L., Ramalho, M., Nadkarni, N., May Kong, W., Higgins, C. F. &
Krauzewicz, N. (2006). Role for Centromeric Heterochromatin and PML Nuclear
Bodies in the Cellular Response to Foreign DNA. Mol. Cell. Biol. 26, 2583-2594.
216
Bogdan, C. (2000). The function of type I interferons in antimicrobial immunity. Current
Opinion in Immunology 12, 419-424.
Bondesson, M., Ohman, K., Manervik, M., Fan, S. & Akusjarvi, G. (1996). Adenovirus
E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A
transactivation of the E4 promoter. J. Virol. 70, 3844-3851.
Borden, K. L. B., Campbell Dwyer, E. J. & Salvato, M. S. (1998). An Arenavirus RING
(Zinc-Binding) Protein Binds the Oncoprotein Promyelocyte Leukemia Protein
(PML) and Relocates PML Nuclear Bodies to the Cytoplasm. J. Virol. 72, 758-766.
Boutell, C., Sadis, S. & Everett, R. D. (2002). Herpes Simplex Virus Type 1 Immediate-
Early Protein ICP0 and Its Isolated RING Finger Domain Act as Ubiquitin E3
Ligases In Vitro. J. Virol. 76, 841-850.
Brasier, A. R., Spratt, H., Wu, Z., Boldogh, I., Zhang, Y., Garofalo, R. P., Casola, A.,
Pashmi, J., Haag, A., Luxon, B. & Kurosky, A. (2004). Nuclear Heat Shock
Response and Novel Nuclear Domain 10 Reorganization in Respiratory Syncytial
Virus-Infected A549 Cells Identified by High-Resolution Two-Dimensional Gel
Electrophoresis. J. Virol. 78, 11461-11476.
Burkham, J., Coen, D. M. & Weller, S. K. (1998). ND10 Protein PML Is Recruited to
Herpes Simplex Virus Type 1 Prereplicative Sites and Replication Compartments in
the Presence of Viral DNA Polymerase. J. Virol. 72, 10100-10107.
Buschbeck, M., Uribesalgo, I., Ledl, A., Gutierrez, A., Minucci, S., Muller, S. & Di
Croce, L. (2007). PML4 induces differentiation by Myc destabilization. Oncogene
26, 3415-3422.
Cantrell, S. R. & Bresnahan, W. A. (2006). Human Cytomegalovirus (HCMV) UL82
Gene Product (pp71) Relieves hDaxx-Mediated Repression of HCMV Replication.
J. Virol. 80, 6188-6191.
Cao, T., Borden, K. L., Freemont, P. S. & Etkin, L. D. (1997). Involvement of the rfp
tripartite motif in protein-protein interactions and subcellular distribution. J Cell Sci
110, 1563-1571.
Caravokyri, C. & Leppard, K. N. (1995). Constitutive episomal expression of polypeptide
IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant
adenovirus type 5. J. Virol. 69, 6627-6633.
Carson, C. T., Orazio, N. I., Lee, D. V., Suh, J., Bekker-Jensen, S., Araujo, F. D.,
Lakdawala, S. S., Lilley, C. E., Bartek, J., Lukas, J. & Weitzman, M. D. (2009).
Mislocalization of the MRN complex prevents ATR signaling during adenovirus
infection. EMBO J 28, 652-662.
Carthagena, L., Bergamaschi, A., Luna, J. M., David, A., Uchil, P. D., Margottin-
Goguet, F., Mothes, W., Hazan, U., Transy, C., Pancino, G. & Nisole, S. b.
(2009). Human TRIM Gene Expression in Response to Interferons. PLoS ONE 4,
e4894.
217
Carvalho, T., Seeler, J. S., Ohman, K., Jordan, P., Pettersson, U., Akusjarvi, G.,
Carmo- Fonseca, M. & Dejean, A. (1995). Targeting of adenovirus E1A and E4-
ORF3 proteins to nuclear matrix- associated PML bodies. J. Cell Biol. 131, 45-56.
Chee, A. V., Lopez, P., Pandolfi, P. P. & Roizman, B. (2003). Promyelocytic Leukemia
Protein Mediates Interferon-Based Anti-Herpes Simplex Virus 1 Effects. J. Virol.
77, 7101-7105.
Chelbi-Alix, M. K., Quignon, F., Pelicano, L., Koken, M. H. M. & de The, H. (1998).
Resistance to Virus Infection Conferred by the Interferon-Induced Promyelocytic
Leukemia Protein. J. Virol. 72, 1043-1051.
Chelbi-Alix, M. K., Vidy, A., Bougrini, J. E. & Blondel, D. (2006). Rabies Viral
Mechanisms to Escape the IFN System: The Viral Protein P Interferes with IRF-3,
Stat1, and PML Nuclear Bodies. Journal of Interferon & Cytokine Research 26,
271-280.
Cheng, G., Zhong, J., Chung, J. & Chisari, F. V. (2007). Double-stranded DNA and
double-stranded RNA induce a common antiviral signaling pathway in human cells.
Proceedings of the National Academy of Sciences 104, 9035-9040.
Chiu, Y.-H., MacMillan, J. B. & Chen, Z. J. (2009). RNA Polymerase III Detects
Cytosolic DNA and Induces Type I Interferons through the RIG-I Pathway. Cell
138, 576-591.
Choi, Y.-H., Bernardi, R., Pandolfi, P. P. & Benveniste, E. N. (2006). The promyelocytic
leukemia protein functions as a negative regulator of IFN-{gamma} signaling. PNAS
103, 18715-18720.
Condemine, W., Takahashi, Y., Zhu, J., Puvion-Dutilleul, F., Guegan, S., Janin, A. &
de The, H. (2006). Characterization of Endogenous Human Promyelocytic
Leukemia Isoforms. Cancer Res 66, 6192-6198.
Day, P. M., Roden, R. B. S., Lowy, D. R. & Schiller, J. T. (1998). The Papillomavirus
Minor Capsid Protein, L2, Induces Localization of the Major Capsid Protein, L1,
and the Viral Transcription/Replication Protein, E2, to PML Oncogenic Domains. J.
Virol. 72, 142-150.
de The, H., Chomienne, C., Lanotte, M., Degos, L. & Dejean, A. (1990). The t(15;17)
translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor
[alpha] gene to a novel transcribed locus. Nature 347, 558-561.
Dellaire, G., Bazett-Jones, D.P. (2004). PML nuclear bodies: dynamic sensors of DNA
damage and cellular stress. BioEssays 26, 963-977.
Dellaire, G., Ching, R. W., Ahmed, K., Jalali, F., Tse, K. C. K., Bristow, R. G. &
Bazett-Jones, D. P. (2006a). Promyelocytic leukemia nuclear bodies behave as
DNA damage sensors whose response to DNA double-strand breaks is regulated by
NBS1 and the kinases ATM, Chk2, and ATR. J. Cell Biol. 175, 55-66.
Dellaire, G., Ching, R. W., Dehghani, H., Ren, Y. & Bazett-Jones, D. P. (2006b). The
number of PML nuclear bodies increases in early S phase by a fission mechanism. J
Cell Sci 119, 1026-1033.
218
Dellaire, G., Eskiw, C. H., Dehghani, H., Ching, R. W. & Bazett-Jones, D. P. (2006c).
Mitotic accumulations of PML protein contribute to the re-establishment of PML
nuclear bodies in G1. J Cell Sci 119, 1034-1042.
Devaux, C., Caillet-Boudin, M. L., Jacrot, B. & Boulanger, P. (1987). Crystallization,
enzymatic cleavage, and the polarity of adenovirus type 2 fiber. Virology 161, 121-
128.
Dix, I. & Leppard, K. N. (1995). Expression of adenovirus type 5 E4 Orf2 protein during
lytic infection. J Gen Virol 76, 1051-1055.
Doucas, V., Ishov, A. M., Romo, A., Juguilon, H., Weitzman, M. D., Evans, R. M. &
Maul, G. G. (1996). Adenovirus replication is coupled with the dynamic properties
of the PML nuclear structure. Genes Dev. 10, 196-207.
Duprez, E., Saurin, A. J., Desterro, J. M., Lallemand-Breitenbach, V., Howe, K.,
Boddy, M. N., Solomon, E., de The, H., Hay, R. T. & Freemont, P. S. (1999).
SUMO-1 modification of the acute promyelocytic leukaemia protein PML:
implications for nuclear localisation. J Cell Sci 112, 381-393.
Emeny, J. M. & Morgan, M. J. (1979). Regulation of the Interferon System: Evidence that
Vero Cells have a Genetic Defect in Interferon Production. J Gen Virol 43, 247-252.
Everett, R. D. (2001). DNA viruses and viral proteins that interact with PML nuclear
bodies. Oncogene 20, 7266-7273.
Everett, R. D. (2006). Interactions between DNA viruses, ND10 and the DNA damage
response. Cellular Microbiology 8, 365-374.
Everett, R. D., Freemont, P., Saitoh, H., Dasso, M., Orr, A., Kathoria, M. & Parkinson,
J. (1998). The Disruption of ND10 during Herpes Simplex Virus Infection
Correlates with the Vmw110- and Proteasome-Dependent Loss of Several PML
Isoforms. J. Virol. 72, 6581-6591.
Everett, R. D., Lomonte, P., Sternsdorf, T., van Driel, R. & Orr, A. (1999). Cell cycle
regulation of PML modification and ND10 composition. J Cell Sci 112, 4581-4588.
Everett, R. D. & Murray, J. (2005). ND10 Components Relocate to Sites Associated with
Herpes Simplex Virus Type 1 Nucleoprotein Complexes during Virus Infection. J.
Virol. 79, 5078-5089.
Everett, R. D. & Orr, A. (2009). Herpes Simplex Virus Type 1 Regulatory Protein ICP0
Aids Infection in Cells with a Preinduced Interferon Response but Does Not Impede
Interferon-Induced Gene Induction. J. Virol. 83, 4978-4983.
Everett, R. D., Rechter, S., Papior, P., Tavalai, N., Stamminger, T. & Orr, A. (2006).
PML Contributes to a Cellular Mechanism of Repression of Herpes Simplex Virus
Type 1 Infection That Is Inactivated by ICP0. J. Virol. 80, 7995-8005.
Everett, R. D., Young, D. F., Randall, R. E. & Orr, A. (2008). STAT-1- and IRF-3-
Dependent Pathways Are Not Essential for Repression of ICP0-Null Mutant Herpes
Simplex Virus Type 1 in Human Fibroblasts. J. Virol. 82, 8871-8881.
219
Farley, D. C., Brown, J. L. & Leppard, K. N. (2004). Activation of the Early-Late Switch
in Adenovirus Type 5 Major Late Transcription Unit Expression by L4 Gene
Products. J. Virol. 78, 1782-1791.
Florin, L., Schäfer, F., Sotlar, K., Streeck, R. E. & Sapp, M. (2002). Reorganization of
Nuclear Domain 10 Induced by Papillomavirus Capsid Protein L2. Virology 295,
97-107.
Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., Pandolfi, P. P.,
Will, H., Schneider, C. & Del Sal, G. (2000). Regulation of p53 activity in nuclear
bodies by a specific PML isoform. The EMBO Journal 19, 6185-6195.
Freemont, P. S. (2000). Ubiquitination: RING for destruction? Current Biology 10, R84-
R87.
Giard, D. J., Aaronson, S.A., Todaro, G.J., Arnstein, P., Kersey, J.H., Dosik, H., and
Parks, W.P. (1973). In vitro cultivation of human tumours: establishment of cell
lines derived from a series of solid tumours. Journal of the National Cancer Institute
51, 1417-23.
Gill, G. (2004). SUMO and ubiquitin in the nucleus: different functions, similar
mechanisms? Genes & Development 18, 2046-2059.
Goddard, A. D., Borrow, J., Freemont, P. S. & Solomon, E. (1991). Characterization of a
zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science
254, 1371-1374.
Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. (1977). Characteristics of a Human
Cell Line Transformed by DNA from Human Adenovirus Type 5. J Gen Virol 36,
59-72.
Greber, U. F., Webster, P., Weber, J. & Helenius, A. (1996). The role of the adenovirus
protease on virus entry into cells. EMBO J 15, 1766-1777.
Gresser, I. & Belardelli, F. (2002). Endogenous type I interferons as a defense against
tumors. Cytokine & Growth Factor Reviews 13, 111-118.
Guccione, E., Lethbridge, K. J., Killick, N., Leppard, K. N. & Banks, L. (2004). HPV E6
proteins interact with specific PML isoforms and allow distinctions to be made
between different POD structures. Oncogene 23, 4662-4672.
Haller, O., Kochs, G. & Weber, F. (2006). The interferon response circuit: Induction and
suppression by pathogenic viruses. Virology 344, 119-130.
Härle, P., Sainz, B., Carr, D. J. J. & Halford, W. P. (2002). The Immediate-Early Protein,
ICP0, Is Essential for the Resistance of Herpes Simplex Virus to Interferon-
[alpha]/[beta]. Virology 293, 295-304.
Hayakawa, F., Abe, A., Kitabayashi, I., Pandolfi, P. P. & Naoe, T. (2008). Acetylation of
PML Is Involved in Histone Deacetylase Inhibitor-mediated Apoptosis. Journal of
Biological Chemistry 283, 24420-24425.
220
Hayakawa, F. & Privalsky, M. L. (2004). Phosphorylation of PML by mitogen-activated
protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell
5, 389-401.
Hayman, A., Comely, S., Lackenby, A., Hartgroves, L. C. S., Goodbourn, S.,
McCauley, J. W. & Barclay, W. S. (2007). NS1 Proteins of Avian Influenza A
Viruses Can Act as Antagonists of the Human Alpha/Beta Interferon Response. J.
Virol. 81, 2318-2327.
Heino, P., Zhou, J. & Lambert, P. F. (2000). Interaction of the Papillomavirus
Transcription/Replication Factor, E2, and the Viral Capsid Protein, L2. Virology
276, 304-314.
Honda, K., Takaoka, A. & Taniguchi, T. (2006). Type I Inteferon Gene Induction by the
Interferon Regulatory Factor Family of Transcription Factors. 25, 349-360.
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N.,
Ohba, Y., Takaoka, A., Yoshida, N. & Taniguchi, T. (2005). IRF-7 is the master
regulator of type-I interferon-dependent immune responses. Nature 434, 772-777.
Hoppe, A., Beech, S. J., Dimmock, J. & Leppard, K. N. (2006). Interaction of the
Adenovirus Type 5 E4 Orf3 Protein with Promyelocytic Leukemia Protein Isoform
II Is Required for ND10 Disruption. J. Virol. 80, 3042-3049.
Huang, M. M. & Hearing, P. (1989). Adenovirus early region 4 encodes two gene products
with redundant effects in lytic infection. J. Virol. 63, 2605-2615.
Iki, S., Yokota, S.-i., Okabayashi, T., Yokosawa, N., Nagata, K. & Fujii, N. (2005).
Serum-dependent expression of promyelocytic leukemia protein suppresses
propagation of influenza virus. Virology 343, 106-115.
Ishov, A. M., Sotnikov, A. G., Negorev, D., Vladimirova, O. V., Neff, N., Kamitani, T.,
Yeh, E. T. H., Strauss, J. F., III & Maul, G. G. (1999). Pml Is Critical for Nd10
Formation and Recruits the Pml-Interacting Protein Daxx to This Nuclear Structure
When Modified by Sumo-1. J. Cell Biol. 147, 221-234.
Jacobs J.P., J. C. M., Baille J.P. (1970). Characteristics of a human diploid cell designated
MRC-5. Nature 11, 168-170.
Jensen, K., Shiels, C. and Freemont, P.S. (2001). PML protein isoforms and the
RBCC/TRIM motif. Oncogene 20, 7223-7233.
Jiang, W. Q., Zhong, Z. H., Henson, J. D. & Reddel, R. R. (2007). Identification of
candidate alternative lengthening of telomeres genes by methionine restriction and
RNA interference. Oncogene 26, 4635-4647.
Jones, N. & Shenk, T. (1978). Isolation of deletion and substitution mutants of adenovirus
type 5. Cell 13, 181-188.
Kamitani, T., Nguyen, H. P., Kito, K., Fukuda-Kamitani, T. & Yeh, E. T. H. (1998).
Covalent Modification of PML by the Sentrin Family of Ubiquitin-like Proteins.
Journal of Biological Chemistry 273, 3117-3120.
221
Kanopka, A., Muhlemann, O., Petersen-Mahrt, S., Estmer, C., Ohrmalm, C. &
Akusjarvi, G. (1998). Regulation of adenovirus alternative RNA splicing by
dephosphorylation of SR proteins. Nature 393, 185-187.
Kentsis, A., Dwyer, E. C., Perez, J. M., Sharma, M., Chen, A., Pan, Z. Q. & Borden, K.
L. B. (2001). The RING domains of the promyelocytic leukemia protein PML and
the arenaviral protein Z repress translation by directly inhibiting translation initiation
factor eIF4E. Journal of Molecular Biology 312, 609-623.
Kieback, E. & Müller, M. (2006). Factors influencing subcellular localization of the human
papillomavirus L2 minor structural protein. Virology 345, 199-208.
King, P. & Goodbourn, S. (1994). The beta-interferon promoter responds to priming
through multiple independent regulatory elements. Journal of Biological Chemistry
269, 30609-30615.
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K.,
Langer, J. A., Sheikh, F., Dickensheets, H. & Donnelly, R. P. (2003). IFN-
[lambda]s mediate antiviral protection through a distinct class II cytokine receptor
complex. Nat Immunol 4, 69-77.
Kozak, M. (1987). At least six nucleotides preceding the AUG initiator codon enhance
translation in mammalian cells. Journal of Molecular Biology 196, 947-950.
Krieghoff-Henning, E. & Hofmann, T. G. (2008). Role of nuclear bodies in apoptosis
signalling. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1783,
2185-2194.
Kumar, H., Kawai, T. & Akira, S. (2009). Toll-like receptors and innate immunity.
Biochemical and Biophysical Research Communications 388, 621-625.
Laemmli, U. K. (1970). Cleavage of Structural Proteins during the Assembly of the Head of
Bacteriophage T4. Nature 227, 680-685.
Lang, M., Jegou, T., Chung, I., Richter, K., Munch, S., Udvarhelyi, A., Cremer, C.,
Hemmerich, P., Engelhardt, J., Hell, S. W. & Rippe, K. (2010). Three-
dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 123,
392-400.
Lavau, C., Marchio, A., Fagioli, M., Jansen, J., Falini, B., Lebon, P., Grosveld, F.,
Pandolfi, P., Pelicci, P. & Dejean, A. (1995). The acute promyelocytic leukaemia-
associated PML gene is induced by interferon. Oncogene 11, 871-876.
Leib, D. A., Harrison, T. E., Laslo, K. M., Machalek, M. A., Moorman, N. J. & Virgin,
H. W. (1999). Interferons Regulate the Phenotype of Wild-type and Mutant Herpes
Simplex Viruses In Vivo. J. Exp. Med. 189, 663-672.
Leppard, K. & Dimmock, J. (2006). Viruses and the Nucleus, 1st edn, pp. Chapter 8: Virus
Interactions with PML Nuclear Bodies. Edited by J. A. Hiscox: John Wiley & Sons.
Leppard, K. N. (1997). E4 gene function in adenovirus, adenovirus vector and adeno-
associated virus infections. J Gen Virol 78, 2131-2138.
222
Leppard, K. N., Emmott, E., Cortese, M. S. & Rich, T. (2009). Adenovirus type 5 E4
Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for
disruption via a sequence in PML isoform II that is predicted as a protein interaction
site by bioinformatic analysis. J Gen Virol 90, 95-104.
Leppard, K. N. & Everett, R. D. (1999). The adenovirus type 5 E1b 55K and E4 Orf3
proteins associate in infected cells and affect ND10 components. J Gen Virol 80,
997-1008.
Levy, D. E. & Garcia-Sastre, A. (2001). The virus battles: IFN induction of the antiviral
state and mechanisms of viral evasion. Cytokine & Growth Factor Reviews 12, 143-
156.
Li, W., Wang, G., Zhang, H., Zhang, D., Zeng, J., Chen, X., Xu, Y. & Li, K. (2009).
Differential suppressive effect of promyelocytic leukemia protein on the replication
of different subtypes/strains of influenza A virus. Biochemical and Biophysical
Research Communications 389, 84-89.
Lin, R., Noyce, R. S., Collins, S. E., Everett, R. D. & Mossman, K. L. (2004). The Herpes
Simplex Virus ICP0 RING Finger Domain Inhibits IRF3- and IRF7-Mediated
Activation of Interferon-Stimulated Genes. J. Virol. 78, 1675-1684.
Louria-Hayon, I., Grossman, T., Sionov, R. V., Alsheich, O., Pandolfi, P. P. & Haupt,
Y. (2003). The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated
Inhibition and Degradation. Journal of Biological Chemistry 278, 33134-33141.
Lutz, P., Rosa-Calatrava, M. & Kedinger, C. (1997). The product of the adenovirus
intermediate gene IX is a transcriptional activator. J. Virol. 71, 5102-5109.
McNally, B. A., Trgovcich, J., Maul, G. G., Liu, Y. & Zheng, P. (2008). A Role for
Cytoplasmic PML in Cellular Resistance to Viral Infection. PLoS ONE 3, e2277.
Meier, O. & Greber, U. (2004). Adenovirus endocytosis. The Journal of Gene Medicine 6,
S152-S163.
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. w., Young,
D. B., Barbosa, M., Mann, M., Manning, A. & Rao, A. (1997). IKK-1 and IKK-2:
Cytokine-Activated I{kappa}B Kinases Essential for NF-B Activation. Science 278,
860-866.
Merika, M., Williams, A. J., Chen, G., Collins, T. & Thanos, D. (1998). Recruitment of
CBP/p300 by the IFN[beta] Enhanceosome Is Required for Synergistic Activation
of Transcription. Molecular Cell 1, 277-287.
Mirzoeva, O. K. & Petrini, J. H. J. (2001). DNA Damage-Dependent Nuclear Dynamics
of the Mre11 Complex. Mol. Cell. Biol. 21, 281-288.
Moore, A. E., Sabachewsky, L. & Toolan, H. W. (1955). Culture Characteristics of Four
Permanent Lines of Human Cancer Cells. Cancer Res 15, 598-602.
Morris, S. J. & Leppard, K. N. (2009). Adenovirus Serotype 5 L4-22K and L4-33K
Proteins Have Distinct Functions in Regulating Late Gene Expression. J. Virol. 83,
3049-3058.
223
Mossman, K. L., Saffran, H. A. & Smiley, J. R. (2000). Herpes Simplex Virus ICP0
Mutants Are Hypersensitive to Interferon. J. Virol. 74, 2052-2056.
Muller, S., Ledl, A. & Schmidt, D. (2004). SUMO: a regulator of gene expression and
genome integrity. Oncogene 23, 1998-2008.
Muller, S., Matunis, M. J. & Dejean, A. (1998). Conjugation with the ubiquitin-related
modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J
17, 61-70.
Nevels, M., Tauber, B., Kremmer, E., Spruss, T., Wolf, H. & Dobner, T. (1999).
Transforming Potential of the Adenovirus Type 5 E4orf3 Protein. J. Virol. 73, 1591-
1600.
Nichol, J. N., Petruccelli, L. A. & Miller Jr., W. H. (2009). Expanding PML's functional
repertoire through post-translational mechanisms. Frontiers in Bioscience, 2293-
2306.
Nisole, S., Stoye, J. P. & Saib, A. (2005). TRIM family proteins: retroviral restriction and
antiviral defence. Nature Reviews Microbiology 3, 799-808.
Nobukazu, S., Toshie, S. & Shunsuke, I. (2008). Modulation of M2-type pyruvate kinase
activity by the cytoplasmic PML tumor suppressor protein. Genes to Cells 13, 245-
254.
Nojima, T., Oshiro-Ideue, T., Nakanoya, H., Kawamura, H., Morimoto, T., Kawaguchi,
Y., Kataoka, N. & Hagiwara, M. (2009). Herpesvirus protein ICP27 switches
PML isoform by altering mRNA splicing. Nucl. Acids Res. 37, 6515-6527.
Nordqvist, K., Ohman, K. & Akusjarvi, G. (1994). Human adenovirus encodes two
proteins which have opposite effects on accumulation of alternatively spliced
mRNAs. Mol. Cell. Biol. 14, 437-445.
Oh, W., Ghim, J., Lee, E.-W., Yang, M.-R., Kim, E. T., Ahn, J.-H. & Song, J. (2009).
PML-IV functions as a negative regulator of telomerase by interacting with TERT. J
Cell Sci 122, 2613-2622.
Öhman, K., Nordqvist, K. & Akusjärvi, G. (1993). Two Adenovirus Proteins with
Redundant Activities in Virus Growth Facilitates Tripartite Leader mRNA
Accumulation. Virology 194, 50-58.
Ozato, K., Shin, D.-M., Chang, T.-H. & Morse, H. C. (2008). TRIM family proteins and
their emerging roles in innate immunity. Nat Rev Immunol 8, 849-860.
Pampin, M., Simonin, Y., Blondel, B., Percherancier, Y. & Chelbi-Alix, M. K. (2006).
Cross Talk between PML and p53 during Poliovirus Infection: Implications for
Antiviral Defense. J. Virol. 80, 8582-8592.
Parham, J., Iannone, M., Overton, L. & Hutchins, J. (1998). Optimization of transient
gene expression in mammalian cells and potential for scale-up using flow
electroporation. Cytotechnology 28, 147-155.
Pavan Kumar, P., Bischof, O., Purbey, P. K., Notani, D., Urlaub, H., Dejean, A. &
Galande, S. (2007). Functional interaction between PML and SATB1 regulates
224
chromatin-loop architecture and transcription of the MHC class I locus. Nat Cell
Biol 9, 45-56.
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S. i.,
Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P. & Pelicci, P. G. (2000).
PML regulates p53 acetylation and premature senescence induced by oncogenic
Ras. Nature 406, 207-210.
Percherancier, Y., Germain-Desprez, D., Galisson, F. d. r., Mascle, X. H., Dianoux, L.,
Estephan, P., Chelbi-Alix, M. K. & Aubry, M. (2009). Role of SUMO in RNF4-
mediated Promyelocytic Leukemia Protein (PML) Degradation. Journal of
Biological Chemistry 284, 16595-16608.
Ponten, J. a. S., E. (1967). Two established in vitro cell lines from human mesenchymal
tumours. International Journal of Cancer 2, 434-437.
Porta, C., Hadj-Slimane, R., Nejmeddine, M., Pampin, M., Tovey, M. G., Espert, L.,
Alvarez, S. & Chelbi-Alix, M. K. (2004). Interferons [alpha] and [gamma] induce
p53-dependent and p53-independent apoptosis, respectively. Oncogene 24, 605-615.
Querido, E., Blanchette, P., Yan, Q., Kamura, T., Morrison, M., Boivin, D., Kaelin, W.
G., Conaway, R. C., Conaway, J. W. & Branton, P. E. (2001). Degradation of
p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism
involving a Cullin-containing complex. Genes & Development 15, 3104-3117.
Quimby, B. B., Yong-Gonzalez, V., Anan, T., Strunnikov, A. V. & Dasso, M. (2006).
The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.
Oncogene 25, 2999-3005.
Rajsbaum, R., Stoye, J., P. & O'Garra, A. (2008). Type I interferon-dependent and -
independent expression of tripartite motif proteins in immune cells. European
Journal of Immunology 38, 619-630.
Randall, R. E. & Goodbourn, S. (2008). Interferons and viruses: an interplay between
induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89,
1-47.
Regad, T., Saib, A., Lallemand-Breitenbach, V., Pandolfi, P. P., de The, H. & Chelbi-
Alix, M. K. (2001). PML mediates the interferon-induced antiviral state against a
complex retrovirus via its association with the viral transactivator. EMBO J 20,
3495-3505.
Reich, N. C., Sarnow, P., Duprey, E. & Levine, A. J. (1983). Monoclonal antibodies
which recognize native and denatured forms of the adenovirus DNA-binding
protein. Virology 30, 480-484.
Reineke, E. L., Lam, M., Liu, Q., Liu, Y., Stanya, K. J., Chang, K.-S., Means, A. R. &
Kao, H.-Y. (2008). Degradation of the Tumor Suppressor PML by Pin1 Contributes
to the Cancer Phenotype of Breast Cancer MDA-MB-231 Cells. Mol. Cell. Biol. 28,
997-1006.
Rosa-Calatrava, M., Grave, L., Puvion-Dutilleul, F., Chatton, B. & Kedinger, C.
(2001). Functional Analysis of Adenovirus Protein IX Identifies Domains Involved
225
in Capsid Stability, Transcriptional Activity, and Nuclear Reorganization. J. Virol.
75, 7131-7141.
Rosa-Calatrava, M., Puvion-Dutilleul, F., Lutz, P., Dreyer, D., De The, H., Chatton, B.
and Kedinger, C. (2003). Adeonvirus protein IX sequesters host-cell promyelocytic
leukaemia protein and contributes to efficient viral replication. EMBO Reports 4,
969-975.
Russell, W. C. (2000). Update on adenovirus and its vectors. J Gen Virol 81, 2573-2604.
Russell, W. C. (2009). Adenoviruses: update on structure and function. J Gen Virol 90, 1-
20.
Saffert, R. T. & Kalejta, R. F. (2006). Inactivating a Cellular Intrinsic Immune Defense
Mediated by Daxx Is the Mechanism through Which the Human Cytomegalovirus
pp71 Protein Stimulates Viral Immediate-Early Gene Expression. J. Virol. 80, 3863-
3871.
Salomoni, P. & Bellodi, C. (2007). New insights into the cytoplasmic function of PML.
Histology and Histopathology 22, 937-946.
Salomoni, P., Ferguson, B. J., Wyllie, A. H. & Rich, T. (2008). New insights into the role
of PML in tumour suppression. Cell Res 18, 622-640.
Sato, Y., Yoshioka, K., Suzuki, C., Awashima, S., Hosaka, Y., Yewdell, J. & Kuroda, K.
(2003). Localization of influenza virus proteins to nuclear dot 10 structures in
influenza virus-infected cells. Virology 310, 29-40.
Scaglioni, P., Yung, T., Choi, S., Baldini, C., Konstantinidou, G. & Pandolfi, P. (2008).
CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML
tumor suppressor. Molecular and Cellular Biochemistry 316, 149-154.
Scaglioni, P. P., Yung, T. M., Cai, L. F., Erdjument-Bromage, H., Kaufman, A. J.,
Singh, B., Teruya-Feldstein, J., Tempst, P. & Pandolfi, P. P. (2006). A CK2-
Dependent Mechanism for Degradation of the PML Tumor Suppressor. Cell 126,
269-283.
Shen, T. H., Lin, H.-K., Scaglioni, P. P., Yung, T. M. & Pandolfi, P. P. (2006). The
Mechanisms of PML-Nuclear Body Formation. Molecular Cell 24, 331-339.
Shenk, T. (1996). Adenoviridae: The Virues and Their Replication. Fields Virology, Third
Edition 2, 2111-2148.
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T.
E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., Ostrander, C., Dong,
D., Shin, J., Presnell, S., Fox, B., Haldeman, B., Cooper, E., Taft, D., Gilbert, T.,
Grant, F. J., Tackett, M., Krivan, W., McKnight, G., Clegg, C., Foster, D. &
Klucher, K. M. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R.
Nat Immunol 4, 63-68.
Shtrichman, R. & Kleinberger, T. (1998). Adenovirus Type 5 E4 Open Reading Frame
4 Protein Induces Apoptosis in Transformed Cells. J. Virol. 72, 2975-2982.
226
Sivachandran, N., Sarkari, F. & Frappier, L. (2008). Epstein-Barr Nuclear Antigen 1
Contributes to Nasopharyngeal Carcinoma through Disruption of PML Nuclear
Bodies. PLoS Pathogens 4, e1000170.
Stetson, D. B. & Medzhitov, R. (2006). Type I Interferons in Host Defense. Immunity 25,
373-381.
Stracker, T. H., Carson, C. T. & Weitzman, M. D. (2002). Adenovirus oncoproteins
inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418, 348-352.
Stracker, T. H., Lee, D. V., Carson, C. T., Araujo, F. D., Ornelles, D. A. & Weitzman,
M. D. (2005). Serotype-Specific Reorganization of the Mre11 Complex by
Adenoviral E4orf3 Proteins. J. Virol. 79, 6664-6673.
Stuurman, N., de Graaf, A., Floore, A., Josso, A., Humbel, B., de Jong, L. & van Driel,
R. (1992). A monoclonal antibody recognizing nuclear matrix-associated nuclear
bodies. J Cell Sci 101, 773-784.
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S.,
Imai, K., Shibue, T., Honda, K. & Taniguchi, T. (2003). Integration of interferon-
[alpha]/[beta] signalling to p53 responses in tumour suppression and antiviral
defence. Nature 424, 516-523.
Takaoka, A. & Yanai, H. (2006). Interferon signalling network in innate defence. Cellular
Microbiology 8, 907-922.
Tan, J.-A. T., Sun, Y., Song, J., Chen, Y., Krontiris, T. G. & Durrin, L. K. (2008).
SUMO Conjugation to the Matrix Attachment Region-binding Protein, Special AT-
rich Sequence-binding Protein-1 (SATB1), Targets SATB1 to Promyelocytic
Nuclear Bodies Where It Undergoes Caspase Cleavage. Journal of Biological
Chemistry 283, 18124-18134.
Tang, J., Xie, W. & Yang, X. (2005). Association of caspase-2 with the promyelocytic
leukamia protein nuclear bodies. Cancer Biology and Therapy 4, 645-649.
Taniguchi, T. & Takaoka, A. (2002). The interferon-[alpha]/[beta] system in antiviral
responses: a multimodal machinery of gene regulation by the IRF family of
transcription factors. Current Opinion in Immunology 14, 111-116.
Tatham, M. H., Geoffroy, M.-C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E.
G., Palvimo, J. J. & Hay, R. T. (2008). RNF4 is a poly-SUMO-specific E3
ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10,
538-546.
Tavalai, N., Papior, P., Rechter, S., Leis, M. & Stamminger, T. (2006). Evidence for a
Role of the Cellular ND10 Protein PML in Mediating Intrinsic Immunity against
Human Cytomegalovirus Infections. J. Virol. 80, 8006-8018.
Tavalai, N. & Stamminger, T. (2008). New insights into the role of the subnuclear
structure ND10 for viral infection. Biochimica et Biophysica Acta (BBA) -
Molecular Cell Research 1783, 2207-2221.
Taylor, J. L., Unverrich, D., O'Brien, W. J. & Wilcox, K. W. (2000). Interferon
Coordinately Inhibits the Disruption of PML-Positive ND10 and Immediate-Early
227
Gene Expression by Herpes Simplex Virus. Journal of Interferon & Cytokine
Research 20, 805-815.
Thanos, D. & Maniatis, T. (1995). Virus induction of human IFN[beta] gene expression
requires the assembly of an enhanceosome. Cell 83, 1091-1100.
Törmänen, H., Backström, E., Carlsson, A. & Akusjärvi, G. (2006). L4-33K, an
Adenovirus-encoded Alternative RNA Splicing Factor. Journal of Biological
Chemistry 281, 36510-36517.
Towbin, H., Staehelin, T. & Gordon, J. (1979). Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proceedings of the National Academy of Sciences of the United States of America
76, 4350-4354.
Towers, G. (2007). The control of viral infection by tripartite motif proteins and cyclophilin
A. Retrovirology 4, 40.
Ullman, A. J. & Hearing, P. (2008). Cellular Proteins PML and Daxx Mediate an Innate
Antiviral Defense Antagonized by the Adenovirus E4 ORF3 Protein. J. Virol. 82,
7325-7335.
Ullman, A. J., Reich, N. C. & Hearing, P. (2007). Adenovirus E4 ORF3 Protein Inhibits
the Interferon-Mediated Antiviral Response. J. Virol. 81, 4744-4752.
Vallian, S., Chin, K.-V. & Chang, K.-S. (1998). The Promyelocytic Leukemia Protein
Interacts with Sp1 and Inhibits Its Transactivation of the Epidermal Growth Factor
Receptor Promoter. Mol. Cell. Biol. 18, 7147-7156.
Van Damme, E., Laukens, K., Hai Dang, T. & Van Ostade, X. (2010). A manually
curated network of the PML nuclear body interactome reveals an important role for
PML-NBs in SUMOylation dynamics. International Journal of Biological Sciences
6, 51-67.
Wang, Z.-G., Ruggero, D., Ronchetti, S., Zhong, S., Gaboli, M., Rivi, R. & Pandolfi, P.
P. (1998). Pml is essential for multiple apoptotic pathways. Nat Genet 20, 266-272.
Webster, A., Russell, W. C. & Kemp, G. D. (1989). Characterization of the Adenovirus
Proteinase: Development and Use of a Specific Peptide Assay. J Gen Virol 70,
3215-3223.
Weidtkamp-Peters, S., Lenser, T., Negorev, D., Gerstner, N., Hofmann, T. G.,
Schwanitz, G., Hoischen, C., Maul, G., Dittrich, P. & Hemmerich, P. (2008).
Dynamics of component exchange at PML nuclear bodies. J Cell Sci 121, 2731-
2743.
Weiss, R. S., McArthur, M. J. & Javier, R. T. (1996). Human adenovirus type 9 E4 open
reading frame 1 encodes a cytoplasmic transforming protein capable of increasing
the oncogenicity of CREF cells. J. Virol. 70, 862-872.
Weitzman, M. D. & Ornelles, D. A. (2005). Inactivating intracellular antiviral responses
during adenovirus infection. Oncogene 24, 7686-7696.
228
Wu, Q., Hu, H., Lan, J., Emenari, C., Wang, Z., Chang, K.-s., Huang, H. & Yao, X.
(2009). PML3 Orchestrates the Nuclear Dynamics and Function of TIP60. Journal
of Biological Chemistry 284, 8747-8759.
Xu, Y., Ahn, J.-H., Cheng, M., apRhys, C. M., Chiou, C.-J., Zong, J., Matunis, M. J. &
Hayward, G. S. (2001). Proteasome-Independent Disruption of PML Oncogenic
Domains (PODs), but Not Covalent Modification by SUMO-1, Is Required for
Human Cytomegalovirus Immediate-Early Protein IE1 To Inhibit PML-Mediated
Transcriptional Repression. J. Virol. 75, 10683-10695.
Xu, Z.-X., Timanova-Atanasova, A., Zhao, R.-X. & Chang, K.-S. (2003). PML
Colocalizes with and Stabilizes the DNA Damage Response Protein TopBP1. Mol.
Cell. Biol. 23, 4247-4256.
Xu, Z.-X., Zou, W.-X., Lin, P. & Chang, K.-S. (2005). A Role for PML3 in Centrosome
Duplication and Genome Stability. Molecular Cell 17, 721-732.
Yie, J., Merika, M., Munshi, N., Chen, G. & Thanos, D. (1999). The role of HMG I(Y) in
the assembly and function of the IFN-[beta] enhanceosome. EMBO J 18, 3074-3089.
Yu, J., Lan, J., Wang, C., Wu, Q., Zhu, Y., Lai, X., Sun, J., Jin, C. & Huang, H. (2009).
PML3 interacts with TRF1 and is essential for ALT-associated PML bodies
assembly in U2OS cells. Cancer Letters 291, 177-186.
